<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Microbiol</journal-id><journal-id journal-id-type="iso-abbrev">Front Microbiol</journal-id><journal-id journal-id-type="publisher-id">Front. Microbiol.</journal-id><journal-title-group><journal-title>Frontiers in Microbiology</journal-title></journal-title-group><issn pub-type="epub">1664-302X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6218626</article-id><article-id pub-id-type="doi">10.3389/fmicb.2018.02603</article-id><article-categories><subj-group subj-group-type="heading"><subject>Microbiology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The Immune Mechanisms of Lung Parenchymal Damage in Tuberculosis and the Role of Host-Directed Therapy</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stek</surname><given-names>Cari</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="c001"><sup>*</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/562844/overview"/></contrib><contrib contrib-type="author"><name><surname>Allwood</surname><given-names>Brian</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Walker</surname><given-names>Naomi F.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/612202/overview"/></contrib><contrib contrib-type="author"><name><surname>Wilkinson</surname><given-names>Robert J.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref><uri xlink:type="simple" xlink:href="http://loop.frontiersin.org/people/402943/overview"/></contrib><contrib contrib-type="author"><name><surname>Lynen</surname><given-names>Lutgarde</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Meintjes</surname><given-names>Graeme</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>, <country>South Africa</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Clinical Sciences, Institute of Tropical Medicine Antwerp</institution>, <addr-line>Antwerp</addr-line>, <country>Belgium</country></aff><aff id="aff3"><sup>3</sup><institution>Department of Medicine, University of Cape Town</institution>, <addr-line>Cape Town</addr-line>, <country>South Africa</country></aff><aff id="aff4"><sup>4</sup><institution>Division of Pulmonology, Department of Medicine, Stellenbosch University</institution>, <addr-line>Stellenbosch</addr-line>, <country>South Africa</country></aff><aff id="aff5"><sup>5</sup><institution>Department of Clinical Research, London School of Hygiene &#x00026; Tropical Medicine</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff><aff id="aff6"><sup>6</sup><institution>Department of Medicine, Imperial College London</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff><aff id="aff7"><sup>7</sup><institution>Francis Crick Institute</institution>, <addr-line>London</addr-line>, <country>United Kingdom</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Alessandro Marcello, International Centre for Genetic Engineering and Biotechnology, Italy</p></fn><fn fn-type="edited-by"><p>Reviewed by: Hridayesh Prakash, Amity University, India; Elsa Anes, Universidade de Lisboa, Portugal</p></fn><corresp id="c001">*Correspondence: Cari Stek, <email>cari_stek@hotmail.com</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Microbial Immunology, a section of the journal Frontiers in Microbiology</p></fn></author-notes><pub-date pub-type="epub"><day>30</day><month>10</month><year>2018</year></pub-date><pub-date pub-type="collection"><year>2018</year></pub-date><volume>9</volume><elocation-id>2603</elocation-id><history><date date-type="received"><day>07</day><month>6</month><year>2018</year></date><date date-type="accepted"><day>11</day><month>10</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2018 Stek, Allwood, Walker, Wilkinson, Lynen and Meintjes.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder>Stek, Allwood, Walker, Wilkinson, Lynen and Meintjes</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><p>Impaired lung function is common in people with a history of tuberculosis. Host-directed therapy added to tuberculosis treatment may reduce lung damage and result in improved lung function. An understanding of the pathogenesis of pulmonary damage in TB is fundamental to successfully predicting which interventions could be beneficial. In this review, we describe the different features of TB immunopathology that lead to impaired lung function, namely cavities, bronchiectasis, and fibrosis. We discuss the immunological processes that cause lung damage, focusing on studies performed in humans, and using chest radiograph abnormalities as a marker for pulmonary damage. We highlight the roles of matrix metalloproteinases, neutrophils, eicosanoids and cytokines, like tumor necrosis factor-&#x003b1; and interleukin 1&#x003b2;, as well as the role of HIV co-infection. Finally, we focus on various existing drugs that affect one or more of the immunological mediators of lung damage and could therefore play a role as host-directed therapy.</p></abstract><kwd-group><kwd>tuberculosis</kwd><kwd>lung damage</kwd><kwd>host-directed therapy</kwd><kwd>cavity</kwd><kwd>pulmonary function</kwd><kwd>matrix metalloproteinase</kwd><kwd>neutrophils</kwd><kwd>immune mechanisms</kwd></kwd-group><counts><fig-count count="2"/><table-count count="1"/><equation-count count="0"/><ref-count count="202"/><page-count count="16"/><word-count count="0"/></counts></article-meta></front><body><sec><title>Introduction</title><p>In 2016, an estimated 10.4 million people developed tuberculosis (TB) worldwide. Although effective diagnosis and treatment saved about 53 million lives between 2000 and 2016, TB remains a major threat worldwide: 16% of TB cases die from the disease, corresponding to 1.7 million deaths in 2016 (<xref rid="B191" ref-type="bibr">World Health Organization, 2017</xref>). Among those who are cured successfully, residual pulmonary impairment is common. Various studies have looked at lung function in patients with a known history of TB; they found abnormal lung function in 34 &#x02013; 94% of patients, varying in severity from mild to severe (<xref rid="B190" ref-type="bibr">Willcox and Ferguson, 1989</xref>; <xref rid="B133" ref-type="bibr">Plit et al., 1998</xref>; <xref rid="B34" ref-type="bibr">de Valliere and Barker, 2004</xref>; <xref rid="B23" ref-type="bibr">Chung et al., 2011</xref>; <xref rid="B179" ref-type="bibr">Vecino et al., 2011</xref>; <xref rid="B2" ref-type="bibr">Akkara et al., 2013</xref>; <xref rid="B7" ref-type="bibr">Baez-Saldana et al., 2013</xref>; <xref rid="B136" ref-type="bibr">Ralph et al., 2013a</xref>; <xref rid="B33" ref-type="bibr">de la Mora et al., 2015</xref>; <xref rid="B121" ref-type="bibr">Nihues Sde et al., 2015</xref>; <xref rid="B94" ref-type="bibr">Manji et al., 2016</xref>). It results in considerable medical costs (<xref rid="B69" ref-type="bibr">Jordan et al., 2010</xref>) and decreased quality of life (<xref rid="B136" ref-type="bibr">Ralph et al., 2013a</xref>; <xref rid="B33" ref-type="bibr">de la Mora et al., 2015</xref>).</p><p>Impaired lung function is associated with chest radiograph (CXR) abnormalities in most of the studies. It can easily be measured using spirometry, which measures air volumes and airflow rates of the lung. Forced vital capacity (FVC) is the maximal volume of air exhaled by a patient from the position of maximal inspiration, by means of a rapid, maximally forced expiration; forced expiratory volume in 1 s (FEV1) is the amount of air exhaled during the first second of the FVC maneuver. The nature and severity of pulmonary impairment can be categorized by combining these two measurements: obstruction is defined as a FEV1/FVC ratio &#x0003c; 70%, restriction is suggested by a low FVC (&#x0003c;80% of the predicted value). Obstruction, low FVC, and mixed defects have all been reported in patients with previous TB.</p></sec><sec><title>Purpose of Review</title><p>The aim of TB treatment is to kill the causative mycobacteria with anti-mycobacterial agents. Because of the lengthy duration of the treatment, the possibilities of drug toxicity, and increasing drug resistance, host-directed therapies (HDT), have gained attention (<xref rid="B61" ref-type="bibr">Hawn et al., 2013</xref>; <xref rid="B186" ref-type="bibr">Wallis and Hafner, 2015</xref>; <xref rid="B202" ref-type="bibr">Zumla et al., 2015</xref>). HDTs are agents that can augment host defense mechanisms, modulate excessive inflammation or both, by manipulating the hosts response to a pathogen rather than targeting the pathogen itself. This may lead to improved clinical treatment outcomes such as reduced morbidity, mortality, and end-organ damage, and long-term functional recovery. Supplementing anti-TB treatment with drugs that reduce pulmonary damage could result in improved pulmonary function. To predict which interventions could be beneficial, an understanding of the pathogenesis of pulmonary damage in TB is important. What are the immunological processes leading to lung damage in humans? Where and how in the process could we intervene to prevent or reduce lung damage? How much damage is already done at diagnosis and how much still occurs during treatment?</p></sec><sec><title>What Does Pulmonary Damage in Human TB Look Like?</title><p>The established paradigm positions the caseating granuloma as the characteristic lesion of TB. However, this paradigm originates from animal studies in the late 20th century, when data on histology of human TB had become rare. Studies done before the 1950s describe two characteristic presentations in human pulmonary TB: the caseous granuloma and the tuberculous pneumonia. They divide lung pathology into primary and post-primary TB. Primary TB is the infection that occurs when people first encounter <italic>Mycobacterium tuberculosis (Mtb).</italic> Post-primary TB occurs later, as a result of reactivation of latent TB or reinfection, and causes the majority of clinical TB (<xref rid="B66" ref-type="bibr">Hunter, 2011</xref>). The two differ with regard to their location in the lung, the host immune response and their histopathology. Primary TB typically occurs mainly in the lower zones of the lung. It is usually self-limiting but leads to consolidative pneumonia or lymphadenitis in a small proportion of individuals. It is characterized by a greater bacillary load and reduced lipid accumulation in the alveoli and the interstitium compared to post-primary TB, as well as an acute inflammatory response; cavitation however, is rare. Post-primary TB is said to develop mainly in the apices of the lung. It is characterized by obstructive pneumonia, which is frequently asymptomatic in its early stages. Endobronchial spread from the small peripheral airways can lead to necrotic caseous pneumonia, associated with progressive tissue necrosis and cavity formation or fibrocaseous disease (<xref rid="B85" ref-type="bibr">Long et al., 1998</xref>; <xref rid="B67" ref-type="bibr">Hunter, 2016</xref>). TB typically heals with persisting cavities, scarring, and pleural adhesions, as observed in autopsies of persons with previous TB who died of other causes (<xref rid="B172" ref-type="bibr">Theegarten et al., 2006</xref>). However, abnormal findings need not be present and viable TB can be found in both macroscopically normal and abnormal appearing lung tissue (<xref rid="B76" ref-type="bibr">Kuhne and Willgeroth, 1988</xref>).</p><p>Chest radiographs are commonly used to visualize pulmonary damage. Radiologists distinguish primary and post-primary TB as the two typical patterns in active TB. Primary TB is characterized by lymphadenopathy and air space consolidation often in the middle or lower lobes, with or without an accompanying pleural effusion. Post-primary TB consists of consolidation and/or nodules, frequently in the upper lobes or apices of the lower lobes, with or without cavitation (<xref rid="B114" ref-type="bibr">Nachiappan et al., 2017</xref>). CXRs of people with previous TB show abnormalities in 14&#x02013;100%, including fibrosis, bronchiectasis, and persisting cavities, the latter occurring more often in re-treatment patients or those with multi-drug resistant TB (<xref rid="B103" ref-type="bibr">Meghji et al., 2016</xref>). All these abnormalities are associated with impaired lung function.</p><p>Computed tomography (CT) scans are more sensitive than CXRs, especially for imaging of centrilobular small nodules or the so-called tree-in-bud sign; these classical features of early endobronchial spread of TB are often underestimated on a CXR (<xref rid="B160" ref-type="bibr">Skoura et al., 2015</xref>); [<sup>18</sup>F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) with CT combines anatomic imaging with imaging of metabolic activity of lesions. It has been used in TB to follow the evolution of lung lesions during treatment (<xref rid="B98" ref-type="bibr">Martinez et al., 2012</xref>; <xref rid="B92" ref-type="bibr">Malherbe et al., 2016</xref>) and, importantly, has shown that metabolically active lung lesions may be present before the onset of clinical disease (<xref rid="B46" ref-type="bibr">Esmail et al., 2016</xref>), and persist after treatment completion (<xref rid="B92" ref-type="bibr">Malherbe et al., 2016</xref>).</p></sec><sec><title>What Happens After Mtb Enters the Lung?</title><p>After <italic>Mtb</italic> enters the lung, the bacilli are taken up by alveolar macrophages, dendritic cells, and neutrophils, or occasionally epithelial cells; the latter possibly resulting in limited early bacterial growth. Infected cells start producing and secreting antimicrobial peptides, cytokines (like interleukin (IL)-1&#x003b2;, tumor necrosis factor (TNF)-&#x003b1;, IL-12, and IL-6) and chemokines. Other immune cells and permissive macrophages are attracted to the site of infection (<xref rid="B123" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>). <italic>Mtb</italic> itself, using multiple strategies, directs the recruitment of macrophages and triggers granuloma formation (<xref rid="B120" ref-type="bibr">Ndlovu and Marakalala, 2016</xref>). Secondary granulomas are formed by infected macrophages departing the primary granuloma or when a granuloma ruptures. While <italic>Mtb</italic> replicates freely in the macrophages, dendritic cells migrate to the local lymph nodes, to activate T cells. The arrival of <italic>Mtb</italic> specific T-cells in the lung usually does not happen until 14&#x02013;21 days after initiation of the infection (<xref rid="B52" ref-type="bibr">Gallegos et al., 2008</xref>). Their production of TNF-&#x003b1; and interferon-&#x003b3; (IFN-&#x003b3;) stimulates killing activities by macrophages. Moreover, T-cells complete granuloma formation by forming the lymphocytic cuff surrounding it (<xref rid="B123" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>).</p><p>The balance between the eicosanoids prostaglandin E2 (PGE2) and lipoxin A4 (LXA4) affects the mode of death of infected macrophages. LXA4 promotes macrophage necrosis, resulting in cell lysis of the macrophage, thereby allowing <italic>Mtb</italic> to escape and spread to neighboring cells. PGE2 stimulates apoptosis, leaving the macrophage plasma membrane intact, containing the bacilli, and enhancing immunity (<xref rid="B20" ref-type="bibr">Chen et al., 2008</xref>). Leukotriene (LT) B4, through regulation of TNF-&#x003b1; production (<xref rid="B173" ref-type="bibr">Tobin et al., 2012</xref>) and possibly attraction of neutrophils (<xref rid="B80" ref-type="bibr">Lammermann et al., 2013</xref>), is also involved, with both high and low levels of LTB4 inducing macrophage necrosis (<xref rid="B173" ref-type="bibr">Tobin et al., 2012</xref>).</p><p>In only 10% of individuals, progressive primary disease occurs; in the remaining 90% the initial infection is contained and latent infection is established (<xref rid="B123" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>). Current thinking views active and latent TB on a spectrum of tuberculosis disease, rather than as two distinct disease states as historically classified. (<xref rid="B9" ref-type="bibr">Barry et al., 2009</xref>).</p></sec><sec><title>Granulomas</title><p>Most human granulomas are composed of a center of infected macrophages, with the ability to differentiate, for example into epithelioid cells, multi-nucleated giant cells, and foamy macrophages. An outer layer of lymphocytes surrounds these cells, and many other cells, including neutrophils, dendritic cells, natural killer (NK) cells and fibroblasts may form part of the granuloma. The granuloma contains the mycobacteria, preventing their spread, but at the same time serves as a site of replication and persistence for <italic>Mtb</italic> (<xref rid="B120" ref-type="bibr">Ndlovu and Marakalala, 2016</xref>). Different types of granuloma exist: cellular, suppurative, fibrotic, or caseous (<xref rid="B18" ref-type="bibr">Canetti, 1955</xref>). Caseous necrosis occurs when cells within the granuloma undergo necrosis (<xref rid="B123" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>); alternatively, it has been suggested that &#x02013; in post-primary TB - granulomas form in response to existing areas of necrotic caseous pneumonia (<xref rid="B67" ref-type="bibr">Hunter, 2016</xref>). Caseous necrosis happens in conjunction with extracellular matrix (ECM) destruction. In the classical paradigm, tissue destruction occurs as a result of caseous necrosis (<xref rid="B123" ref-type="bibr">O&#x02019;Garra et al., 2013</xref>). However, an alternative theory proposes that collagen destruction precedes caseation and, therefore, ECM destruction is the initial pathological event (<xref rid="B3" ref-type="bibr">Al Shammari et al., 2015</xref>).</p><p>Diverse types of granulomas can be present in one lung at the same time, ranging from small cellular granulomas to multiple caseous granulomas that coalesce and expel their contents to form large cavities; they behave independently of each other, and different immunologic profiles exist between (<xref rid="B177" ref-type="bibr">Ulrichs et al., 2005</xref>; <xref rid="B167" ref-type="bibr">Subbian et al., 2015</xref>) and within (<xref rid="B95" ref-type="bibr">Marakalala et al., 2016</xref>) granulomas. Granulomas can be stable, or either resolve or progress. Clinically, the behavior of a few or even a single poorly controlled granuloma can determine the outcome of the disease on a host level (<xref rid="B49" ref-type="bibr">Flynn, 2018</xref>).</p></sec><sec><title>Cavities, Bronchiectasis and Fibrosis</title><p>The lung consists of both cellular and extracellular components. The ECM is comprised of the interstitial connective tissue matrix, which forms the parenchyma of the lung, surrounding cells and providing structural scaffolding, and the basement membrane, which separates the alveolar epithelium or endothelium from the surrounding stroma. Support of the alveoli by the ECM is needed for normal lung function; destruction or abnormal remodeling of the ECM occurs in many pulmonary diseases and leads to pulmonary impairment (<xref rid="B44" ref-type="bibr">Elkington and Friedland, 2006</xref>). The ECM of the lung is mainly made up of type I collagen and elastin. Type III and IV collagen are important components of the alveolar wall and basement membrane. Large fibers are connected by smaller fibrils. Dissemination of mycobacteria from the lung parenchyma into the airways as well as formation of cavities requires destruction of the ECM through cleavage of both small fibrils and large fibers. Collagens, however, are highly resistant to cleavage by proteolytic enzymes; only matrix metalloproteinases (MMPs) are capable of completely degrading the ECM (<xref rid="B44" ref-type="bibr">Elkington and Friedland, 2006</xref>). Consequently, MMPs play an important role in the development of cavities, bronchiectasis as well as fibrosis.</p><p>The development of cavities in TB has been studied extensively in rabbits, using <italic>Mycobacterium bovis</italic>. In these studies, cavities developed from liquefied caseating granulomas, that contained large numbers of actively growing bacteria. Bacteria release high amounts of tuberculin-like products causing a tissue-damaging delayed-type hypersensitivity reaction (<xref rid="B31" ref-type="bibr">Dannenberg, 2006</xref>). This T-cell mediated immune reaction is important; cavities developed mainly in pre-sensitized rabbits and desensitization or immune suppression could prevent cavity formation (<xref rid="B197" ref-type="bibr">Yamamura et al., 1968</xref>; <xref rid="B196" ref-type="bibr">Yamamura et al., 1974</xref>). Cavities are formed when expanding granulomas ruptures their caseous contents into a bronchus (<xref rid="B31" ref-type="bibr">Dannenberg, 2006</xref>).</p><p>Histologic studies in humans show a different picture of cavity formation that challenges the paradigm described in rabbits (<xref rid="B67" ref-type="bibr">Hunter, 2016</xref>): cavities do not develop from liquefied caseating granulomas, but from a caseous pneumonia. Host lipids and mycobacterial antigens accumulate in the alveoli, but only small numbers of bacteria are present. Similar to the rabbit model, sudden necrosis related to a delayed-type hypersensitivity reaction against mycobacterial antigens occurs (<xref rid="B67" ref-type="bibr">Hunter, 2016</xref>). However, an alternative yet controversial theory, based on the small numbers of bacteria observed and several observations related to autoimmunity seen in patients with TB, proposes a role for autoimmunity: mycobacteria induce inappropriate host responses to self-antigens, causing autoimmune inflammation (<xref rid="B43" ref-type="bibr">Elkington et al., 2016</xref>). A considerable overlap in gene expression signatures between TB and autoimmune diseases, greater than seen with other infectious diseases, supports this theory (<xref rid="B24" ref-type="bibr">Clayton et al., 2017</xref>).</p><p>The lipid-rich necrotic material in granulomas does not have the enzymatic activity to degrade collagen and consequently, its build-up is only one component of cavity formation. Extracellular matrix breakdown takes place and involves MMPs. Indeed, increased concentrations of MMPs have been found in TB cavities in rabbits (<xref rid="B75" ref-type="bibr">Kubler et al., 2015</xref>) and in humans (<xref rid="B145" ref-type="bibr">Sakamoto et al., 2013</xref>; <xref rid="B124" ref-type="bibr">Ong et al., 2015</xref>). Neutrophils have also been found in cavities (<xref rid="B124" ref-type="bibr">Ong et al., 2015</xref>).</p><p>Bronchiectasis, an irreversible dilatation of the bronchi, is caused by an ongoing inflammatory process (like TB), which results in damage to the airway epithelium, leading to an inability to clear secretions, as well as destruction of the elastin in the airway walls (<xref rid="B109" ref-type="bibr">Milliron et al., 2015</xref>). Similar to cavity formation, MMPs have been implicated in the development of bronchiectasis, with increased levels being found in sputum, bronchoalveolar lavage fluid (BALF), and the lamina propria of patients with bronchiectasis (<xref rid="B153" ref-type="bibr">Sepper et al., 1995</xref>; <xref rid="B201" ref-type="bibr">Zheng et al., 2002</xref>; <xref rid="B56" ref-type="bibr">Guan et al., 2015</xref>). Neutrophils, together with macrophages and T-cells, are the dominant cell type in bronchiectatic inflammation (<xref rid="B74" ref-type="bibr">King, 2009</xref>). Alternatively, traction bronchiectasis can occur, secondary to scarring of the adjacent parenchyma or narrowing of more proximal bronchi (<xref rid="B109" ref-type="bibr">Milliron et al., 2015</xref>).</p><p>Fibrosis results from the excessive deposition of components of the ECM such as collagen and fibronectin in and around inflamed or damaged tissue by myofibroblasts. Its pathogenesis is complicated (<xref rid="B194" ref-type="bibr">Wynn and Ramalingam, 2012</xref>), with many innate and adaptive immune cells and cytokines playing a role. Transforming growth factor (TGF-&#x003b2;), produced by macrophages, lung epithelial cells, and fibroblasts, is one of the key players (<xref rid="B194" ref-type="bibr">Wynn and Ramalingam, 2012</xref>) and indeed, higher levels of TGF-&#x003b2; in serum and BALF correlate with an increase in fibrosis seen on high-resolution CT scan in patients with TB 6 months after the start of treatment (<xref rid="B4" ref-type="bibr">Ameglio et al., 2005</xref>). TNF-&#x003b1;, IL-&#x003b2;, and IL-17-induced neutrophil recruitment also seems to play a crucial role in the development of fibrosis (<xref rid="B194" ref-type="bibr">Wynn and Ramalingam, 2012</xref>). MMPs appear to be involved: some MMPs reduce fibrosis, but others &#x02013; perhaps counterintuitively &#x02013; promote it (<xref rid="B54" ref-type="bibr">Giannandrea and Parks, 2014</xref>). In a Taiwanese study, patients with an <italic>MMP-1 (-1607G)</italic> gene polymorphism, leading to excessive MMP-1 production, were more likely to have moderate to advanced fibrosis on CXR 1 year after completion of TB treatment (<xref rid="B189" ref-type="bibr">Wang et al., 2010</xref>).</p></sec><sec><title>What Are the Immunological Mediators and Processes Leading to Lung Damage?</title><p>Much of our recent knowledge of immunological processes in TB comes from animal models. Mice, rabbits, guinea pigs, and zebra-fish have all been used to study TB. However, none of these models completely replicate the immunopathology seen in human TB. More recently, non-human primates have also been used, exhibiting a spectrum of pathology closely resembling TB in humans (<xref rid="B50" ref-type="bibr">Flynn et al., 2015</xref>).</p><p>For this review, we included studies done in humans, where serum and BALF markers are commonly used to assess the immunological processes in the lung. Serum measurements reflect systemic responses and do not represent what happens in individual granulomas, as was shown by a difference in gene expression patterns between granuloma and blood (<xref rid="B167" ref-type="bibr">Subbian et al., 2015</xref>). BALF more closely reflects responses taking place in the lung, however, even BALF only reflects processes taking place in the airways and not necessarily those in the lung parenchyma. Histology is the only way to assess the immunological processes occurring within a granuloma; however, histological samples are more difficult to obtain and, therefore, most study findings in humans are built on assumptions using available body fluid. Studies that do include histological samples cannot present longitudinal data.</p><p>When conducting our review, we searched for studies that assessed inflammatory mediators, and associated them with radiological abnormalities as a marker for pulmonary damage (Figure <xref ref-type="fig" rid="F1">1</xref>).</p><fig id="F1" position="float"><label>FIGURE 1</label><caption><p>Mediators of lung damage in TB and interplay with [lightning flash cartoon], virulent <italic>Mtb;</italic> COX, cyclooxygenase; IFN-I, type I interferon; IFN-&#x003b3;, interferon gamma; IL, interleukin; LOX, lipoxygenase; LT, leukotriene; LTA4H, leukotriene A4 hydrolase; LX, lipoxin; m&#x003c6;, macrophage; MMP, matrix metalloproteinase; Mtb, mycobacterium tuberculosis; neu, neutrophil recruitment; NO, nitric oxide; PGE2, prostaglandin E2; TNF, tumor necrosis factor. NO inhibits assembly of the NLRP3 inflammasome (<xref rid="B112" ref-type="bibr">Mishra et al., 2013</xref>).</p></caption><graphic xlink:href="fmicb-09-02603-g001"/></fig></sec><sec><title>Matrix Metalloproteinases</title><p>There are 23 MMPs in humans. They can be secreted by a variety of cells, including macrophages/monocytes, neutrophils, and lung epithelial cells. Their generation is tightly regulated. They are not stored requiring gene transcription immediately before secretion; exceptions being MMP-8 and -9 stored in neutrophils. Once activated, they are regulated by endogenous inhibitors, called tissue inhibitors of metalloproteinases (TIMPs). Expression of MMPs is increased by prostaglandin and several cytokines (including IL-1&#x003b2;, IL-17 (<xref rid="B158" ref-type="bibr">Singh et al., 2018</xref>), TNF-&#x003b1;, and IFN-&#x003b3;) (<xref rid="B42" ref-type="bibr">Elkington P.T. et al., 2011</xref>); hypoxic conditions, present in TB lesions, also increase expression and secretion of MMP-1 through the induction of hypoxia-inducible factor 1&#x003b1; (<xref rid="B11" ref-type="bibr">Belton et al., 2016</xref>). A recent study has demonstrated a role for platelets in MMP-1 upregulation in <italic>Mtb-</italic>infected monocytes, in addition to upregulation of IL-1&#x003b2; and IL-10 (<xref rid="B51" ref-type="bibr">Fox et al., 2018</xref>).</p><p>As described above, degradation of collagens and elastins by MMPs during active TB leads to the formation of cavities. Strong evidence of the role of MMPs in lung damage comes from studies in transgenic mice expressing human MMP-1. Wildtype mice do not express the ortholog of MMP-1 in lung and do not develop caseous necrosis or cavities in response to <italic>Mtb</italic>; in human MMP-1 transgenic mice, however, infection with TB leads to collagen destruction and caseous necrosis (<xref rid="B41" ref-type="bibr">Elkington P. et al., 2011</xref>; <xref rid="B3" ref-type="bibr">Al Shammari et al., 2015</xref>). MMPs also play a role in granuloma formation (<xref rid="B128" ref-type="bibr">Parasa et al., 2017</xref>).</p><p>Several MMPs are upregulated in blood, sputum, and BALF of patients with active TB, primarily MMP-1, -3, -7, -8, and -9 (<xref rid="B42" ref-type="bibr">Elkington P.T. et al., 2011</xref>). MMP-1 is the dominant collagenase in TB (<xref rid="B41" ref-type="bibr">Elkington P. et al., 2011</xref>); its secretion is driven by <italic>Mtb</italic> directly by activation of multiple intracellular signaling pathways and by intercellular networks (<xref rid="B125" ref-type="bibr">Ong et al., 2014</xref>). Corresponding TIMPs are not similarly upregulated by <italic>Mtb</italic>, leading to a matrix-degrading phenotype in TB (<xref rid="B134" ref-type="bibr">Price et al., 2001</xref>). In a zebrafish model, using <italic>M. marinum</italic> to study granuloma formation, mycobacterial-derived ESAT-6 induced MMP-9 secretion, enhancing monocyte recruitment to granulomas (<xref rid="B171" ref-type="bibr">Taylor et al., 2006</xref>; <xref rid="B182" ref-type="bibr">Volkman et al., 2010</xref>).</p><p>Increased levels of MMPs correlate with pulmonary damage: sputum levels of MMP-1, -2, and -8 were elevated in patients with cavities and correlated positively with the extent of infiltrates on CXR (<xref rid="B183" ref-type="bibr">Walker et al., 2012</xref>; <xref rid="B124" ref-type="bibr">Ong et al., 2015</xref>). Similarly, sputum levels of membrane type-1 MMP (a membrane-bound collagenase expressed on monocytes), plasma concentrations of procollagen III N-terminal propeptide (PIIINP, a degradation product of collagen type III), BALF levels of MMP-3, -7, and -8, and serum concentrations of MMP- 1, -8, and -9, correlated with more extensive CXR abnormalities in patients with TB from several different countries (<xref rid="B64" ref-type="bibr">Hrabec et al., 2002</xref>; <xref rid="B152" ref-type="bibr">Seddon et al., 2013</xref>; <xref rid="B156" ref-type="bibr">Singh et al., 2014a</xref>; <xref rid="B148" ref-type="bibr">Sathyamoorthy et al., 2015</xref>; <xref rid="B155" ref-type="bibr">Sigal et al., 2017</xref>). These findings suggest a central role for MMPs and extracellular matrix degradation in the development of lung damage in TB.</p></sec><sec><title>Neutrophils</title><p>Neutrophils are abundant in the airways of humans with active TB (<xref rid="B47" ref-type="bibr">Eum et al., 2010</xref>). Their role in TB appears dichotomous: high numbers of neutrophils in the blood at the time of exposure are associated with lower likelihood of infection (<xref rid="B96" ref-type="bibr">Martineau et al., 2007</xref>). Conversely later in TB their numbers in blood were associated with worse patient outcomes (<xref rid="B8" ref-type="bibr">Barnes et al., 1988</xref>; <xref rid="B86" ref-type="bibr">Lowe et al., 2013</xref>). Various soluble mediators (amongst others Il-1&#x003b2;, IL-8, IL-17, PGE2, LTB4, and granulocyte colony-stimulating factor) promote neutrophil recruitment (<xref rid="B88" ref-type="bibr">Lowe et al., 2012</xref>); others, like IFN-&#x003b3; and nitric oxide (NO), reduce neutrophil recruitment and survival, partly via inhibition of IL-17 (<xref rid="B118" ref-type="bibr">Nandi and Behar, 2011</xref>), IL-1&#x003b2; and 12-lipooxygenase (12-LOX) (<xref rid="B111" ref-type="bibr">Mishra et al., 2017</xref>).</p><p>At the time of presentation with active TB, neutrophils are associated with lung damage: a neutrophil-driven, IFN-inducible whole-blood transcript signature (<xref rid="B13" ref-type="bibr">Berry et al., 2010</xref>), higher blood (<xref rid="B1" ref-type="bibr">Abakay et al., 2015</xref>; <xref rid="B127" ref-type="bibr">Panteleev et al., 2017</xref>) and BALF (<xref rid="B122" ref-type="bibr">Nolan et al., 2013</xref>) neutrophil counts, and higher serum levels of S100 proteins (a protein produced by neutrophils, promoting their own recruitment) (<xref rid="B55" ref-type="bibr">Gopal et al., 2013</xref>; <xref rid="B12" ref-type="bibr">Berrocal-Almanza et al., 2016</xref>) in patients with active TB all relate with the extent of lung radiographic disease. Lung damage is thought to be contributed to by their indiscriminate killing mechanisms, which can result in significant bystander damage to surrounding host tissue. Moreover, neutrophils are the only cells that store MMPs (<xref rid="B124" ref-type="bibr">Ong et al., 2015</xref>), while they do not synthesize TIMPs, thus allowing for unrestrained effects of MMPs (<xref rid="B99" ref-type="bibr">Masure et al., 1991</xref>). Removing infected or dying neutrophils is necessary to protect the surrounding tissue. Removal of apoptotic neutrophils by macrophages promotes subsequent killing of <italic>Mtb</italic>, whereas removal of necrotic neutrophils allows for mycobacterial survival and proliferation inside the macrophages. <italic>Mtb</italic> drives neutrophil necrosis, a process that requires neutrophil-derived reactive oxygen species (ROS) (<xref rid="B30" ref-type="bibr">Dallenga et al., 2017b</xref>). Inhibition of ROS-production could restore growth control of <italic>Mtb</italic> by macrophages (<xref rid="B29" ref-type="bibr">Dallenga et al., 2017a</xref>).</p></sec><sec><title>Eicosanoids</title><p>The eicosanoids PGE2, LXA4, and LTB4 are all metabolites of arachidonic acid (AA). Cyclooxygenase (COX) converts AA into PGE2, while 5-lipooxygenase (5-LOX) generates LTA4, which is again converted into either LXA4 by 12-LOX, or LTB4 by leukotriene A4 hydrolase (LTA4H) (<xref rid="B36" ref-type="bibr">Dietzold et al., 2015</xref>). As mentioned previously, the balance between these eicosanoids influences the mechanism of macrophage death (<xref rid="B20" ref-type="bibr">Chen et al., 2008</xref>). Macrophage apoptosis leads to an early immune response with better control of the infection and minimal immunopathology, while macrophage necrosis leads to a delayed immune response, inadequate control of infection and greater immunopathology (<xref rid="B37" ref-type="bibr">Divangahi et al., 2013</xref>). Virulent strains of <italic>Mtb</italic> promote LXA4 production, thereby stimulating necrosis and mycobacterial spread (<xref rid="B20" ref-type="bibr">Chen et al., 2008</xref>). To our knowledge, no studies have correlated PGE2 or LXA4 with pulmonary function in human TB; one can speculate that tipping the eicosanoid-balance toward PGE2 may result in less lung damage. Findings in mice and latent TB in humans, however, show that levels of PGE2 were low early in the infection and increased later in and during active TB (<xref rid="B139" ref-type="bibr">Rangel Moreno et al., 2002</xref>; <xref rid="B154" ref-type="bibr">Shu et al., 2013</xref>; <xref rid="B101" ref-type="bibr">Mayer-Barber et al., 2014</xref>; <xref rid="B82" ref-type="bibr">Lee et al., 2015</xref>). This underlines the complex and poorly elucidated role of PGE2 in TB infection and may even suggest a changing role for PGE2 during the course of the disease. LTB4, which is generated by LTA4H, has been correlated with severity of TB on CXRs in one study (<xref rid="B40" ref-type="bibr">el-Ahmady et al., 1997</xref>).</p></sec><sec><title>Cytokines</title><p>Various studies have assessed the association between cytokines (including IFN&#x02013;y and TNF&#x02013;&#x003b1;, and several pro- and anti-inflammatory interleukins) and CXR abnormalities in TB (<xref rid="B38" ref-type="bibr">Dlugovitzky et al., 1997</xref>; <xref rid="B163" ref-type="bibr">Sodhi et al., 1997</xref>; <xref rid="B19" ref-type="bibr">Casarini et al., 1999</xref>; <xref rid="B174" ref-type="bibr">Tsao et al., 1999</xref>, <xref rid="B175" ref-type="bibr">2000</xref>, <xref rid="B176" ref-type="bibr">2002</xref>; <xref rid="B178" ref-type="bibr">van Crevel et al., 2000</xref>; <xref rid="B102" ref-type="bibr">Mazzarella et al., 2003</xref>; <xref rid="B4" ref-type="bibr">Ameglio et al., 2005</xref>; <xref rid="B193" ref-type="bibr">Wu et al., 2007</xref>; <xref rid="B13" ref-type="bibr">Berry et al., 2010</xref>; <xref rid="B166" ref-type="bibr">Su et al., 2010</xref>; <xref rid="B183" ref-type="bibr">Walker et al., 2012</xref>; <xref rid="B122" ref-type="bibr">Nolan et al., 2013</xref>; <xref rid="B22" ref-type="bibr">Chowdhury et al., 2014</xref>; <xref rid="B48" ref-type="bibr">Fan et al., 2015</xref>; <xref rid="B155" ref-type="bibr">Sigal et al., 2017</xref>). The different measuring methods used and the fact that several cytokines are not limited to a single effector function make comparison and interpretation challenging.</p><p>Only TNF-&#x003b1; and IL-1&#x003b2; in both blood and BALF seem to unambiguously correlate with CXR abnormalities. Higher levels of TNF-&#x003b1; and IL-1&#x003b2; correlate with the presence or size of cavities (<xref rid="B175" ref-type="bibr">Tsao et al., 2000</xref>; <xref rid="B4" ref-type="bibr">Ameglio et al., 2005</xref>; <xref rid="B22" ref-type="bibr">Chowdhury et al., 2014</xref>; <xref rid="B155" ref-type="bibr">Sigal et al., 2017</xref>) and with the extent of pulmonary involvement (<xref rid="B19" ref-type="bibr">Casarini et al., 1999</xref>; <xref rid="B183" ref-type="bibr">Walker et al., 2012</xref>). Moreover, lower levels of these cytokines were found in patients with an early radiological response to TB treatment (improved CXR after 2 months of treatment) compared to those with a later (at 6 months) response (<xref rid="B166" ref-type="bibr">Su et al., 2010</xref>). In animal models, the effect of TNF-&#x003b1; seems to be dose dependent, where both high and low doses lead to tissue destruction (<xref rid="B10" ref-type="bibr">Bekker et al., 2000</xref>; <xref rid="B173" ref-type="bibr">Tobin et al., 2012</xref>). LTA4H polymorphism, and subsequently eicosanoid patterns, play a role in its regulation (<xref rid="B173" ref-type="bibr">Tobin et al., 2012</xref>). Both TNF-&#x003b1; and IL-1&#x003b2; affect secretion of MMPs and MMPs in their turn can play a role in the release, activation or inactivation of TNF-&#x003b1; and IL-1&#x003b2; (<xref rid="B44" ref-type="bibr">Elkington and Friedland, 2006</xref>). IL-1&#x003b2; also associates with activation of fibroblasts (<xref rid="B16" ref-type="bibr">Borthwick, 2016</xref>) and the recruitment of neutrophils (<xref rid="B88" ref-type="bibr">Lowe et al., 2012</xref>; <xref rid="B111" ref-type="bibr">Mishra et al., 2017</xref>), which all associate with lung damage.</p></sec><sec><title>Autophagy</title><p>Autophagy is an intracellular self-digestion process: cytosolic material is engulfed by a double-membrane vesicle called the autophagosome, that delivers it to lysosomes for degradation and subsequently releases the degraded products back to the cytosol. Autophagy can be used by the host to eliminate intracellular pathogens and plays an important role in defense against <italic>Mtb</italic> (<xref rid="B59" ref-type="bibr">Gutierrez et al., 2004</xref>); both IFN-&#x003b3; and TNF-&#x003b1; can induce autophagy (<xref rid="B164" ref-type="bibr">Songane et al., 2012</xref>). It can also downregulate IL-1&#x003b2; production mediated through the inflammasome (an intracellular multiprotein complex that triggers formation of proinflammatory cytokines), by removing large inflammasome complexes or damaged mitochondria - which, through production of ROS, trigger the inflammasome (<xref rid="B140" ref-type="bibr">Rathinam et al., 2012</xref>). Virulent <italic>Mtb</italic> can inhibit autophagy (<xref rid="B57" ref-type="bibr">Gupta et al., 2016</xref>), subsequently leading to increased IL-1&#x003b2; production (<xref rid="B164" ref-type="bibr">Songane et al., 2012</xref>). It was found that patients infected by <italic>Mtb</italic> strains with poor <italic>in vitro</italic> autophagy-inducing ability displayed more severe radiographic extent of disease (<xref rid="B83" ref-type="bibr">Li et al., 2016</xref>). Consequently, inducing autophagy could limit lung damage.</p></sec><sec><title>The Modulating Role of HIV</title><p>Globally, 13 percent of people with active TB who know their HIV status are co-infected with HIV-1 (<xref rid="B191" ref-type="bibr">World Health Organization, 2017</xref>). Although TB is also a risk factor for airflow obstruction in patients with HIV (<xref rid="B147" ref-type="bibr">Samperiz et al., 2014</xref>; <xref rid="B131" ref-type="bibr">Pefura-Yone et al., 2015</xref>; <xref rid="B58" ref-type="bibr">Gupte et al., 2017</xref>), in HIV positive patients with a low CD4 count (CD4 &#x0003c; 200/mm<sup>3</sup>) TB often presents with atypical CXR findings or even normal CXRs, while cavitation is 4-fold less common (<xref rid="B77" ref-type="bibr">Kwan and Ernst, 2011</xref>). These findings suggest that TB-related pulmonary damage might be reduced in HIV co-infected patients and the host immune response, necessary for protection against TB, is required for the development of cavities. Indeed, several of the factors previously discussed and implicated in pulmonary damage, are affected by HIV co-infection. For example, sputum levels of MMP-1, -2, -8, and -9 are reduced in HIV-TB co-infected patients, compared to patients without HIV (<xref rid="B183" ref-type="bibr">Walker et al., 2012</xref>, <xref rid="B184" ref-type="bibr">2017</xref>) as is the activity and life span of neutrophils (<xref rid="B87" ref-type="bibr">Lowe et al., 2015</xref>). The effect of HIV co-infection on the levels of several of the other cytokines is variable across studies and thus it is difficult to interpret a clear trend (<xref rid="B200" ref-type="bibr">Zhang et al., 1994</xref>; <xref rid="B45" ref-type="bibr">Elliott et al., 1999</xref>; <xref rid="B32" ref-type="bibr">de Castro Cunha et al., 2005</xref>; <xref rid="B143" ref-type="bibr">Riou et al., 2012</xref>; <xref rid="B183" ref-type="bibr">Walker et al., 2012</xref>; <xref rid="B108" ref-type="bibr">Mihret et al., 2014</xref>; <xref rid="B72" ref-type="bibr">Kassa et al., 2016</xref>).</p><p>Paradoxical TB-associated immune reconstitution inflammatory syndrome (TB-IRIS) develops in approximately 18% (95% CI 16&#x02013;21%) of patients on treatment for HIV-associated TB, usually within the first few weeks after starting ART (<xref rid="B117" ref-type="bibr">Namale et al., 2015</xref>). It results in new or recurrent TB signs and symptoms, commonly involving the lungs, such as cough, chest pain, and worsening radiographic pulmonary infiltrates. TB-IRIS is associated with increased levels of several cytokines, particularly IL-6, TNF-&#x003b1; and IFN-&#x003b3; (<xref rid="B169" ref-type="bibr">Tadokera et al., 2011</xref>; <xref rid="B25" ref-type="bibr">Conesa-Botella et al., 2012</xref>; <xref rid="B79" ref-type="bibr">Lai et al., 2015</xref>; <xref rid="B142" ref-type="bibr">Ravimohan et al., 2015</xref>) and inflammasome activation (<xref rid="B79" ref-type="bibr">Lai et al., 2015</xref>). It results in increased neutrophil recruitment (<xref rid="B116" ref-type="bibr">Nakiwala et al., 2018</xref>), and up-regulation of MMP-1, -3, -7, -8, and -10 (<xref rid="B170" ref-type="bibr">Tadokera et al., 2014</xref>; <xref rid="B141" ref-type="bibr">Ravimohan et al., 2016</xref>; <xref rid="B184" ref-type="bibr">Walker et al., 2017</xref>). LT4AH also appears to play a role, as more severe TB-IRIS has been reported in patients with mutant (TT and CT) LTA4H genotypes (<xref rid="B119" ref-type="bibr">Narendran et al., 2016</xref>).</p><p>These findings suggest that TB-IRIS could result in pulmonary damage and impaired lung function. To date, only one study has explored the relationship between TB-IRIS and lung function in 14 patients with HIV-associated TB, 3 of whom developed TB-IRIS (<xref rid="B141" ref-type="bibr">Ravimohan et al., 2016</xref>). The study found that an increase in MMP-8 between baseline pre-ART and 4 weeks post-ART initiation strongly associated with impairment in lung function, but the small sample size limits definitive conclusions.</p></sec><sec><title>Where Can We Intervene to Prevent or Reduce Lung Damage?</title><p>There are several uncertain areas around therapies to prevent or limit lung damage in TB. Changes in the lungs start to develop before clinical symptoms appear (<xref rid="B46" ref-type="bibr">Esmail et al., 2016</xref>; <xref rid="B199" ref-type="bibr">Zak et al., 2016</xref>; <xref rid="B151" ref-type="bibr">Scriba et al., 2017</xref>), and therefore, a large proportion of lung damage may already have occurred by the time the patient presents; several mediators of lung damage may have different roles at different stages of the disease; granulomas in various stages can be present at the same time in a single individual, and only a single or a few progressive granulomas can determine the outcome of the disease. Therefore, it remains uncertain what happens for example to the contained granulomas if we systemically treat the patient with potentially immunosuppressive therapy or what the right time is to intervene (Figure <xref ref-type="fig" rid="F2">2</xref>).</p><fig id="F2" position="float"><label>FIGURE 2</label><caption><p>The potential effect of immune mediators on the development of lung damage at different stages of disease. G-CSF, granulocyte-colony stimulating factor; IL, interleukin; LTB4, leukotriene B4; LXA4, lipoxin A4; m&#x003c6;, macrophage; neutro, neutrophils; NO, nitric oxide; PGE2, prostaglandin E2; TNF, tumor necrosis factor.</p></caption><graphic xlink:href="fmicb-09-02603-g002"/></fig></sec><sec><title>Antituberculous Therapy as Host-Directed Therapy</title><p>Sputum <italic>Mtb</italic> load is associated with systemic inflammation and, combined with pre-treatment C-reactive protein levels, inversely correlates with CXR improvement 60 days after start of treatment (<xref rid="B107" ref-type="bibr">Mesquita et al., 2016</xref>). Time between first TB symptoms and start of treatment (<xref rid="B34" ref-type="bibr">de Valliere and Barker, 2004</xref>; <xref rid="B7" ref-type="bibr">Baez-Saldana et al., 2013</xref>), duration of treatment (<xref rid="B23" ref-type="bibr">Chung et al., 2011</xref>), and smear positivity (<xref rid="B23" ref-type="bibr">Chung et al., 2011</xref>) are associated with impaired pulmonary function, suggesting that prompt diagnosis and treatment will limit lung damage. In addition to a direct anti-mycobacterial effect, <italic>in vitro</italic> studies suggest that some antimycobacterial agents may have immunomodulatory action. Pyrazinamide directly reduces levels of TNF-&#x003b1;, IL-6 and IL-1&#x003b2; (<xref rid="B93" ref-type="bibr">Manca et al., 2013</xref>), quinolones downregulate MMP-1, -3, and -9 (<xref rid="B156" ref-type="bibr">Singh et al., 2014a</xref>), and rifampicin downregulates MMP-3 production by bronchial epithelial cells (<xref rid="B156" ref-type="bibr">Singh et al., 2014a</xref>) and inhibits PGE2 production (<xref rid="B198" ref-type="bibr">Yuhas et al., 2007</xref>). P-aminosalicylic acid (PAS), which is an aspirin derivate, suppresses PGE2-dependent MMP-1 production (<xref rid="B138" ref-type="bibr">Rand et al., 2009</xref>). Both isoniazid (INH) and pyrazinamide (PZA) enhance autophagy (<xref rid="B73" ref-type="bibr">Kim et al., 2012</xref>).</p></sec><sec><title>Medicines Used in Other Human Diseases as Host-Directed Therapy for TB</title><p>In an adjunctive approach to TB therapy, treatment could be supplemented with host-directed therapies. Several readily available drugs affect cytokines, MMPs or eicosanoids and therefore potentially reduce pulmonary damage (Table <xref rid="T1" ref-type="table">1</xref>).</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Host-directed therapies potentially inhibiting lung damage and/or promoting lung repair.</p></caption><table frame="hsides" rules="groups" cellspacing="5" cellpadding="5"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Host-directed inhibiting lung damage</th><th valign="top" align="left" rowspan="1" colspan="1">Potential mechanism</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Steroids</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; INF-&#x003b3;, TNF-&#x003b1;, IL-1&#x003b2; (and IL-6, IL-10, IL-12p40, and IP-10 in TB-IRIS)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; MMP-7 (in TB-IRIS)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Doxycycline</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; MMP-1, -3, and -9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vitamin D</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; MMP-7 and -9</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; IFN-&#x003b3;, IL-6, IL-10, TNF-&#x003b1;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02191; autophagy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Rapamycin, everolimus</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; MMP-1 and -3</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02191; autophagy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">NSAIDs</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; PGE2<sup>1</sup> and &#x02191; LXA4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zileuton</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; 5-LOX</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Phosphodiesterase-4 inhibitors</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; TNF-&#x003b1;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; neutrophil recruitment</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Metformin</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; TNF-&#x003b1;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">&#x02191; autophagy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Statins</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191; autophagy</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">TNF-&#x003b1; blockers</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02193; TNF-&#x003b1;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">PGE2</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191; PGE2<sup>1</sup></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">IFN-&#x003b3;</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02191; IFN-&#x003b3;</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Mesenchymal stromal cells</td><td valign="top" align="left" rowspan="1" colspan="1">Control inflammation and mediate tissue repair</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><attrib><italic><sup><italic>1</italic></sup>The effect of inhibiting or increasing PGE2 on lung damage could vary depending on the stage of the disease.</italic></attrib></table-wrap-foot></table-wrap><p><bold>Steroids</bold> have been used as adjunctive treatment in TB for several decades (<xref rid="B39" ref-type="bibr">Dooley et al., 1997</xref>; <xref rid="B28" ref-type="bibr">Critchley et al., 2013</xref>), mainly in TB meningitis, pericarditis, and TB-IRIS, even though corticosteroid use without concomitant TB treatment increases the risk of developing TB (<xref rid="B68" ref-type="bibr">Jick et al., 2006</xref>). Two recent reviews concluded that there is no high quality evidence that steroid treatment significantly affects mortality or sputum conversion rate in pulmonary TB (<xref rid="B27" ref-type="bibr">Critchley et al., 2014</xref>; <xref rid="B150" ref-type="bibr">Schutz et al., 2018</xref>). An earlier review &#x02013; including mostly studies done in the 1960s and patients not on rifampicin-based TB treatment &#x02013; did find a beneficial effect of steroids on radiographic resolution and regression of cavities (<xref rid="B162" ref-type="bibr">Smego and Ahmed, 2003</xref>). A meta-regression analysis of 12 studies found steroids do accelerate sputum TB culture conversion (<xref rid="B185" ref-type="bibr">Wallis, 2014</xref>) &#x02013; which is inversely associated with development of airflow obstruction (<xref rid="B135" ref-type="bibr">Radovic et al., 2016</xref>); however, high doses (134 mg prednisone daily) for an extended period (2 months) are required to reach clinically relevant outcomes (<xref rid="B185" ref-type="bibr">Wallis, 2014</xref>). Moreover, the only two studies in this analysis in which patients were on rifampicin-based treatment show contradicting results.</p><p>Corticosteroids inhibit various cytokines in TB (IFN-&#x003b3;, TNF-&#x003b1;, IL-1&#x003b2;) and TB-IRIS (IL-6, IL-10, IL-12p40, TNF-&#x003b1;, IFN-&#x003b3;, and IP-10) (<xref rid="B89" ref-type="bibr">Mahuad et al., 2004</xref>; <xref rid="B100" ref-type="bibr">Mayanja-Kizza et al., 2005</xref>; <xref rid="B104" ref-type="bibr">Meintjes et al., 2012</xref>; <xref rid="B15" ref-type="bibr">Bongiovanni et al., 2015</xref>). In patients with tuberculous meningitis, the effect of corticosteroids was found to be LTA4H genotype modulated, with only patients with the mutant TT genotype, leading to a higher inflammatory response, benefitting from steroid treatment (<xref rid="B173" ref-type="bibr">Tobin et al., 2012</xref>). In patients with TB-IRIS, however, this difference in genotype on the effect of steroid treatment was not confirmed (<xref rid="B119" ref-type="bibr">Narendran et al., 2016</xref>). The effect of corticosteroid treatment and TB-IRIS on pulmonary function is being assessed in a substudy of the PredART trial (<xref rid="B105" ref-type="bibr">Meintjes et al., 2017</xref>).</p><p>Little evidence is available for other <bold>TNF-&#x003b1; blocking therapies</bold>. A trial of 16 patients with HIV-associated TB treated with etanercept (but no ART) showed a tendency to greater CXR improvement from baseline to 6 months compared to a placebo group, although this was not statistically significant (<italic>p</italic> = 0.2) (<xref rid="B187" ref-type="bibr">Wallis et al., 2004</xref>). Case reports describe successful treatment of paradoxical TB reactions or TB-IRIS &#x02013; involving the pleura, lymph nodes or brain &#x02013; with infliximab (<xref rid="B14" ref-type="bibr">Blackmore et al., 2008</xref>; <xref rid="B70" ref-type="bibr">Jorge et al., 2012</xref>; <xref rid="B65" ref-type="bibr">Hsu et al., 2016</xref>), or adalimumab (<xref rid="B188" ref-type="bibr">Wallis et al., 2009</xref>; <xref rid="B81" ref-type="bibr">Lee et al., 2012</xref>). Although only one case refers to pulmonary TB-IRIS [occurring after interruption of prior anti-TNF-&#x003b1; treatment (<xref rid="B188" ref-type="bibr">Wallis et al., 2009</xref>)], these case reports support the possible benefits of TNF-&#x003b1; blockers in the treatment of (complicated) TB. Restarting TNF-&#x003b1; blockers during or after TB treatment was safe and only led to one recurrence of TB in a cohort of 22 patients in Turkey followed for a median of 53 months (<xref rid="B126" ref-type="bibr">Ozguler et al., 2016</xref>).</p><p>Doxycycline is the only licensed <bold>MMP-inhibitor</bold> for use in humans. It suppresses MMP-1, -3, and -9 secretion by <italic>Mtb</italic> infected human macrophages and bronchial epithelial cells (<xref rid="B183" ref-type="bibr">Walker et al., 2012</xref>). Other agents also inhibit MMPs <italic>in vitro</italic>: prednisone &#x02013; in patients with TB-IRIS &#x02013; suppresses MMP-7 gene expression (<xref rid="B170" ref-type="bibr">Tadokera et al., 2014</xref>), vitamin D inhibits secretion of MMP-7 and -9 (<xref rid="B5" ref-type="bibr">Anand and Selvaraj, 2009</xref>; <xref rid="B26" ref-type="bibr">Coussens et al., 2009</xref>), and <bold>rapamycin</bold> (an mTOR-inhibitor and a known autophagy inducer that can also affect macrophage polarization (<xref rid="B106" ref-type="bibr">Mercalli et al., 2013</xref>)) inhibits MMP-1 and MMP-3 (<xref rid="B157" ref-type="bibr">Singh et al., 2014b</xref>). Use of the latter in TB is limited by the interaction with rifampicin. In mice, broad spectrum inhibition of MMPs enhances the efficacy of INH and RIF treatment (<xref rid="B195" ref-type="bibr">Xu et al., 2018</xref>). Conceptually, inhibition of MMPs may lead to less pulmonary damage, but so far, no clinical trials have directly assessed this. Currently, everolimus, a rapamycin derivate, is being tested as HDT in patients with moderate to far advanced pulmonary tuberculosis (together with vitamin D, auranofin [a gold complex with antimicrobial activity used in rheumatoid arthiritis], and CC-11050 [a phosphodiesterase 4 (PDE4) inhibitor]), using rifabutin-based anti-TB treatment (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> NCT02968927); with change in FEV1 being one of the secondary outcomes. Both rapamycin, its derivates, and vitamin D could theoretically reduce lung damage through inhibition of MMPs, although the effect of vitamin D treatment on CXR abnormalities is variable (see below). PDE4 inhibitors, in combination with INH treatment, have been shown to reduce TB-associated lung damage in rabbits (<xref rid="B168" ref-type="bibr">Subbian et al., 2011</xref>) and pulmonary bacillary load in mice (<xref rid="B91" ref-type="bibr">Maiga et al., 2015</xref>). Doxycycline is being investigated for its potentially modulating effect on tissue destruction in pulmonary TB (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> NCT02774993).</p><p><bold>NSAIDs</bold> inhibit the enzyme cyclooxygenase (COX), thereby inhibiting PGE2 production and enhancing LXA4 production. An adjunctive role for NSAIDs in treatment of human TB has only been shown for acetylsalicylic acid in reducing PZA-induced arthralgia (<xref rid="B132" ref-type="bibr">Petty and Dalrymple, 1964</xref>; <xref rid="B63" ref-type="bibr">Horsfall et al., 1979</xref>) and possibly in TB meningitis (<xref rid="B113" ref-type="bibr">Misra et al., 2010</xref>; <xref rid="B149" ref-type="bibr">Schoeman et al., 2011</xref>; <xref rid="B90" ref-type="bibr">Mai et al., 2018</xref>). Negative effects have been described: a Taiwanese study found an association between NSAID use (both traditional NSAIDs and selective COX-2 inhibitors) and an increased risk of active TB (<xref rid="B192" ref-type="bibr">Wu et al., 2017</xref>). However, it is not clear whether this association is causative (i.e., decreased apoptosis at the very early stages of TB) or merely reflects an increased use of NSAIDs early during TB. In mice, inhibition of PGE2 by the NSAID ibuprofen was shown to affect lung pathology: inhibition early in the disease process leads to an increase in pulmonary inflammation and pathology (<xref rid="B139" ref-type="bibr">Rangel Moreno et al., 2002</xref>), whereas inhibition later during disease decreased lung pathology and neutrophil influx (<xref rid="B139" ref-type="bibr">Rangel Moreno et al., 2002</xref>; <xref rid="B181" ref-type="bibr">Vilaplana et al., 2013</xref>). Increasing <bold>PGE2</bold> by early (day one post infection) administration of exogenous PGE2 (dinoproston &#x02013; normally used for induction of labor) and/or the 5-lipo-oxygenase inhibitor zileuton (used in the treatment of asthma) to IL-1 deficient mice resulted in less necrotic lung pathology by TB (<xref rid="B101" ref-type="bibr">Mayer-Barber et al., 2014</xref>). No studies with dinoproston or zileuton have been performed in human TB to date. A pilot study is currently investigating the effect of ibuprofen added to multi-drug resistant TB treatment on radiological improvement of TB, amongst other endpoints (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov">ClinicalTrials.gov</ext-link> NCT02781909).</p><p>In <italic>in vitro</italic> models, <bold>metformin,</bold> a widely used antidiabetic agent, has been shown to inhibit TNF production by monocytes (<xref rid="B6" ref-type="bibr">Arai et al., 2010</xref>), affect macrophage polarization (<xref rid="B115" ref-type="bibr">Nadella et al., 2017</xref>), and promote autophagy (<xref rid="B159" ref-type="bibr">Singhal et al., 2014</xref>). It affects Th1 responses, but data are conflicting: in mice infected with TB, metformin treatment promotes the expansion of <italic>Mtb</italic>-specific IFN-&#x003b3; secreting T cells in the lungs (<xref rid="B159" ref-type="bibr">Singhal et al., 2014</xref>), whereas in human THP-1 cells (not infected with <italic>Mtb</italic>) metformin suppressed the production of Th1-related cytokines (<xref rid="B21" ref-type="bibr">Chen et al., 2018</xref>). Metformin use in patients with diabetes mellitus on treatment for TB was associated with decreased mortality compared to patients using other anti-diabetic drugs in two retrospective observational cohorts (<xref rid="B159" ref-type="bibr">Singhal et al., 2014</xref>; <xref rid="B35" ref-type="bibr">Degner et al., 2018</xref>). A retrospective cohort study of TB patients with diabetes mellitus showed that those using metformin at diagnosis and during TB treatment had fewer cavities and fewer CXR abnormalities compared to those using other anti-diabetic drugs (<xref rid="B159" ref-type="bibr">Singhal et al., 2014</xref>). Another retrospective study, however, showed increased cavitatory disease in patients using metformin (<xref rid="B35" ref-type="bibr">Degner et al., 2018</xref>).</p><p><bold>Vitamin D3</bold> induces autophagy (<xref rid="B17" ref-type="bibr">Campbell and Spector, 2012</xref>) and inhibits the secretion of MMP-7, -9 (<xref rid="B5" ref-type="bibr">Anand and Selvaraj, 2009</xref>; <xref rid="B26" ref-type="bibr">Coussens et al., 2009</xref>), and several cytokines, for example IFN-y, TNF-&#x003b1;, IL-6, and IL-10 (<xref rid="B180" ref-type="bibr">Vidyarani et al., 2007</xref>; <xref rid="B60" ref-type="bibr">Harishankar et al., 2014</xref>) <italic>in vitro</italic>. However, its effect on radiological outcomes are ambiguous: three trials comparing vitamin D3 as adjunctive therapy demonstrated no effect on CXR score (<xref rid="B97" ref-type="bibr">Martineau et al., 2011</xref>; <xref rid="B137" ref-type="bibr">Ralph et al., 2013b</xref>; <xref rid="B110" ref-type="bibr">Mily et al., 2015</xref>) or pulmonary function (<xref rid="B137" ref-type="bibr">Ralph et al., 2013b</xref>), while one study found more CXR improvement in the vitamin-D3 treated group (<xref rid="B146" ref-type="bibr">Salahuddin et al., 2013</xref>).</p><p><bold>Statins</bold> are widely used inhibitors of cholesterol biosynthesis. They induce autophagy <italic>in vitro</italic> (<xref rid="B130" ref-type="bibr">Parihar et al., 2014</xref>) with broad anti-inflammatory effects, although not directly demonstrated in TB (<xref rid="B62" ref-type="bibr">Hennessy et al., 2016</xref>). Their use has been associated with a reduced risk of developing active TB in some studies (<xref rid="B78" ref-type="bibr">Lai et al., 2016</xref>; <xref rid="B84" ref-type="bibr">Liao et al., 2017</xref>; <xref rid="B165" ref-type="bibr">Su et al., 2017</xref>), but not in all (<xref rid="B71" ref-type="bibr">Kang et al., 2014</xref>). No studies have been performed in humans assessing statins in relation to pulmonary damage in TB; in mice, statins have been found to reduce lung pathology (<xref rid="B130" ref-type="bibr">Parihar et al., 2014</xref>). A future study will look at the effect of pravastatin added to standard TB treatment on pulmonary function (NCT03456102).</p><p>Several studies looked at the effect of <bold>IFN-&#x003b3;</bold> as adjunctive therapy for TB (<xref rid="B53" ref-type="bibr">Gao et al., 2011</xref>). The studies were small, and most were performed in patients with multi-drug resistant TB. Aerosolized IFN-&#x003b3; in combination with TB treatment resulted in better CXR outcomes compared to TB treatment alone. This contradicts the finding in mice, where adding IFN-&#x003b3; resulted in worse pulmonary outcomes (<xref rid="B144" ref-type="bibr">Sakai et al., 2016</xref>). The authors conclude that IFN-&#x003b3; might be beneficial as adjunctive therapy in TB, but larger trials are needed to confirm this.</p><p><bold>Mesenchymal stromal cells</bold> are tissue-resident non-hematopoietic adult progenitor cells. They are believed to facilitate organ homeostasis and tissue repair and can modulate immune responses; they have been used in treatment of graft-versus-host-disease and autoimmune diseases (<xref rid="B129" ref-type="bibr">Parida et al., 2015</xref>). In a phase 1 trial in patients with drug resistant TB, infusions of autologous mesenchymal stromal cells, 4 weeks after starting TB treatment, was safe and resulted in CXR improvement in 25/36 patients compared to 15/36 controls (<xref rid="B161" ref-type="bibr">Skrahin et al., 2016</xref>).</p></sec><sec><title>Conclusion</title><p>The immune mechanisms of parenchymal lung damage in human TB are complex and incompletely understood. The difference between pulmonary damage in animal models (mostly occurring as a result of primary TB) and humans (mostly occurring as a result of post-primary TB) further complicates study of this phenomenon. Processes taking place in the lung are heterogeneous, with granulomas with varying degrees of mycobacterial control existing next to each other and inflammatory cells and cytokines appearing to have different effects at different time points. MMPs seem to play an important role and consequently, inhibition of MMPs may lead to reduction in pulmonary damage, however, this remains to be proven in clinical trials. Neutrophils are another key mediator of pulmonary damage, whose recruitment could potentially be inhibited by NSAIDs. The role of other effectors is less clear and better insight into their effects over the course of TB infection and disease is needed to be able to guide potential intervention. Future studies of human TB and (host-directed) therapy should include radiographically assessed lung damage and pulmonary function as an outcome.</p></sec><sec><title>Author Contributions</title><p>CS wrote the first draft of the manuscript. GM, BA, NW, RW, and LL critically revised the manuscript. All authors read and approved the submitted version.</p></sec><sec><title>Conflict of Interest Statement</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p><bold>Funding.</bold> RW was funded by The Wellcome Trust (104803 and 203135) and the Francis Crick Institute, which receives support from The Wellcome Trust (FC0010218); Research Councils United Kingdom (FC0010218); Cancer Research United Kingdom (FC0010218); National Institutes of Health (U01 A1 115940); The European &#x00026; Developing Countries Clinical Trials Partnership (SRIA2015-1065). GM was supported by the Wellcome Trust (098316 and 203135/Z/16/Z), the South African Research Chairs Initiative of the Department of Science and Technology and National Research Foundation (NRF) of South Africa (Grant No. 64787), NRF incentive funding (UID: 85858) and the South African Medical Research Council through its TB and HIV Collaborating Centres Programme with funds received from the National Department of Health (RFA# SAMRC-RFA-CC: TB/HIV/AIDS-01-2014). The funders had no role in the writing of this review. The opinions, findings, and conclusion expressed in this manuscript reflect those of the authors alone.</p></fn></fn-group><ref-list><title>References</title><ref id="B1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abakay</surname><given-names>O.</given-names></name><name><surname>Abakay</surname><given-names>A.</given-names></name><name><surname>Sen</surname><given-names>H. S.</given-names></name><name><surname>Tanrikulu</surname><given-names>A. C.</given-names></name></person-group> (<year>2015</year>). <article-title>The relationship between inflammatory marker levels and pulmonary tuberculosis severity.</article-title>
<source><italic>Inflammation</italic></source>
<volume>38</volume>
<fpage>691</fpage>&#x02013;<lpage>696</lpage>. <pub-id pub-id-type="doi">10.1007/s10753-014-9978-y</pub-id>
<?supplied-pmid 25028104?><pub-id pub-id-type="pmid">25028104</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akkara</surname><given-names>S. A.</given-names></name><name><surname>Shah</surname><given-names>A. D.</given-names></name><name><surname>Adalja</surname><given-names>M.</given-names></name><name><surname>Akkara</surname><given-names>A. G.</given-names></name><name><surname>Rathi</surname><given-names>A.</given-names></name><name><surname>Shah</surname><given-names>D. N.</given-names></name></person-group> (<year>2013</year>). <article-title>Pulmonary tuberculosis: the day after.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>17</volume>
<fpage>810</fpage>&#x02013;<lpage>813</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.12.0317</pub-id>
<?supplied-pmid 23676167?><pub-id pub-id-type="pmid">23676167</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al Shammari</surname><given-names>B.</given-names></name><name><surname>Shiomi</surname><given-names>T.</given-names></name><name><surname>Tezera</surname><given-names>L.</given-names></name><name><surname>Bielecka</surname><given-names>M. K.</given-names></name><name><surname>Workman</surname><given-names>V.</given-names></name><name><surname>Sathyamoorthy</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>The extracellular matrix regulates granuloma necrosis in tuberculosis.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>212</volume>
<fpage>463</fpage>&#x02013;<lpage>473</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv076</pub-id>
<?supplied-pmid 25676469?><pub-id pub-id-type="pmid">25676469</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ameglio</surname><given-names>F.</given-names></name><name><surname>Casarini</surname><given-names>M.</given-names></name><name><surname>Capoluongo</surname><given-names>E.</given-names></name><name><surname>Mattia</surname><given-names>P.</given-names></name><name><surname>Puglisi</surname><given-names>G.</given-names></name><name><surname>Giosue</surname><given-names>S.</given-names></name></person-group> (<year>2005</year>). <article-title>Post-treatment changes of six cytokines in active pulmonary tuberculosis: differences between patients with stable or increased fibrosis.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>9</volume>
<fpage>98</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">15675558</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>S. P.</given-names></name><name><surname>Selvaraj</surname><given-names>P.</given-names></name></person-group> (<year>2009</year>). <article-title>Effect of 1, 25 dihydroxyvitamin D(3) on matrix metalloproteinases MMP-7, MMP-9 and the inhibitor TIMP-1 in pulmonary tuberculosis.</article-title>
<source><italic>Clin. Immunol.</italic></source>
<volume>133</volume>
<fpage>126</fpage>&#x02013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.clim.2009.06.009</pub-id>
<?supplied-pmid 19615945?><pub-id pub-id-type="pmid">19615945</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>M.</given-names></name><name><surname>Uchiba</surname><given-names>M.</given-names></name><name><surname>Komura</surname><given-names>H.</given-names></name><name><surname>Mizuochi</surname><given-names>Y.</given-names></name><name><surname>Harada</surname><given-names>N.</given-names></name><name><surname>Okajima</surname><given-names>K.</given-names></name></person-group> (<year>2010</year>). <article-title>Metformin, an antidiabetic agent, suppresses the production of tumor necrosis factor and tissue factor by inhibiting early growth response factor-1 expression in human monocytes in vitro.</article-title>
<source><italic>J. Pharmacol. Exp. Ther.</italic></source>
<volume>334</volume>
<fpage>206</fpage>&#x02013;<lpage>213</lpage>. <pub-id pub-id-type="doi">10.1124/jpet.109.164970</pub-id>
<?supplied-pmid 20371705?><pub-id pub-id-type="pmid">20371705</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baez-Saldana</surname><given-names>R.</given-names></name><name><surname>Lopez-Arteaga</surname><given-names>Y.</given-names></name><name><surname>Bizarron-Muro</surname><given-names>A.</given-names></name><name><surname>Ferreira-Guerrero</surname><given-names>E.</given-names></name><name><surname>Ferreyra-Reyes</surname><given-names>L.</given-names></name><name><surname>Delgado-Sanchez</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>A novel scoring system to measure radiographic abnormalities and related spirometric values in cured pulmonary tuberculosis.</article-title>
<source><italic>PLoS One</italic></source>
<volume>8</volume>:<issue>e78926</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0078926</pub-id>
<?supplied-pmid 24223865?><pub-id pub-id-type="pmid">24223865</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>P. F.</given-names></name><name><surname>Leedom</surname><given-names>J. M.</given-names></name><name><surname>Chan</surname><given-names>L. S.</given-names></name><name><surname>Wong</surname><given-names>S. F.</given-names></name><name><surname>Shah</surname><given-names>J.</given-names></name><name><surname>Vachon</surname><given-names>L. A.</given-names></name><etal/></person-group> (<year>1988</year>). <article-title>Predictors of short-term prognosis in patients with pulmonary tuberculosis.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>158</volume>
<fpage>366</fpage>&#x02013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/158.2.366</pub-id><pub-id pub-id-type="pmid">3403993</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barry</surname><given-names>C. E.</given-names><suffix>III</suffix></name><name><surname>Boshoff</surname><given-names>H. I.</given-names></name><name><surname>Dartois</surname><given-names>V.</given-names></name><name><surname>Dick</surname><given-names>T.</given-names></name><name><surname>Ehrt</surname><given-names>S.</given-names></name><name><surname>Flynn</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>The spectrum of latent tuberculosis: rethinking the biology and intervention strategies.</article-title>
<source><italic>Nat. Rev. Microbiol.</italic></source>
<volume>7</volume>
<fpage>845</fpage>&#x02013;<lpage>855</lpage>. <pub-id pub-id-type="doi">10.1038/nrmicro2236</pub-id>
<?supplied-pmid 19855401?><pub-id pub-id-type="pmid">19855401</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bekker</surname><given-names>L. G.</given-names></name><name><surname>Moreira</surname><given-names>A. L.</given-names></name><name><surname>Bergtold</surname><given-names>A.</given-names></name><name><surname>Freeman</surname><given-names>S.</given-names></name><name><surname>Ryffel</surname><given-names>B.</given-names></name><name><surname>Kaplan</surname><given-names>G.</given-names></name></person-group> (<year>2000</year>). <article-title>Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent.</article-title>
<source><italic>Infect. Immun.</italic></source>
<volume>68</volume>
<fpage>6954</fpage>&#x02013;<lpage>6961</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.68.12.6954-6961.2000</pub-id>
<?supplied-pmid 11083819?><pub-id pub-id-type="pmid">11083819</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belton</surname><given-names>M.</given-names></name><name><surname>Brilha</surname><given-names>S.</given-names></name><name><surname>Manavaki</surname><given-names>R.</given-names></name><name><surname>Mauri</surname><given-names>F.</given-names></name><name><surname>Nijran</surname><given-names>K.</given-names></name><name><surname>Hong</surname><given-names>Y. T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Hypoxia and tissue destruction in pulmonary TB.</article-title>
<source><italic>Thorax</italic></source>
<volume>71</volume>
<fpage>1145</fpage>&#x02013;<lpage>1153</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-207402</pub-id>
<?supplied-pmid 27245780?><pub-id pub-id-type="pmid">27245780</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berrocal-Almanza</surname><given-names>L. C.</given-names></name><name><surname>Goyal</surname><given-names>S.</given-names></name><name><surname>Hussain</surname><given-names>A.</given-names></name><name><surname>Klassert</surname><given-names>T. E.</given-names></name><name><surname>Driesch</surname><given-names>D.</given-names></name><name><surname>Grozdanovic</surname><given-names>Z.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>S100A12 is up-regulated in pulmonary tuberculosis and predicts the extent of alveolar infiltration on chest radiography: an observational study.</article-title>
<source><italic>Sci. Rep.</italic></source>
<volume>6</volume>:<issue>31798</issue>. <pub-id pub-id-type="doi">10.1038/srep31798</pub-id>
<?supplied-pmid 27539060?><pub-id pub-id-type="pmid">27539060</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berry</surname><given-names>M. P.</given-names></name><name><surname>Graham</surname><given-names>C. M.</given-names></name><name><surname>McNab</surname><given-names>F. W.</given-names></name><name><surname>Xu</surname><given-names>Z.</given-names></name><name><surname>Bloch</surname><given-names>S. A.</given-names></name><name><surname>Oni</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.</article-title>
<source><italic>Nature</italic></source>
<volume>466</volume>
<fpage>973</fpage>&#x02013;<lpage>977</lpage>. <pub-id pub-id-type="doi">10.1038/nature09247</pub-id>
<?supplied-pmid 20725040?><pub-id pub-id-type="pmid">20725040</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackmore</surname><given-names>T. K.</given-names></name><name><surname>Manning</surname><given-names>L.</given-names></name><name><surname>Taylor</surname><given-names>W. J.</given-names></name><name><surname>Wallis</surname><given-names>R. S.</given-names></name></person-group> (<year>2008</year>). <article-title>Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>47</volume>
<fpage>e83</fpage>&#x02013;<lpage>e85</lpage>. <pub-id pub-id-type="doi">10.1086/592695</pub-id>
<?supplied-pmid 18840076?><pub-id pub-id-type="pmid">18840076</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bongiovanni</surname><given-names>B.</given-names></name><name><surname>Mata-Espinosa</surname><given-names>D.</given-names></name><name><surname>D&#x02019;Attilio</surname><given-names>L.</given-names></name><name><surname>Leon-Contreras</surname><given-names>J. C.</given-names></name><name><surname>Marquez-Velasco</surname><given-names>R.</given-names></name><name><surname>Bottasso</surname><given-names>O.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Effect of cortisol and/or DHEA on THP1-derived macrophages infected with <italic>Mycobacterium tuberculosis</italic>.</article-title>
<source><italic>Tuberculosis</italic></source>
<volume>95</volume>
<fpage>562</fpage>&#x02013;<lpage>569</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2015.05.011</pub-id>
<?supplied-pmid 26099547?><pub-id pub-id-type="pmid">26099547</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borthwick</surname><given-names>L. A.</given-names></name></person-group> (<year>2016</year>). <article-title>The IL-1 cytokine family and its role in inflammation and fibrosis in the lung.</article-title>
<source><italic>Semin. Immunopathol.</italic></source>
<volume>38</volume>
<fpage>517</fpage>&#x02013;<lpage>534</lpage>. <pub-id pub-id-type="doi">10.1007/s00281-016-0559-z</pub-id>
<?supplied-pmid 27001429?><pub-id pub-id-type="pmid">27001429</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>G. R.</given-names></name><name><surname>Spector</surname><given-names>S. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Vitamin D inhibits human immunodeficiency virus type 1 and <italic>Mycobacterium tuberculosis</italic> infection in macrophages through the induction of autophagy.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>8</volume>:<issue>e1002689</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1002689</pub-id>
<?supplied-pmid 22589721?><pub-id pub-id-type="pmid">22589721</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Canetti</surname><given-names>G.</given-names></name></person-group> (<year>1955</year>). <source><italic>The Tubercle Bacillus in the Pulmonary Lesion of Man.</italic></source>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer Publishing</publisher-name>.</mixed-citation></ref><ref id="B19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casarini</surname><given-names>M.</given-names></name><name><surname>Ameglio</surname><given-names>F.</given-names></name><name><surname>Alemanno</surname><given-names>L.</given-names></name><name><surname>Zangrilli</surname><given-names>P.</given-names></name><name><surname>Mattia</surname><given-names>P.</given-names></name><name><surname>Paone</surname><given-names>G.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>Cytokine levels correlate with a radiologic score in active pulmonary tuberculosis.</article-title>
<source><italic>Am. J. Respir. Crit. Care Med.</italic></source>
<volume>159</volume>
<fpage>143</fpage>&#x02013;<lpage>148</lpage>. <pub-id pub-id-type="doi">10.1164/ajrccm.159.1.9803066</pub-id>
<?supplied-pmid 9872832?><pub-id pub-id-type="pmid">9872832</pub-id></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>M.</given-names></name><name><surname>Divangahi</surname><given-names>M.</given-names></name><name><surname>Gan</surname><given-names>H.</given-names></name><name><surname>Shin</surname><given-names>D. S.</given-names></name><name><surname>Hong</surname><given-names>S.</given-names></name><name><surname>Lee</surname><given-names>D. M.</given-names></name><etal/></person-group> (<year>2008</year>). <article-title>Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death.</article-title>
<source><italic>J. Exp. Med.</italic></source>
<volume>205</volume>
<fpage>2791</fpage>&#x02013;<lpage>2801</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20080767</pub-id>
<?supplied-pmid 18955568?><pub-id pub-id-type="pmid">18955568</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y. C.</given-names></name><name><surname>Kuo</surname><given-names>C. H.</given-names></name><name><surname>Tsai</surname><given-names>Y. M.</given-names></name><name><surname>Lin</surname><given-names>Y. C.</given-names></name><name><surname>Hsiao</surname><given-names>H. P.</given-names></name><name><surname>Chen</surname><given-names>B. H.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Suppressive effects of metformin on T-helper 1-related chemokines expression in the human monocytic leukemia cell line THP-1.</article-title>
<source><italic>Endocr. Res.</italic></source>
<pub-id pub-id-type="doi">10.1080/07435800.2018.1460605</pub-id> [Epub ahead of print]. <?supplied-pmid 29630425?><pub-id pub-id-type="pmid">29630425</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chowdhury</surname><given-names>I. H.</given-names></name><name><surname>Ahmed</surname><given-names>A. M.</given-names></name><name><surname>Choudhuri</surname><given-names>S.</given-names></name><name><surname>Sen</surname><given-names>A.</given-names></name><name><surname>Hazra</surname><given-names>A.</given-names></name><name><surname>Pal</surname><given-names>N. K.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Alteration of serum inflammatory cytokines in active pulmonary tuberculosis following anti-tuberculosis drug therapy.</article-title>
<source><italic>Mol. Immunol.</italic></source>
<volume>62</volume>
<fpage>159</fpage>&#x02013;<lpage>168</lpage>. <pub-id pub-id-type="doi">10.1016/j.molimm.2014.06.002</pub-id>
<?supplied-pmid 25019566?><pub-id pub-id-type="pmid">25019566</pub-id></mixed-citation></ref><ref id="B23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>K. P.</given-names></name><name><surname>Chen</surname><given-names>J. Y.</given-names></name><name><surname>Lee</surname><given-names>C. H.</given-names></name><name><surname>Wu</surname><given-names>H. D.</given-names></name><name><surname>Wang</surname><given-names>J. Y.</given-names></name><name><surname>Lee</surname><given-names>L. N.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Trends and predictors of changes in pulmonary function after treatment for pulmonary tuberculosis.</article-title>
<source><italic>Clinics</italic></source>
<volume>66</volume>
<fpage>549</fpage>&#x02013;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1590/S1807-59322011000400005</pub-id>
<?supplied-pmid 21655745?><pub-id pub-id-type="pmid">21655745</pub-id></mixed-citation></ref><ref id="B24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>K.</given-names></name><name><surname>Polak</surname><given-names>M. E.</given-names></name><name><surname>Woelk</surname><given-names>C. H.</given-names></name><name><surname>Elkington</surname><given-names>P.</given-names></name></person-group> (<year>2017</year>). <article-title>Gene expression signatures in tuberculosis have greater overlap with autoimmune diseases than with infectious diseases.</article-title>
<source><italic>Am. J. Respir. Crit. Care Med.</italic></source>
<volume>196</volume>
<fpage>655</fpage>&#x02013;<lpage>656</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201706-1248LE</pub-id>
<?supplied-pmid 28753379?><pub-id pub-id-type="pmid">28753379</pub-id></mixed-citation></ref><ref id="B25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conesa-Botella</surname><given-names>A.</given-names></name><name><surname>Meintjes</surname><given-names>G.</given-names></name><name><surname>Coussens</surname><given-names>A. K.</given-names></name><name><surname>van der Plas</surname><given-names>H.</given-names></name><name><surname>Goliath</surname><given-names>R.</given-names></name><name><surname>Schutz</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Corticosteroid therapy, vitamin D status, and inflammatory cytokine profile in the HIV-tuberculosis immune reconstitution inflammatory syndrome.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>55</volume>
<fpage>1004</fpage>&#x02013;<lpage>1011</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cis577</pub-id>
<?supplied-pmid 22715179?><pub-id pub-id-type="pmid">22715179</pub-id></mixed-citation></ref><ref id="B26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>A.</given-names></name><name><surname>Timms</surname><given-names>P. M.</given-names></name><name><surname>Boucher</surname><given-names>B. J.</given-names></name><name><surname>Venton</surname><given-names>T. R.</given-names></name><name><surname>Ashcroft</surname><given-names>A. T.</given-names></name><name><surname>Skolimowska</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2009</year>). <article-title>1alpha,25-dihydroxyvitamin D3 inhibits matrix metalloproteinases induced by <italic>Mycobacterium tuberculosis</italic> infection.</article-title>
<source><italic>Immunology</italic></source>
<volume>127</volume>
<fpage>539</fpage>&#x02013;<lpage>548</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2567.2008.03024.x</pub-id>
<?supplied-pmid 19178594?><pub-id pub-id-type="pmid">19178594</pub-id></mixed-citation></ref><ref id="B27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Critchley</surname><given-names>J. A.</given-names></name><name><surname>Orton</surname><given-names>L. C.</given-names></name><name><surname>Pearson</surname><given-names>F.</given-names></name></person-group> (<year>2014</year>). <article-title>Adjunctive steroid therapy for managing pulmonary tuberculosis.</article-title>
<source><italic>Cochrane Database Syst. Rev.</italic></source>
<volume>11</volume>:<issue>CD011370</issue>. <pub-id pub-id-type="doi">10.1002/14651858.CD011370</pub-id>
<?supplied-pmid 25387839?><pub-id pub-id-type="pmid">25387839</pub-id></mixed-citation></ref><ref id="B28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Critchley</surname><given-names>J. A.</given-names></name><name><surname>Young</surname><given-names>F.</given-names></name><name><surname>Orton</surname><given-names>L.</given-names></name><name><surname>Garner</surname><given-names>P.</given-names></name></person-group> (<year>2013</year>). <article-title>Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis.</article-title>
<source><italic>Lancet Infect. Dis.</italic></source>
<volume>13</volume>
<fpage>223</fpage>&#x02013;<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(12)70321-3</pub-id>
<?supplied-pmid 23369413?><pub-id pub-id-type="pmid">23369413</pub-id></mixed-citation></ref><ref id="B29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallenga</surname><given-names>T.</given-names></name><name><surname>Linnemann</surname><given-names>L.</given-names></name><name><surname>Paudyal</surname><given-names>B.</given-names></name><name><surname>Repnik</surname><given-names>U.</given-names></name><name><surname>Griffiths</surname><given-names>G.</given-names></name><name><surname>Schaible</surname><given-names>U. E.</given-names></name></person-group> (<year>2017a</year>). <article-title>Targeting neutrophils for host-directed therapy to treat tuberculosis.</article-title>
<source><italic>Int. J. Med. Microbiol.</italic></source>
<pub-id pub-id-type="doi">10.1016/j.ijmm.2017.10.001</pub-id> [Epub ahead of print]. <?supplied-pmid 29055689?><pub-id pub-id-type="pmid">29055689</pub-id></mixed-citation></ref><ref id="B30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dallenga</surname><given-names>T.</given-names></name><name><surname>Repnik</surname><given-names>U.</given-names></name><name><surname>Corleis</surname><given-names>B.</given-names></name><name><surname>Eich</surname><given-names>J.</given-names></name><name><surname>Reimer</surname><given-names>R.</given-names></name><name><surname>Griffiths</surname><given-names>G. W.</given-names></name><etal/></person-group> (<year>2017b</year>). <article-title><italic>M. tuberculosis</italic>-induced necrosis of infected neutrophils promotes bacterial growth following phagocytosis by macrophages.</article-title>
<source><italic>Cell Host Microbe</italic></source>
<volume>22</volume>
<fpage>519</fpage>&#x02013;<lpage>530.e3</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2017.09.003</pub-id>
<?supplied-pmid 29024644?><pub-id pub-id-type="pmid">29024644</pub-id></mixed-citation></ref><ref id="B31"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Dannenberg</surname><given-names>A. M.</given-names><suffix>Jr.</suffix></name></person-group> (<year>2006</year>). <source><italic>Pathogenesis of Human Pulmonary Tuberculosis: Insights from the Rabbit Model.</italic></source>
<publisher-loc>Washington, DC</publisher-loc>: <publisher-name>ASM Press</publisher-name>
<pub-id pub-id-type="doi">10.1128/9781555815684</pub-id></mixed-citation></ref><ref id="B32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Castro Cunha</surname><given-names>R. M.</given-names></name><name><surname>Kallas</surname><given-names>E. G.</given-names></name><name><surname>Rodrigues</surname><given-names>D. S.</given-names></name><name><surname>Nascimento Burattini</surname><given-names>M.</given-names></name><name><surname>Salomao</surname><given-names>R.</given-names></name></person-group> (<year>2005</year>). <article-title>Interferon-gamma and tumour necrosis factor-alpha production by CD4<sup>+</sup> T and CD8<sup>+</sup> T lymphocytes in AIDS patients with tuberculosis.</article-title>
<source><italic>Clin. Exp. Immunol.</italic></source>
<volume>140</volume>
<fpage>491</fpage>&#x02013;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2249.2005.02796.x</pub-id>
<?supplied-pmid 15932510?><pub-id pub-id-type="pmid">15932510</pub-id></mixed-citation></ref><ref id="B33"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de la Mora</surname><given-names>I. L.</given-names></name><name><surname>Martinez-Oceguera</surname><given-names>D.</given-names></name><name><surname>Laniado-Laborin</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Chronic airway obstruction after successful treatment of tuberculosis and its impact on quality of life.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>19</volume>
<fpage>808</fpage>&#x02013;<lpage>810</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.14.0983</pub-id>
<?supplied-pmid 26056106?><pub-id pub-id-type="pmid">26056106</pub-id></mixed-citation></ref><ref id="B34"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Valliere</surname><given-names>S.</given-names></name><name><surname>Barker</surname><given-names>R. D.</given-names></name></person-group> (<year>2004</year>). <article-title>Residual lung damage after completion of treatment for multidrug-resistant tuberculosis.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>8</volume>
<fpage>767</fpage>&#x02013;<lpage>771</lpage>. <?supplied-pmid 15182148?><pub-id pub-id-type="pmid">15182148</pub-id></mixed-citation></ref><ref id="B35"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Degner</surname><given-names>N. R.</given-names></name><name><surname>Wang</surname><given-names>J. Y.</given-names></name><name><surname>Golub</surname><given-names>J. E.</given-names></name><name><surname>Karakousis</surname><given-names>P. C.</given-names></name></person-group> (<year>2018</year>). <article-title>Metformin use reverses the increased mortality associated with diabetes mellitus during tuberculosis treatment.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>66</volume>
<fpage>198</fpage>&#x02013;<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cix819</pub-id>
<?supplied-pmid 29325084?><pub-id pub-id-type="pmid">29325084</pub-id></mixed-citation></ref><ref id="B36"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dietzold</surname><given-names>J.</given-names></name><name><surname>Gopalakrishnan</surname><given-names>A.</given-names></name><name><surname>Salgame</surname><given-names>P.</given-names></name></person-group> (<year>2015</year>). <article-title>Duality of lipid mediators in host response against <italic>Mycobacterium tuberculosis</italic>: good cop, bad cop.</article-title>
<source><italic>F1000Prime Rep.</italic></source>
<volume>7</volume>:<issue>29</issue>. <pub-id pub-id-type="doi">10.12703/P7-29</pub-id>
<?supplied-pmid 25926980?><pub-id pub-id-type="pmid">25926980</pub-id></mixed-citation></ref><ref id="B37"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Divangahi</surname><given-names>M.</given-names></name><name><surname>Behar</surname><given-names>S. M.</given-names></name><name><surname>Remold</surname><given-names>H.</given-names></name></person-group> (<year>2013</year>). <article-title>Dying to live: how the death modality of the infected macrophage affects immunity to tuberculosis.</article-title>
<source><italic>Adv. Exp. Med. Biol.</italic></source>
<volume>783</volume>
<fpage>103</fpage>&#x02013;<lpage>120</lpage>. <pub-id pub-id-type="doi">10.1007/978-1-4614-6111-1_6</pub-id>
<?supplied-pmid 23468106?><pub-id pub-id-type="pmid">23468106</pub-id></mixed-citation></ref><ref id="B38"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dlugovitzky</surname><given-names>D.</given-names></name><name><surname>Torres-Morales</surname><given-names>A.</given-names></name><name><surname>Rateni</surname><given-names>L.</given-names></name><name><surname>Farroni</surname><given-names>M. A.</given-names></name><name><surname>Largacha</surname><given-names>C.</given-names></name><name><surname>Molteni</surname><given-names>O.</given-names></name><etal/></person-group> (<year>1997</year>). <article-title>Circulating profile of Th1 and Th2 cytokines in tuberculosis patients with different degrees of pulmonary involvement.</article-title>
<source><italic>FEMS Immunol. Med. Microbiol.</italic></source>
<volume>18</volume>
<fpage>203</fpage>&#x02013;<lpage>207</lpage>. <pub-id pub-id-type="doi">10.1111/j.1574-695X.1997.tb01046.x</pub-id>
<?supplied-pmid 9271171?><pub-id pub-id-type="pmid">9271171</pub-id></mixed-citation></ref><ref id="B39"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dooley</surname><given-names>D. P.</given-names></name><name><surname>Carpenter</surname><given-names>J. L.</given-names></name><name><surname>Rademacher</surname><given-names>S.</given-names></name></person-group> (<year>1997</year>). <article-title>Adjunctive corticosteroid therapy for tuberculosis: a critical reappraisal of the literature.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>25</volume>
<fpage>872</fpage>&#x02013;<lpage>887</lpage>. <pub-id pub-id-type="doi">10.1086/515543</pub-id>
<?supplied-pmid 9356803?><pub-id pub-id-type="pmid">9356803</pub-id></mixed-citation></ref><ref id="B40"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>el-Ahmady</surname><given-names>O.</given-names></name><name><surname>Mansour</surname><given-names>M.</given-names></name><name><surname>Zoeir</surname><given-names>H.</given-names></name><name><surname>Mansour</surname><given-names>O.</given-names></name></person-group> (<year>1997</year>). <article-title>Elevated concentrations of interleukins and leukotriene in response to <italic>Mycobacterium tuberculosis</italic> infection.</article-title>
<source><italic>Ann. Clin. Biochem.</italic></source>
<volume>34</volume>(Pt 2), <fpage>160</fpage>&#x02013;<lpage>164</lpage>. <pub-id pub-id-type="doi">10.1177/000456329703400205</pub-id>
<?supplied-pmid 9133249?><pub-id pub-id-type="pmid">9133249</pub-id></mixed-citation></ref><ref id="B41"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkington</surname><given-names>P.</given-names></name><name><surname>Shiomi</surname><given-names>T.</given-names></name><name><surname>Breen</surname><given-names>R.</given-names></name><name><surname>Nuttall</surname><given-names>R. K.</given-names></name><name><surname>Ugarte-Gil</surname><given-names>C. A.</given-names></name><name><surname>Walker</surname><given-names>N. F.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>MMP-1 drives immunopathology in human tuberculosis and transgenic mice.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>121</volume>
<fpage>1827</fpage>&#x02013;<lpage>1833</lpage>. <pub-id pub-id-type="doi">10.1172/JCI45666</pub-id>
<?supplied-pmid 21519144?><pub-id pub-id-type="pmid">21519144</pub-id></mixed-citation></ref><ref id="B42"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkington</surname><given-names>P. T.</given-names></name><name><surname>Ugarte-Gil</surname><given-names>C. A.</given-names></name><name><surname>Friedland</surname><given-names>J. S.</given-names></name></person-group> (<year>2011</year>). <article-title>Matrix metalloproteinases in tuberculosis.</article-title>
<source><italic>Eur. Respir. J.</italic></source>
<volume>38</volume>
<fpage>456</fpage>&#x02013;<lpage>464</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00015411</pub-id>
<?supplied-pmid 21659415?><pub-id pub-id-type="pmid">21659415</pub-id></mixed-citation></ref><ref id="B43"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkington</surname><given-names>P.</given-names></name><name><surname>Tebruegge</surname><given-names>M.</given-names></name><name><surname>Mansour</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>Tuberculosis: an infection-initiated autoimmune disease?</article-title>
<source><italic>Trends Immunol.</italic></source>
<volume>37</volume>
<fpage>815</fpage>&#x02013;<lpage>818</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2016.09.007</pub-id>
<?supplied-pmid 27773684?><pub-id pub-id-type="pmid">27773684</pub-id></mixed-citation></ref><ref id="B44"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elkington</surname><given-names>P. T.</given-names></name><name><surname>Friedland</surname><given-names>J. S.</given-names></name></person-group> (<year>2006</year>). <article-title>Matrix metalloproteinases in destructive pulmonary pathology.</article-title>
<source><italic>Thorax</italic></source>
<volume>61</volume>
<fpage>259</fpage>&#x02013;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1136/thx.2005.051979</pub-id>
<?supplied-pmid 16227332?><pub-id pub-id-type="pmid">16227332</pub-id></mixed-citation></ref><ref id="B45"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>A. M.</given-names></name><name><surname>Hurst</surname><given-names>T. J.</given-names></name><name><surname>Balyeku</surname><given-names>M. N.</given-names></name><name><surname>Quigley</surname><given-names>M. A.</given-names></name><name><surname>Kaleebu</surname><given-names>P.</given-names></name><name><surname>French</surname><given-names>N.</given-names></name><etal/></person-group> (<year>1999</year>). <article-title>The immune response to <italic>Mycobacterium tuberculosis</italic> in HIV-infected and uninfected adults in Uganda: application of a whole blood cytokine assay in an epidemiological study.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>3</volume>
<fpage>239</fpage>&#x02013;<lpage>247</lpage>. <?supplied-pmid 10094326?><pub-id pub-id-type="pmid">10094326</pub-id></mixed-citation></ref><ref id="B46"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esmail</surname><given-names>H.</given-names></name><name><surname>Lai</surname><given-names>R. P.</given-names></name><name><surname>Lesosky</surname><given-names>M.</given-names></name><name><surname>Wilkinson</surname><given-names>K. A.</given-names></name><name><surname>Graham</surname><given-names>C. M.</given-names></name><name><surname>Coussens</surname><given-names>A. K.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Characterization of progressive HIV-associated tuberculosis using 2-deoxy-2-[18F]fluoro-D-glucose positron emission and computed tomography.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>22</volume>
<fpage>1090</fpage>&#x02013;<lpage>1093</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4161</pub-id>
<?supplied-pmid 27595321?><pub-id pub-id-type="pmid">27595321</pub-id></mixed-citation></ref><ref id="B47"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eum</surname><given-names>S. Y.</given-names></name><name><surname>Kong</surname><given-names>J. H.</given-names></name><name><surname>Hong</surname><given-names>M. S.</given-names></name><name><surname>Lee</surname><given-names>Y. J.</given-names></name><name><surname>Kim</surname><given-names>J. H.</given-names></name><name><surname>Hwang</surname><given-names>S. H.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB.</article-title>
<source><italic>Chest</italic></source>
<volume>137</volume>
<fpage>122</fpage>&#x02013;<lpage>128</lpage>. <pub-id pub-id-type="doi">10.1378/chest.09-0903</pub-id>
<?supplied-pmid 19749004?><pub-id pub-id-type="pmid">19749004</pub-id></mixed-citation></ref><ref id="B48"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>L.</given-names></name><name><surname>Xiao</surname><given-names>H.</given-names></name><name><surname>Mai</surname><given-names>G.</given-names></name><name><surname>Su</surname><given-names>B.</given-names></name><name><surname>Ernst</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Z.</given-names></name></person-group> (<year>2015</year>). <article-title>Impaired <italic>M. tuberculosis</italic> antigen-specific IFN-gamma response without IL-17 enhancement in patients with severe cavitary pulmonary tuberculosis.</article-title>
<source><italic>PLoS One</italic></source>
<volume>10</volume>:<issue>e0127087</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0127087</pub-id>
<?supplied-pmid 26018190?><pub-id pub-id-type="pmid">26018190</pub-id></mixed-citation></ref><ref id="B49"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>J.</given-names></name></person-group> (<year>2018</year>). <source><italic>Pathogenesis of Tuberculosis and Vaccine Prevention, CROI; Abstract Number 13.</italic></source>
<publisher-loc>Pittsburgh, PA</publisher-loc>: <publisher-name>University of Pittsburgh</publisher-name>.</mixed-citation></ref><ref id="B50"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>J. L.</given-names></name><name><surname>Gideon</surname><given-names>H. P.</given-names></name><name><surname>Mattila</surname><given-names>J. T.</given-names></name><name><surname>Lin</surname><given-names>P. L.</given-names></name></person-group> (<year>2015</year>). <article-title>Immunology studies in non-human primate models of tuberculosis.</article-title>
<source><italic>Immunol. Rev.</italic></source>
<volume>264</volume>
<fpage>60</fpage>&#x02013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1111/imr.12258</pub-id>
<?supplied-pmid 25703552?><pub-id pub-id-type="pmid">25703552</pub-id></mixed-citation></ref><ref id="B51"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fox</surname><given-names>K. A.</given-names></name><name><surname>Kirwan</surname><given-names>D. E.</given-names></name><name><surname>Whittington</surname><given-names>A. M.</given-names></name><name><surname>Krishnan</surname><given-names>N.</given-names></name><name><surname>Robertson</surname><given-names>B. D.</given-names></name><name><surname>Gilman</surname><given-names>R. H.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Platelets regulate pulmonary inflammation and tissue destruction in tuberculosis.</article-title>
<source><italic>Am. J. Respir. Crit. Care Med.</italic></source>
<volume>198</volume>
<fpage>245</fpage>&#x02013;<lpage>255</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201710-2102OC</pub-id>
<?supplied-pmid 29420060?><pub-id pub-id-type="pmid">29420060</pub-id></mixed-citation></ref><ref id="B52"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gallegos</surname><given-names>A. M.</given-names></name><name><surname>Pamer</surname><given-names>E. G.</given-names></name><name><surname>Glickman</surname><given-names>M. S.</given-names></name></person-group> (<year>2008</year>). <article-title>Delayed protection by ESAT-6-specific effector CD4<sup>+</sup> T cells after airborne <italic>M. tuberculosis</italic> infection.</article-title>
<source><italic>J. Exp. Med.</italic></source>
<volume>205</volume>
<fpage>2359</fpage>&#x02013;<lpage>2368</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20080353</pub-id>
<?supplied-pmid 18779346?><pub-id pub-id-type="pmid">18779346</pub-id></mixed-citation></ref><ref id="B53"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X. F.</given-names></name><name><surname>Yang</surname><given-names>Z. W.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name></person-group> (<year>2011</year>). <article-title>Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review.</article-title>
<source><italic>Int. J. Infect. Dis.</italic></source>
<volume>15</volume>
<fpage>e594</fpage>&#x02013;<lpage>e600</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2011.05.002</pub-id>
<?supplied-pmid 21715206?><pub-id pub-id-type="pmid">21715206</pub-id></mixed-citation></ref><ref id="B54"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giannandrea</surname><given-names>M.</given-names></name><name><surname>Parks</surname><given-names>W. C.</given-names></name></person-group> (<year>2014</year>). <article-title>Diverse functions of matrix metalloproteinases during fibrosis.</article-title>
<source><italic>Dis. Model. Mech.</italic></source>
<volume>7</volume>
<fpage>193</fpage>&#x02013;<lpage>203</lpage>. <pub-id pub-id-type="doi">10.1242/dmm.012062</pub-id>
<?supplied-pmid 24713275?><pub-id pub-id-type="pmid">24713275</pub-id></mixed-citation></ref><ref id="B55"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gopal</surname><given-names>R.</given-names></name><name><surname>Monin</surname><given-names>L.</given-names></name><name><surname>Torres</surname><given-names>D.</given-names></name><name><surname>Slight</surname><given-names>S.</given-names></name><name><surname>Mehra</surname><given-names>S.</given-names></name><name><surname>McKenna</surname><given-names>K. C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>S100A8/A9 proteins mediate neutrophilic inflammation and lung pathology during tuberculosis.</article-title>
<source><italic>Am. J. Respir. Crit. Care Med.</italic></source>
<volume>188</volume>
<fpage>1137</fpage>&#x02013;<lpage>1146</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201304-0803OC</pub-id>
<?supplied-pmid 24047412?><pub-id pub-id-type="pmid">24047412</pub-id></mixed-citation></ref><ref id="B56"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W. J.</given-names></name><name><surname>Gao</surname><given-names>Y. H.</given-names></name><name><surname>Xu</surname><given-names>G.</given-names></name><name><surname>Lin</surname><given-names>Z. Y.</given-names></name><name><surname>Tang</surname><given-names>Y.</given-names></name><name><surname>Gu</surname><given-names>Y. Y.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Sputum matrix metalloproteinase-8 and -9 and tissue inhibitor of metalloproteinase-1 in bronchiectasis: clinical correlates and prognostic implications.</article-title>
<source><italic>Respirology</italic></source>
<volume>20</volume>
<fpage>1073</fpage>&#x02013;<lpage>1081</lpage>. <pub-id pub-id-type="doi">10.1111/resp.12582</pub-id>
<?supplied-pmid 26122009?><pub-id pub-id-type="pmid">26122009</pub-id></mixed-citation></ref><ref id="B57"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>A.</given-names></name><name><surname>Misra</surname><given-names>A.</given-names></name><name><surname>Deretic</surname><given-names>V.</given-names></name></person-group> (<year>2016</year>). <article-title>Targeted pulmonary delivery of inducers of host macrophage autophagy as a potential host-directed chemotherapy of tuberculosis.</article-title>
<source><italic>Adv. Drug Deliv. Rev.</italic></source>
<volume>102</volume>
<fpage>10</fpage>&#x02013;<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.addr.2016.01.016</pub-id>
<?supplied-pmid 26829287?><pub-id pub-id-type="pmid">26829287</pub-id></mixed-citation></ref><ref id="B58"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupte</surname><given-names>A. N.</given-names></name><name><surname>Wong</surname><given-names>M. L.</given-names></name><name><surname>Msandiwa</surname><given-names>R.</given-names></name><name><surname>Barnes</surname><given-names>G. L.</given-names></name><name><surname>Golub</surname><given-names>J.</given-names></name><name><surname>Chaisson</surname><given-names>R. E.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Factors associated with pulmonary impairment in HIV-infected South African adults.</article-title>
<source><italic>PLoS One</italic></source>
<volume>12</volume>:<issue>e0184530</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0184530</pub-id>
<?supplied-pmid 28902919?><pub-id pub-id-type="pmid">28902919</pub-id></mixed-citation></ref><ref id="B59"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gutierrez</surname><given-names>M. G.</given-names></name><name><surname>Master</surname><given-names>S. S.</given-names></name><name><surname>Singh</surname><given-names>S. B.</given-names></name><name><surname>Taylor</surname><given-names>G. A.</given-names></name><name><surname>Colombo</surname><given-names>M. I.</given-names></name><name><surname>Deretic</surname><given-names>V.</given-names></name></person-group> (<year>2004</year>). <article-title>Autophagy is a defense mechanism inhibiting BCG and <italic>Mycobacterium tuberculosis</italic> survival in infected macrophages.</article-title>
<source><italic>Cell</italic></source>
<volume>119</volume>
<fpage>753</fpage>&#x02013;<lpage>766</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2004.11.038</pub-id>
<?supplied-pmid 15607973?><pub-id pub-id-type="pmid">15607973</pub-id></mixed-citation></ref><ref id="B60"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harishankar</surname><given-names>M.</given-names></name><name><surname>Afsal</surname><given-names>K.</given-names></name><name><surname>Banurekha</surname><given-names>V. V.</given-names></name><name><surname>Meenakshi</surname><given-names>N.</given-names></name><name><surname>Selvaraj</surname><given-names>P.</given-names></name></person-group> (<year>2014</year>). <article-title>1,25-Dihydroxy vitamin D3 downregulates pro-inflammatory cytokine response in pulmonary tuberculosis.</article-title>
<source><italic>Int. Immunopharmacol.</italic></source>
<volume>23</volume>
<fpage>148</fpage>&#x02013;<lpage>152</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2014.08.021</pub-id>
<?supplied-pmid 25194676?><pub-id pub-id-type="pmid">25194676</pub-id></mixed-citation></ref><ref id="B61"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hawn</surname><given-names>T. R.</given-names></name><name><surname>Matheson</surname><given-names>A. I.</given-names></name><name><surname>Maley</surname><given-names>S. N.</given-names></name><name><surname>Vandal</surname><given-names>O.</given-names></name></person-group> (<year>2013</year>). <article-title>Host-directed therapeutics for tuberculosis: can we harness the host?</article-title>
<source><italic>Microbiol. Mol. Biol. Rev.</italic></source>
<volume>77</volume>
<fpage>608</fpage>&#x02013;<lpage>627</lpage>. <pub-id pub-id-type="doi">10.1128/MMBR.00032-13</pub-id>
<?supplied-pmid 24296574?><pub-id pub-id-type="pmid">24296574</pub-id></mixed-citation></ref><ref id="B62"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hennessy</surname><given-names>E.</given-names></name><name><surname>Adams</surname><given-names>C.</given-names></name><name><surname>Reen</surname><given-names>F. J.</given-names></name><name><surname>O&#x02019;Gara</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Is there potential for repurposing statins as novel antimicrobials?</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>60</volume>
<fpage>5111</fpage>&#x02013;<lpage>5121</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00192-16</pub-id>
<?supplied-pmid 27324773?><pub-id pub-id-type="pmid">27324773</pub-id></mixed-citation></ref><ref id="B63"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsfall</surname><given-names>P. A.</given-names></name><name><surname>Plummer</surname><given-names>J.</given-names></name><name><surname>Allan</surname><given-names>W. G.</given-names></name><name><surname>Girling</surname><given-names>D. J.</given-names></name><name><surname>Nunn</surname><given-names>A. J.</given-names></name><name><surname>Fox</surname><given-names>W.</given-names></name></person-group> (<year>1979</year>). <article-title>Double blind controlled comparison of aspirin, allopurinol and placebo in the management of arthralgia during pyrazinamide administration.</article-title>
<source><italic>Tubercle</italic></source>
<volume>60</volume>
<fpage>13</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/0041-3879(79)90051-5</pub-id>
<?supplied-pmid 377739?><pub-id pub-id-type="pmid">377739</pub-id></mixed-citation></ref><ref id="B64"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hrabec</surname><given-names>E.</given-names></name><name><surname>Strek</surname><given-names>M.</given-names></name><name><surname>Zieba</surname><given-names>M.</given-names></name><name><surname>Kwiatkowska</surname><given-names>S.</given-names></name><name><surname>Hrabec</surname><given-names>Z.</given-names></name></person-group> (<year>2002</year>). <article-title>Circulation level of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>6</volume>
<fpage>713</fpage>&#x02013;<lpage>719</lpage>. <?supplied-pmid 12150484?><pub-id pub-id-type="pmid">12150484</pub-id></mixed-citation></ref><ref id="B65"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>D. C.</given-names></name><name><surname>Faldetta</surname><given-names>K. F.</given-names></name><name><surname>Pei</surname><given-names>L.</given-names></name><name><surname>Sheikh</surname><given-names>V.</given-names></name><name><surname>Utay</surname><given-names>N. S.</given-names></name><name><surname>Roby</surname><given-names>G.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>A paradoxical treatment for a paradoxical condition: infliximab use in three cases of mycobacterial IRIS.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>62</volume>
<fpage>258</fpage>&#x02013;<lpage>261</lpage>. <pub-id pub-id-type="doi">10.1093/cid/civ841</pub-id>
<?supplied-pmid 26394669?><pub-id pub-id-type="pmid">26394669</pub-id></mixed-citation></ref><ref id="B66"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>R. L.</given-names></name></person-group> (<year>2011</year>). <article-title>Pathology of post primary tuberculosis of the lung: an illustrated critical review.</article-title>
<source><italic>Tuberculosis</italic></source>
<volume>91</volume>
<fpage>497</fpage>&#x02013;<lpage>509</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2011.03.007</pub-id>
<?supplied-pmid 21733755?><pub-id pub-id-type="pmid">21733755</pub-id></mixed-citation></ref><ref id="B67"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>R. L.</given-names></name></person-group> (<year>2016</year>). <article-title>Tuberculosis as a three-act play: a new paradigm for the pathogenesis of pulmonary tuberculosis.</article-title>
<source><italic>Tuberculosis</italic></source>
<volume>97</volume>
<fpage>8</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2015.11.010</pub-id>
<?supplied-pmid 26980490?><pub-id pub-id-type="pmid">26980490</pub-id></mixed-citation></ref><ref id="B68"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jick</surname><given-names>S. S.</given-names></name><name><surname>Lieberman</surname><given-names>E. S.</given-names></name><name><surname>Rahman</surname><given-names>M. U.</given-names></name><name><surname>Choi</surname><given-names>H. K.</given-names></name></person-group> (<year>2006</year>). <article-title>Glucocorticoid use, other associated factors, and the risk of tuberculosis.</article-title>
<source><italic>Arthritis Rheum.</italic></source>
<volume>55</volume>
<fpage>19</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1002/art.21705</pub-id>
<?supplied-pmid 16463407?><pub-id pub-id-type="pmid">16463407</pub-id></mixed-citation></ref><ref id="B69"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>T. S.</given-names></name><name><surname>Spencer</surname><given-names>E. M.</given-names></name><name><surname>Davies</surname><given-names>P.</given-names></name></person-group> (<year>2010</year>). <article-title>Tuberculosis, bronchiectasis and chronic airflow obstruction.</article-title>
<source><italic>Respirology</italic></source>
<volume>15</volume>
<fpage>623</fpage>&#x02013;<lpage>628</lpage>. <pub-id pub-id-type="doi">10.1111/j.1440-1843.2010.01749.x</pub-id>
<?supplied-pmid 20409028?><pub-id pub-id-type="pmid">20409028</pub-id></mixed-citation></ref><ref id="B70"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorge</surname><given-names>J. H.</given-names></name><name><surname>Graciela</surname><given-names>C.</given-names></name><name><surname>Pablo</surname><given-names>A. P.</given-names></name><name><surname>Luis</surname><given-names>S. H.</given-names></name></person-group> (<year>2012</year>). <article-title>A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis.</article-title>
<source><italic>J. Clin. Rheumatol.</italic></source>
<volume>18</volume>
<fpage>189</fpage>&#x02013;<lpage>191</lpage>. <pub-id pub-id-type="doi">10.1097/RHU.0b013e318258b725</pub-id>
<?supplied-pmid 22647865?><pub-id pub-id-type="pmid">22647865</pub-id></mixed-citation></ref><ref id="B71"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>Y. A.</given-names></name><name><surname>Choi</surname><given-names>N. K.</given-names></name><name><surname>Seong</surname><given-names>J. M.</given-names></name><name><surname>Heo</surname><given-names>E. Y.</given-names></name><name><surname>Koo</surname><given-names>B. K.</given-names></name><name><surname>Hwang</surname><given-names>S. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>The effects of statin use on the development of tuberculosis among patients with diabetes mellitus.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>18</volume>
<fpage>717</fpage>&#x02013;<lpage>724</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.13.0854</pub-id>
<?supplied-pmid 24903944?><pub-id pub-id-type="pmid">24903944</pub-id></mixed-citation></ref><ref id="B72"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kassa</surname><given-names>D.</given-names></name><name><surname>de Jager</surname><given-names>W.</given-names></name><name><surname>Gebremichael</surname><given-names>G.</given-names></name><name><surname>Alemayehu</surname><given-names>Y.</given-names></name><name><surname>Ran</surname><given-names>L.</given-names></name><name><surname>Fransen</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>The effect of HIV coinfection, HAART and TB treatment on cytokine/chemokine responses to <italic>Mycobacterium tuberculosis</italic> (Mtb) antigens in active TB patients and latently Mtb infected individuals.</article-title>
<source><italic>Tuberculosis</italic></source>
<volume>96</volume>
<fpage>131</fpage>&#x02013;<lpage>140</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2015.05.015</pub-id>
<?supplied-pmid 26631832?><pub-id pub-id-type="pmid">26631832</pub-id></mixed-citation></ref><ref id="B73"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J. J.</given-names></name><name><surname>Lee</surname><given-names>H. M.</given-names></name><name><surname>Shin</surname><given-names>D. M.</given-names></name><name><surname>Kim</surname><given-names>W.</given-names></name><name><surname>Yuk</surname><given-names>J. M.</given-names></name><name><surname>Jin</surname><given-names>H. S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Host cell autophagy activated by antibiotics is required for their effective antimycobacterial drug action.</article-title>
<source><italic>Cell Host Microbe</italic></source>
<volume>11</volume>
<fpage>457</fpage>&#x02013;<lpage>468</lpage>. <pub-id pub-id-type="doi">10.1016/j.chom.2012.03.008</pub-id>
<?supplied-pmid 22607799?><pub-id pub-id-type="pmid">22607799</pub-id></mixed-citation></ref><ref id="B74"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>P. T.</given-names></name></person-group> (<year>2009</year>). <article-title>The pathophysiology of bronchiectasis.</article-title>
<source><italic>Int. J. Chron. Obstruct. Pulmon. Dis.</italic></source>
<volume>4</volume>
<fpage>411</fpage>&#x02013;<lpage>419</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S6133</pub-id><pub-id pub-id-type="pmid">20037680</pub-id></mixed-citation></ref><ref id="B75"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubler</surname><given-names>A.</given-names></name><name><surname>Luna</surname><given-names>B.</given-names></name><name><surname>Larsson</surname><given-names>C.</given-names></name><name><surname>Ammerman</surname><given-names>N. C.</given-names></name><name><surname>Andrade</surname><given-names>B. B.</given-names></name><name><surname>Orandle</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title><italic>Mycobacterium tuberculosis</italic> dysregulates MMP/TIMP balance to drive rapid cavitation and unrestrained bacterial proliferation.</article-title>
<source><italic>J. Pathol.</italic></source>
<volume>235</volume>
<fpage>431</fpage>&#x02013;<lpage>444</lpage>. <pub-id pub-id-type="doi">10.1002/path.4432</pub-id>
<?supplied-pmid 25186281?><pub-id pub-id-type="pmid">25186281</pub-id></mixed-citation></ref><ref id="B76"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuhne</surname><given-names>W.</given-names></name><name><surname>Willgeroth</surname><given-names>C.</given-names></name></person-group> (<year>1988</year>). <article-title>[The significance of tuberculosis today and its pathomorphism, demonstrated in postmortem material].</article-title>
<source><italic>Zentralbl. Allg. Pathol.</italic></source>
<volume>134</volume>
<fpage>665</fpage>&#x02013;<lpage>669</lpage>. <?supplied-pmid 3245350?><pub-id pub-id-type="pmid">3245350</pub-id></mixed-citation></ref><ref id="B77"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kwan</surname><given-names>C. K.</given-names></name><name><surname>Ernst</surname><given-names>J. D.</given-names></name></person-group> (<year>2011</year>). <article-title>HIV and tuberculosis: a deadly human syndemic.</article-title>
<source><italic>Clin. Microbiol. Rev.</italic></source>
<volume>24</volume>
<fpage>351</fpage>&#x02013;<lpage>376</lpage>. <pub-id pub-id-type="doi">10.1128/CMR.00042-10</pub-id>
<?supplied-pmid 21482729?><pub-id pub-id-type="pmid">21482729</pub-id></mixed-citation></ref><ref id="B78"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>C. C.</given-names></name><name><surname>Lee</surname><given-names>M. T.</given-names></name><name><surname>Lee</surname><given-names>S. H.</given-names></name><name><surname>Hsu</surname><given-names>W. T.</given-names></name><name><surname>Chang</surname><given-names>S. S.</given-names></name><name><surname>Chen</surname><given-names>S. C.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Statin treatment is associated with a decreased risk of active tuberculosis: an analysis of a nationally representative cohort.</article-title>
<source><italic>Thorax</italic></source>
<volume>71</volume>
<fpage>646</fpage>&#x02013;<lpage>651</lpage>. <pub-id pub-id-type="doi">10.1136/thoraxjnl-2015-207052</pub-id>
<?supplied-pmid 26941271?><pub-id pub-id-type="pmid">26941271</pub-id></mixed-citation></ref><ref id="B79"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>R. P.</given-names></name><name><surname>Meintjes</surname><given-names>G.</given-names></name><name><surname>Wilkinson</surname><given-names>K. A.</given-names></name><name><surname>Graham</surname><given-names>C. M.</given-names></name><name><surname>Marais</surname><given-names>S.</given-names></name><name><surname>Van der Plas</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling.</article-title>
<source><italic>Nat. Commun.</italic></source>
<volume>6</volume>:<issue>8451</issue>. <pub-id pub-id-type="doi">10.1038/ncomms9451</pub-id>
<?supplied-pmid 26399326?><pub-id pub-id-type="pmid">26399326</pub-id></mixed-citation></ref><ref id="B80"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lammermann</surname><given-names>T.</given-names></name><name><surname>Afonso</surname><given-names>P. V.</given-names></name><name><surname>Angermann</surname><given-names>B. R.</given-names></name><name><surname>Wang</surname><given-names>J. M.</given-names></name><name><surname>Kastenmuller</surname><given-names>W.</given-names></name><name><surname>Parent</surname><given-names>C. A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo.</article-title>
<source><italic>Nature</italic></source>
<volume>498</volume>
<fpage>371</fpage>&#x02013;<lpage>375</lpage>. <pub-id pub-id-type="doi">10.1038/nature12175</pub-id>
<?supplied-pmid 23708969?><pub-id pub-id-type="pmid">23708969</pub-id></mixed-citation></ref><ref id="B81"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. S.</given-names></name><name><surname>Lee</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>S. O.</given-names></name><name><surname>Choi</surname><given-names>S. H.</given-names></name><name><surname>Kim</surname><given-names>Y. S.</given-names></name><name><surname>Woo</surname><given-names>J. H.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Adalimumab treatment may replace or enhance the activity of steroids in steroid-refractory tuberculous meningitis.</article-title>
<source><italic>J. Infect. Chemother.</italic></source>
<volume>18</volume>
<fpage>555</fpage>&#x02013;<lpage>557</lpage>. <pub-id pub-id-type="doi">10.1007/s10156-011-0334-y</pub-id>
<?supplied-pmid 22045163?><pub-id pub-id-type="pmid">22045163</pub-id></mixed-citation></ref><ref id="B82"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J. Y.</given-names></name><name><surname>Jung</surname><given-names>Y. W.</given-names></name><name><surname>Jeong</surname><given-names>I.</given-names></name><name><surname>Joh</surname><given-names>J. S.</given-names></name><name><surname>Sim</surname><given-names>S. Y.</given-names></name><name><surname>Choi</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Immune parameters differentiating active from latent tuberculosis infection in humans.</article-title>
<source><italic>Tuberculosis</italic></source>
<volume>95</volume>
<fpage>758</fpage>&#x02013;<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2015.08.003</pub-id>
<?supplied-pmid 26520601?><pub-id pub-id-type="pmid">26520601</pub-id></mixed-citation></ref><ref id="B83"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Gao</surname><given-names>B.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>L.</given-names></name><name><surname>Xiong</surname><given-names>S.</given-names></name></person-group> (<year>2016</year>). <article-title>The defect in autophagy induction by clinical isolates of <italic>Mycobacterium tuberculosis</italic> is correlated with poor tuberculosis outcomes.</article-title>
<source><italic>PLoS One</italic></source>
<volume>11</volume>:<issue>e0147810</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0147810</pub-id>
<?supplied-pmid 26815035?><pub-id pub-id-type="pmid">26815035</pub-id></mixed-citation></ref><ref id="B84"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>K. F.</given-names></name><name><surname>Lin</surname><given-names>C. L.</given-names></name><name><surname>Lai</surname><given-names>S. W.</given-names></name></person-group> (<year>2017</year>). <article-title>Population-based case-control study assessing the association between statins use and pulmonary tuberculosis in Taiwan.</article-title>
<source><italic>Front. Pharmacol.</italic></source>
<volume>8</volume>:<issue>597</issue>. <pub-id pub-id-type="doi">10.3389/fphar.2017.00597</pub-id>
<?supplied-pmid 28912719?><pub-id pub-id-type="pmid">28912719</pub-id></mixed-citation></ref><ref id="B85"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>R.</given-names></name><name><surname>Maycher</surname><given-names>B.</given-names></name><name><surname>Dhar</surname><given-names>A.</given-names></name><name><surname>Manfreda</surname><given-names>J.</given-names></name><name><surname>Hershfield</surname><given-names>E.</given-names></name><name><surname>Anthonisen</surname><given-names>N.</given-names></name></person-group> (<year>1998</year>). <article-title>Pulmonary tuberculosis treated with directly observed therapy: serial changes in lung structure and function.</article-title>
<source><italic>Chest</italic></source>
<volume>113</volume>
<fpage>933</fpage>&#x02013;<lpage>943</lpage>. <pub-id pub-id-type="doi">10.1378/chest.113.4.933</pub-id><pub-id pub-id-type="pmid">9554628</pub-id></mixed-citation></ref><ref id="B86"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>D. M.</given-names></name><name><surname>Bandara</surname><given-names>A. K.</given-names></name><name><surname>Packe</surname><given-names>G. E.</given-names></name><name><surname>Barker</surname><given-names>R. D.</given-names></name><name><surname>Wilkinson</surname><given-names>R. J.</given-names></name><name><surname>Griffiths</surname><given-names>C. J.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Neutrophilia independently predicts death in tuberculosis.</article-title>
<source><italic>Eur. Respir. J.</italic></source>
<volume>42</volume>
<fpage>1752</fpage>&#x02013;<lpage>1757</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00140913</pub-id>
<?supplied-pmid 24114967?><pub-id pub-id-type="pmid">24114967</pub-id></mixed-citation></ref><ref id="B87"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>D. M.</given-names></name><name><surname>Bangani</surname><given-names>N.</given-names></name><name><surname>Goliath</surname><given-names>R.</given-names></name><name><surname>Kampmann</surname><given-names>B.</given-names></name><name><surname>Wilkinson</surname><given-names>K. A.</given-names></name><name><surname>Wilkinson</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Effect of antiretroviral therapy on HIV-mediated impairment of the neutrophil antimycobacterial response.</article-title>
<source><italic>Ann. Am. Thorac. Soc.</italic></source>
<volume>12</volume>
<fpage>1627</fpage>&#x02013;<lpage>1637</lpage>. <pub-id pub-id-type="doi">10.1513/AnnalsATS.201507-463OC</pub-id>
<?supplied-pmid 26368270?><pub-id pub-id-type="pmid">26368270</pub-id></mixed-citation></ref><ref id="B88"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowe</surname><given-names>D. M.</given-names></name><name><surname>Redford</surname><given-names>P. S.</given-names></name><name><surname>Wilkinson</surname><given-names>R. J.</given-names></name><name><surname>O&#x02019;Garra</surname><given-names>A.</given-names></name><name><surname>Martineau</surname><given-names>A. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Neutrophils in tuberculosis: friend or foe?</article-title>
<source><italic>Trends Immunol.</italic></source>
<volume>33</volume>
<fpage>14</fpage>&#x02013;<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.it.2011.10.003</pub-id>
<?supplied-pmid 22094048?><pub-id pub-id-type="pmid">22094048</pub-id></mixed-citation></ref><ref id="B89"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahuad</surname><given-names>C.</given-names></name><name><surname>Bay</surname><given-names>M. L.</given-names></name><name><surname>Farroni</surname><given-names>M. A.</given-names></name><name><surname>Bozza</surname><given-names>V.</given-names></name><name><surname>Del Rey</surname><given-names>A.</given-names></name><name><surname>Besedovsky</surname><given-names>H.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>Cortisol and dehydroepiandrosterone affect the response of peripheral blood mononuclear cells to mycobacterial antigens during tuberculosis.</article-title>
<source><italic>Scand. J. Immunol.</italic></source>
<volume>60</volume>
<fpage>639</fpage>&#x02013;<lpage>646</lpage>. <pub-id pub-id-type="doi">10.1111/j.0300-9475.2004.01514.x</pub-id>
<?supplied-pmid 15584976?><pub-id pub-id-type="pmid">15584976</pub-id></mixed-citation></ref><ref id="B90"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>N. T.</given-names></name><name><surname>Dobbs</surname><given-names>N.</given-names></name><name><surname>Phu</surname><given-names>N. H.</given-names></name><name><surname>Colas</surname><given-names>R. A.</given-names></name><name><surname>Thao</surname><given-names>L. T.</given-names></name><name><surname>Thuong</surname><given-names>N. T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>A randomised double blind placebo controlled phase 2 trial of adjunctive aspirin for tuberculous meningitis in HIV-uninfected adults.</article-title>
<source><italic>eLife</italic></source>
<volume>7</volume>:<issue>e33478</issue>. <pub-id pub-id-type="doi">10.7554/eLife.33478</pub-id>
<?supplied-pmid 29482717?><pub-id pub-id-type="pmid">29482717</pub-id></mixed-citation></ref><ref id="B91"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maiga</surname><given-names>M. C.</given-names></name><name><surname>Ahidjo</surname><given-names>B. A.</given-names></name><name><surname>Maiga</surname><given-names>M.</given-names></name><name><surname>Bishai</surname><given-names>W. R.</given-names></name></person-group> (<year>2015</year>). <article-title>Roflumilast, a type 4 phosphodiesterase inhibitor, shows promising adjunctive, host-directed therapeutic activity in a mouse model of tuberculosis.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>59</volume>
<fpage>7888</fpage>&#x02013;<lpage>7890</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.02145-15</pub-id>
<?supplied-pmid 26438491?><pub-id pub-id-type="pmid">26438491</pub-id></mixed-citation></ref><ref id="B92"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malherbe</surname><given-names>S. T.</given-names></name><name><surname>Shenai</surname><given-names>S.</given-names></name><name><surname>Ronacher</surname><given-names>K.</given-names></name><name><surname>Loxton</surname><given-names>A. G.</given-names></name><name><surname>Dolganov</surname><given-names>G.</given-names></name><name><surname>Kriel</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Persisting positron emission tomography lesion activity and <italic>Mycobacterium tuberculosis</italic> mRNA after tuberculosis cure.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>22</volume>
<fpage>1094</fpage>&#x02013;<lpage>1100</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4177</pub-id>
<?supplied-pmid 29216039?><pub-id pub-id-type="pmid">27595324</pub-id></mixed-citation></ref><ref id="B93"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manca</surname><given-names>C.</given-names></name><name><surname>Koo</surname><given-names>M. S.</given-names></name><name><surname>Peixoto</surname><given-names>B.</given-names></name><name><surname>Fallows</surname><given-names>D.</given-names></name><name><surname>Kaplan</surname><given-names>G.</given-names></name><name><surname>Subbian</surname><given-names>S.</given-names></name></person-group> (<year>2013</year>). <article-title>Host targeted activity of pyrazinamide in <italic>Mycobacterium tuberculosis</italic> infection.</article-title>
<source><italic>PLoS One</italic></source>
<volume>8</volume>:<issue>e74082</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0074082</pub-id>
<?supplied-pmid 24015316?><pub-id pub-id-type="pmid">24015316</pub-id></mixed-citation></ref><ref id="B94"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manji</surname><given-names>M.</given-names></name><name><surname>Shayo</surname><given-names>G.</given-names></name><name><surname>Mamuya</surname><given-names>S.</given-names></name><name><surname>Mpembeni</surname><given-names>R.</given-names></name><name><surname>Jusabani</surname><given-names>A.</given-names></name><name><surname>Mugusi</surname><given-names>F.</given-names></name></person-group> (<year>2016</year>). <article-title>Lung functions among patients with pulmonary tuberculosis in Dar es Salaam - a cross-sectional study.</article-title>
<source><italic>BMC Pulm. Med.</italic></source>
<volume>16</volume>:<issue>58</issue>. <pub-id pub-id-type="doi">10.1186/s12890-016-0213-5</pub-id>
<?supplied-pmid 27107713?><pub-id pub-id-type="pmid">27107713</pub-id></mixed-citation></ref><ref id="B95"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marakalala</surname><given-names>M. J.</given-names></name><name><surname>Raju</surname><given-names>R. M.</given-names></name><name><surname>Sharma</surname><given-names>K.</given-names></name><name><surname>Zhang</surname><given-names>Y. J.</given-names></name><name><surname>Eugenin</surname><given-names>E. A.</given-names></name><name><surname>Prideaux</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Inflammatory signaling in human tuberculosis granulomas is spatially organized.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>22</volume>
<fpage>531</fpage>&#x02013;<lpage>538</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4073</pub-id>
<?supplied-pmid 27043495?><pub-id pub-id-type="pmid">27043495</pub-id></mixed-citation></ref><ref id="B96"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martineau</surname><given-names>A. R.</given-names></name><name><surname>Newton</surname><given-names>S. M.</given-names></name><name><surname>Wilkinson</surname><given-names>K. A.</given-names></name><name><surname>Kampmann</surname><given-names>B.</given-names></name><name><surname>Hall</surname><given-names>B. M.</given-names></name><name><surname>Nawroly</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2007</year>). <article-title>Neutrophil-mediated innate immune resistance to mycobacteria.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>117</volume>
<fpage>1988</fpage>&#x02013;<lpage>1994</lpage>. <pub-id pub-id-type="doi">10.1172/JCI31097</pub-id>
<?supplied-pmid 17607367?><pub-id pub-id-type="pmid">17607367</pub-id></mixed-citation></ref><ref id="B97"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martineau</surname><given-names>A. R.</given-names></name><name><surname>Timms</surname><given-names>P. M.</given-names></name><name><surname>Bothamley</surname><given-names>G. H.</given-names></name><name><surname>Hanifa</surname><given-names>Y.</given-names></name><name><surname>Islam</surname><given-names>K.</given-names></name><name><surname>Claxton</surname><given-names>A. P.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial.</article-title>
<source><italic>Lancet</italic></source>
<volume>377</volume>
<fpage>242</fpage>&#x02013;<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(10)61889-2</pub-id><pub-id pub-id-type="pmid">21215445</pub-id></mixed-citation></ref><ref id="B98"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martinez</surname><given-names>V.</given-names></name><name><surname>Castilla-Lievre</surname><given-names>M. A.</given-names></name><name><surname>Guillet-Caruba</surname><given-names>C.</given-names></name><name><surname>Grenier</surname><given-names>G.</given-names></name><name><surname>Fior</surname><given-names>R.</given-names></name><name><surname>Desarnaud</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>(18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>16</volume>
<fpage>1180</fpage>&#x02013;<lpage>1185</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.12.0010</pub-id>
<?supplied-pmid 22794271?><pub-id pub-id-type="pmid">22794271</pub-id></mixed-citation></ref><ref id="B99"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Masure</surname><given-names>S.</given-names></name><name><surname>Proost</surname><given-names>P.</given-names></name><name><surname>Van Damme</surname><given-names>J.</given-names></name><name><surname>Opdenakker</surname><given-names>G.</given-names></name></person-group> (<year>1991</year>). <article-title>Purification and identification of 91-kDa neutrophil gelatinase. Release by the activating peptide interleukin-8.</article-title>
<source><italic>Eur. J. Biochem.</italic></source>
<volume>198</volume>
<fpage>391</fpage>&#x02013;<lpage>398</lpage>. <pub-id pub-id-type="doi">10.1111/j.1432-1033.1991.tb16027.x</pub-id>
<?supplied-pmid 1645657?><pub-id pub-id-type="pmid">1645657</pub-id></mixed-citation></ref><ref id="B100"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayanja-Kizza</surname><given-names>H.</given-names></name><name><surname>Jones-Lopez</surname><given-names>E.</given-names></name><name><surname>Okwera</surname><given-names>A.</given-names></name><name><surname>Wallis</surname><given-names>R. S.</given-names></name><name><surname>Ellner</surname><given-names>J. J.</given-names></name><name><surname>Mugerwa</surname><given-names>R. D.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>191</volume>
<fpage>856</fpage>&#x02013;<lpage>865</lpage>. <pub-id pub-id-type="doi">10.1086/427995</pub-id>
<?supplied-pmid 15717259?><pub-id pub-id-type="pmid">15717259</pub-id></mixed-citation></ref><ref id="B101"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mayer-Barber</surname><given-names>K. D.</given-names></name><name><surname>Andrade</surname><given-names>B. B.</given-names></name><name><surname>Oland</surname><given-names>S. D.</given-names></name><name><surname>Amaral</surname><given-names>E. P.</given-names></name><name><surname>Barber</surname><given-names>D. L.</given-names></name><name><surname>Gonzales</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk.</article-title>
<source><italic>Nature</italic></source>
<volume>511</volume>
<fpage>99</fpage>&#x02013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1038/nature13489</pub-id>
<?supplied-pmid 24990750?><pub-id pub-id-type="pmid">24990750</pub-id></mixed-citation></ref><ref id="B102"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzarella</surname><given-names>G.</given-names></name><name><surname>Bianco</surname><given-names>A.</given-names></name><name><surname>Perna</surname><given-names>F.</given-names></name><name><surname>D&#x02019;Auria</surname><given-names>D.</given-names></name><name><surname>Grella</surname><given-names>E.</given-names></name><name><surname>Moscariello</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2003</year>). <article-title>T lymphocyte phenotypic profile in lung segments affected by cavitary and non-cavitary tuberculosis.</article-title>
<source><italic>Clin. Exp. Immunol.</italic></source>
<volume>132</volume>
<fpage>283</fpage>&#x02013;<lpage>288</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2249.2003.02121.x</pub-id>
<?supplied-pmid 12699418?><pub-id pub-id-type="pmid">12699418</pub-id></mixed-citation></ref><ref id="B103"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meghji</surname><given-names>J.</given-names></name><name><surname>Simpson</surname><given-names>H.</given-names></name><name><surname>Squire</surname><given-names>S. B.</given-names></name><name><surname>Mortimer</surname><given-names>K.</given-names></name></person-group> (<year>2016</year>). <article-title>A systematic review of the prevalence and pattern of imaging defined post-TB lung disease.</article-title>
<source><italic>PLoS One</italic></source>
<volume>11</volume>:<issue>e0161176</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0161176</pub-id>
<?supplied-pmid 27518438?><pub-id pub-id-type="pmid">27518438</pub-id></mixed-citation></ref><ref id="B104"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meintjes</surname><given-names>G.</given-names></name><name><surname>Skolimowska</surname><given-names>K. H.</given-names></name><name><surname>Wilkinson</surname><given-names>K. A.</given-names></name><name><surname>Matthews</surname><given-names>K.</given-names></name><name><surname>Tadokera</surname><given-names>R.</given-names></name><name><surname>Conesa-Botella</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome.</article-title>
<source><italic>Am. J. Respir. Crit. Care Med.</italic></source>
<volume>186</volume>
<fpage>369</fpage>&#x02013;<lpage>377</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201201-0094OC</pub-id>
<?supplied-pmid 22700860?><pub-id pub-id-type="pmid">22700860</pub-id></mixed-citation></ref><ref id="B105"><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Meintjes</surname><given-names>G.</given-names></name><name><surname>Stek</surname><given-names>C.</given-names></name><name><surname>Blumenthal</surname><given-names>L.</given-names></name><name><surname>Thienemann</surname><given-names>F.</given-names></name><name><surname>Schutz</surname><given-names>C.</given-names></name><name><surname>Buyze</surname><given-names>J.</given-names></name><etal/></person-group> (<year>2017</year>). <source><italic>Randomized Controlled Trial of Prednisone for the Prevention of TB-IRIS, CROI; Abstract Number 81LB.</italic></source>
<publisher-loc>Cape Town</publisher-loc>: <publisher-name>University of Cape Town</publisher-name>.</mixed-citation></ref><ref id="B106"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercalli</surname><given-names>A.</given-names></name><name><surname>Calavita</surname><given-names>I.</given-names></name><name><surname>Dugnani</surname><given-names>E.</given-names></name><name><surname>Citro</surname><given-names>A.</given-names></name><name><surname>Cantarelli</surname><given-names>E.</given-names></name><name><surname>Nano</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Rapamycin unbalances the polarization of human macrophages to M1.</article-title>
<source><italic>Immunology</italic></source>
<volume>140</volume>
<fpage>179</fpage>&#x02013;<lpage>190</lpage>. <pub-id pub-id-type="doi">10.1111/imm.12126</pub-id>
<?supplied-pmid 23710834?><pub-id pub-id-type="pmid">23710834</pub-id></mixed-citation></ref><ref id="B107"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mesquita</surname><given-names>E. D.</given-names></name><name><surname>Gil-Santana</surname><given-names>L.</given-names></name><name><surname>Ramalho</surname><given-names>D.</given-names></name><name><surname>Tonomura</surname><given-names>E.</given-names></name><name><surname>Silva</surname><given-names>E. C.</given-names></name><name><surname>Oliveira</surname><given-names>M. M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Associations between systemic inflammation, mycobacterial loads in sputum and radiological improvement after treatment initiation in pulmonary TB patients from Brazil: a prospective cohort study.</article-title>
<source><italic>BMC Infect. Dis.</italic></source>
<volume>16</volume>:<issue>368</issue>. <pub-id pub-id-type="doi">10.1186/s12879-016-1736-3</pub-id>
<?supplied-pmid 27494953?><pub-id pub-id-type="pmid">27494953</pub-id></mixed-citation></ref><ref id="B108"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihret</surname><given-names>A.</given-names></name><name><surname>Abebe</surname><given-names>M.</given-names></name><name><surname>Bekele</surname><given-names>Y.</given-names></name><name><surname>Aseffa</surname><given-names>A.</given-names></name><name><surname>Walzl</surname><given-names>G.</given-names></name><name><surname>Howe</surname><given-names>R.</given-names></name></person-group> (<year>2014</year>). <article-title>Impact of HIV co-infection on plasma level of cytokines and chemokines of pulmonary tuberculosis patients.</article-title>
<source><italic>BMC Infect. Dis.</italic></source>
<volume>14</volume>:<issue>125</issue>. <pub-id pub-id-type="doi">10.1186/1471-2334-14-125</pub-id>
<?supplied-pmid 24592945?><pub-id pub-id-type="pmid">24592945</pub-id></mixed-citation></ref><ref id="B109"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milliron</surname><given-names>B.</given-names></name><name><surname>Henry</surname><given-names>T. S.</given-names></name><name><surname>Veeraraghavan</surname><given-names>S.</given-names></name><name><surname>Little</surname><given-names>B. P.</given-names></name></person-group> (<year>2015</year>). <article-title>Bronchiectasis: mechanisms and imaging clues of associated common and uncommon diseases.</article-title>
<source><italic>Radiographics</italic></source>
<volume>35</volume>
<fpage>1011</fpage>&#x02013;<lpage>1030</lpage>. <pub-id pub-id-type="doi">10.1148/rg.2015140214</pub-id>
<?supplied-pmid 26024063?><pub-id pub-id-type="pmid">26024063</pub-id></mixed-citation></ref><ref id="B110"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mily</surname><given-names>A.</given-names></name><name><surname>Rekha</surname><given-names>R. S.</given-names></name><name><surname>Kamal</surname><given-names>S. M.</given-names></name><name><surname>Arifuzzaman</surname><given-names>A. S.</given-names></name><name><surname>Rahim</surname><given-names>Z.</given-names></name><name><surname>Khan</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Significant effects of oral phenylbutyrate and vitamin D3 adjunctive therapy in pulmonary tuberculosis: a randomized controlled trial.</article-title>
<source><italic>PLoS One</italic></source>
<volume>10</volume>:<issue>e0138340</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0138340</pub-id>
<?supplied-pmid 26394045?><pub-id pub-id-type="pmid">26394045</pub-id></mixed-citation></ref><ref id="B111"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>B. B.</given-names></name><name><surname>Lovewell</surname><given-names>R. R.</given-names></name><name><surname>Olive</surname><given-names>A. J.</given-names></name><name><surname>Zhang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Eugenin</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Nitric oxide prevents a pathogen-permissive granulocytic inflammation during tuberculosis.</article-title>
<source><italic>Nat. Microbiol.</italic></source>
<volume>2</volume>:<issue>17072</issue>. <pub-id pub-id-type="doi">10.1038/nmicrobiol.2017.72</pub-id>
<?supplied-pmid 28504669?><pub-id pub-id-type="pmid">28504669</pub-id></mixed-citation></ref><ref id="B112"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>B. B.</given-names></name><name><surname>Rathinam</surname><given-names>V. A.</given-names></name><name><surname>Martens</surname><given-names>G. W.</given-names></name><name><surname>Martinot</surname><given-names>A. J.</given-names></name><name><surname>Kornfeld</surname><given-names>H.</given-names></name><name><surname>Fitzgerald</surname><given-names>K. A.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Nitric oxide controls the immunopathology of tuberculosis by inhibiting NLRP3 inflammasome-dependent processing of IL-1beta.</article-title>
<source><italic>Nat. Immunol.</italic></source>
<volume>14</volume>
<fpage>52</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2474</pub-id>
<?supplied-pmid 23160153?><pub-id pub-id-type="pmid">23160153</pub-id></mixed-citation></ref><ref id="B113"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misra</surname><given-names>U. K.</given-names></name><name><surname>Kalita</surname><given-names>J.</given-names></name><name><surname>Nair</surname><given-names>P. P.</given-names></name></person-group> (<year>2010</year>). <article-title>Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial.</article-title>
<source><italic>J. Neurol. Sci.</italic></source>
<volume>293</volume>
<fpage>12</fpage>&#x02013;<lpage>17</lpage>. <pub-id pub-id-type="doi">10.1016/j.jns.2010.03.025</pub-id>
<?supplied-pmid 20421121?><pub-id pub-id-type="pmid">20421121</pub-id></mixed-citation></ref><ref id="B114"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nachiappan</surname><given-names>A. C.</given-names></name><name><surname>Rahbar</surname><given-names>K.</given-names></name><name><surname>Shi</surname><given-names>X.</given-names></name><name><surname>Guy</surname><given-names>E. S.</given-names></name><name><surname>Mortani Barbosa</surname><given-names>E. J.</given-names><suffix>Jr.</suffix></name><name><surname>Shroff</surname><given-names>G. S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Pulmonary tuberculosis: role of radiology in diagnosis and management.</article-title>
<source><italic>Radiographics</italic></source>
<volume>37</volume>
<fpage>52</fpage>&#x02013;<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1148/rg.2017160032</pub-id>
<?supplied-pmid 28076011?><pub-id pub-id-type="pmid">28076011</pub-id></mixed-citation></ref><ref id="B115"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nadella</surname><given-names>V.</given-names></name><name><surname>Mohanty</surname><given-names>A.</given-names></name><name><surname>Sharma</surname><given-names>L.</given-names></name><name><surname>Yellaboina</surname><given-names>S.</given-names></name><name><surname>Mollenkopf</surname><given-names>H. J.</given-names></name><name><surname>Mazumdar</surname><given-names>V. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Inhibitors of apoptosis protein antagonists (Smac mimetic compounds) control polarization of macrophages during microbial challenge and sterile inflammatory responses.</article-title>
<source><italic>Front. Immunol.</italic></source>
<volume>8</volume>:<issue>1792</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.01792</pub-id>
<?supplied-pmid 29375545?><pub-id pub-id-type="pmid">29375545</pub-id></mixed-citation></ref><ref id="B116"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakiwala</surname><given-names>J. K.</given-names></name><name><surname>Walker</surname><given-names>N. F.</given-names></name><name><surname>Diedrich</surname><given-names>C. R.</given-names></name><name><surname>Worodria</surname><given-names>W.</given-names></name><name><surname>Meintjes</surname><given-names>G.</given-names></name><name><surname>Wilkinson</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Neutrophil activation and enhanced release of granule products in HIV-TB immune reconstitution inflammatory syndrome.</article-title>
<source><italic>J. Acquir. Immune Defic. Syndr.</italic></source>
<volume>77</volume>
<fpage>221</fpage>&#x02013;<lpage>229</lpage>. <pub-id pub-id-type="doi">10.1097/QAI.0000000000001582</pub-id>
<?supplied-pmid 29135655?><pub-id pub-id-type="pmid">29135655</pub-id></mixed-citation></ref><ref id="B117"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Namale</surname><given-names>P. E.</given-names></name><name><surname>Abdullahi</surname><given-names>L. H.</given-names></name><name><surname>Fine</surname><given-names>S.</given-names></name><name><surname>Kamkuemah</surname><given-names>M.</given-names></name><name><surname>Wilkinson</surname><given-names>R. J.</given-names></name><name><surname>Meintjes</surname><given-names>G.</given-names></name></person-group> (<year>2015</year>). <article-title>Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis.</article-title>
<source><italic>Future Microbiol.</italic></source>
<volume>10</volume>
<fpage>1077</fpage>&#x02013;<lpage>1099</lpage>. <pub-id pub-id-type="doi">10.2217/fmb.15.9</pub-id>
<?supplied-pmid 26059627?><pub-id pub-id-type="pmid">26059627</pub-id></mixed-citation></ref><ref id="B118"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandi</surname><given-names>B.</given-names></name><name><surname>Behar</surname><given-names>S. M.</given-names></name></person-group> (<year>2011</year>). <article-title>Regulation of neutrophils by interferon-gamma limits lung inflammation during tuberculosis infection.</article-title>
<source><italic>J. Exp. Med.</italic></source>
<volume>208</volume>
<fpage>2251</fpage>&#x02013;<lpage>2262</lpage>. <pub-id pub-id-type="doi">10.1084/jem.20110919</pub-id>
<?supplied-pmid 21967766?><pub-id pub-id-type="pmid">21967766</pub-id></mixed-citation></ref><ref id="B119"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narendran</surname><given-names>G.</given-names></name><name><surname>Kavitha</surname><given-names>D.</given-names></name><name><surname>Karunaianantham</surname><given-names>R.</given-names></name><name><surname>Gil-Santana</surname><given-names>L.</given-names></name><name><surname>Almeida-Junior</surname><given-names>J. L.</given-names></name><name><surname>Reddy</surname><given-names>S. D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Role of LTA4H polymorphism in tuberculosis-associated immune reconstitution inflammatory syndrome occurrence and clinical severity in patients infected with HIV.</article-title>
<source><italic>PLoS One</italic></source>
<volume>11</volume>:<issue>e0163298</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0163298</pub-id>
<?supplied-pmid 27643598?><pub-id pub-id-type="pmid">27643598</pub-id></mixed-citation></ref><ref id="B120"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ndlovu</surname><given-names>H.</given-names></name><name><surname>Marakalala</surname><given-names>M. J.</given-names></name></person-group> (<year>2016</year>). <article-title>Granulomas and inflammation: host-directed therapies for tuberculosis.</article-title>
<source><italic>Front. Immunol.</italic></source>
<volume>7</volume>:<issue>434</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2016.00434</pub-id>
<?supplied-pmid 27822210?><pub-id pub-id-type="pmid">27822210</pub-id></mixed-citation></ref><ref id="B121"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nihues Sde</surname><given-names>S.</given-names></name><name><surname>Mancuzo</surname><given-names>E. V.</given-names></name><name><surname>Sulmonetti</surname><given-names>N.</given-names></name><name><surname>Sacchi</surname><given-names>F. P.</given-names></name><name><surname>Viana Vde</surname><given-names>S.</given-names></name><name><surname>Netto</surname><given-names>E. M.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Chronic symptoms and pulmonary dysfunction in post-tuberculosis Brazilian patients.</article-title>
<source><italic>Braz. J. Infect. Dis.</italic></source>
<volume>19</volume>
<fpage>492</fpage>&#x02013;<lpage>497</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjid.2015.06.005</pub-id>
<?supplied-pmid 26254689?><pub-id pub-id-type="pmid">26254689</pub-id></mixed-citation></ref><ref id="B122"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolan</surname><given-names>A.</given-names></name><name><surname>Condos</surname><given-names>R.</given-names></name><name><surname>Huie</surname><given-names>M. L.</given-names></name><name><surname>Dawson</surname><given-names>R.</given-names></name><name><surname>Dheda</surname><given-names>K.</given-names></name><name><surname>Bateman</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Elevated IP-10 and IL-6 from bronchoalveolar lavage cells are biomarkers of non-cavitary tuberculosis.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>17</volume>
<fpage>922</fpage>&#x02013;<lpage>927</lpage>. <pub-id pub-id-type="doi">10.5588/ijtld.12.0610</pub-id>
<?supplied-pmid 23743311?><pub-id pub-id-type="pmid">23743311</pub-id></mixed-citation></ref><ref id="B123"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Garra</surname><given-names>A.</given-names></name><name><surname>Redford</surname><given-names>P. S.</given-names></name><name><surname>McNab</surname><given-names>F. W.</given-names></name><name><surname>Bloom</surname><given-names>C. I.</given-names></name><name><surname>Wilkinson</surname><given-names>R. J.</given-names></name><name><surname>Berry</surname><given-names>M. P.</given-names></name></person-group> (<year>2013</year>). <article-title>The immune response in tuberculosis.</article-title>
<source><italic>Annu. Rev. Immunol.</italic></source>
<volume>31</volume>
<fpage>475</fpage>&#x02013;<lpage>527</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-immunol-032712-095939</pub-id>
<?supplied-pmid 23516984?><pub-id pub-id-type="pmid">23516984</pub-id></mixed-citation></ref><ref id="B124"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>C. W.</given-names></name><name><surname>Elkington</surname><given-names>P. T.</given-names></name><name><surname>Brilha</surname><given-names>S.</given-names></name><name><surname>Ugarte-Gil</surname><given-names>C.</given-names></name><name><surname>Tome-Esteban</surname><given-names>M. T.</given-names></name><name><surname>Tezera</surname><given-names>L. B.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Neutrophil-derived MMP-8 drives AMPK-dependent matrix destruction in human pulmonary tuberculosis.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>11</volume>:<issue>e1004917</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1004917</pub-id>
<?supplied-pmid 25996154?><pub-id pub-id-type="pmid">25996154</pub-id></mixed-citation></ref><ref id="B125"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>C. W.</given-names></name><name><surname>Elkington</surname><given-names>P. T.</given-names></name><name><surname>Friedland</surname><given-names>J. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.</article-title>
<source><italic>Am. J. Respir. Crit. Care Med.</italic></source>
<volume>190</volume>
<fpage>9</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201311-2106PP</pub-id>
<?supplied-pmid 24713029?><pub-id pub-id-type="pmid">24713029</pub-id></mixed-citation></ref><ref id="B126"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozguler</surname><given-names>Y.</given-names></name><name><surname>Hatemi</surname><given-names>G.</given-names></name><name><surname>Ugurlu</surname><given-names>S.</given-names></name><name><surname>Seyahi</surname><given-names>E.</given-names></name><name><surname>Melikoglu</surname><given-names>M.</given-names></name><name><surname>Borekci</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Re-initiation of biologics after the development of tuberculosis under anti-TNF therapy.</article-title>
<source><italic>Rheumatol. Int.</italic></source>
<volume>36</volume>
<fpage>1719</fpage>&#x02013;<lpage>1725</lpage>. <pub-id pub-id-type="doi">10.1007/s00296-016-3575-3</pub-id>
<?supplied-pmid 27699578?><pub-id pub-id-type="pmid">27699578</pub-id></mixed-citation></ref><ref id="B127"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Panteleev</surname><given-names>A. V.</given-names></name><name><surname>Nikitina</surname><given-names>I. Y.</given-names></name><name><surname>Burmistrova</surname><given-names>I. A.</given-names></name><name><surname>Kosmiadi</surname><given-names>G. A.</given-names></name><name><surname>Radaeva</surname><given-names>T. V.</given-names></name><name><surname>Amansahedov</surname><given-names>R. B.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Severe tuberculosis in humans correlates best with neutrophil abundance and lymphocyte deficiency and does not correlate with antigen-specific CD4 T-cell response.</article-title>
<source><italic>Front. Immunol.</italic></source>
<volume>8</volume>:<issue>963</issue>. <pub-id pub-id-type="doi">10.3389/fimmu.2017.00963</pub-id>
<?supplied-pmid 28871253?><pub-id pub-id-type="pmid">28871253</pub-id></mixed-citation></ref><ref id="B128"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parasa</surname><given-names>V. R.</given-names></name><name><surname>Muvva</surname><given-names>J. R.</given-names></name><name><surname>Rose</surname><given-names>J. F.</given-names></name><name><surname>Braian</surname><given-names>C.</given-names></name><name><surname>Brighenti</surname><given-names>S.</given-names></name><name><surname>Lerm</surname><given-names>M.</given-names></name></person-group> (<year>2017</year>). <article-title>Inhibition of tissue matrix metalloproteinases interferes with <italic>Mycobacterium tuberculosis</italic>-induced granuloma formation and reduces bacterial load in a human lung tissue model.</article-title>
<source><italic>Front. Microbiol.</italic></source>
<volume>8</volume>:<issue>2370</issue>. <pub-id pub-id-type="doi">10.3389/fmicb.2017.02370</pub-id>
<?supplied-pmid 29259583?><pub-id pub-id-type="pmid">29259583</pub-id></mixed-citation></ref><ref id="B129"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parida</surname><given-names>S. K.</given-names></name><name><surname>Madansein</surname><given-names>R.</given-names></name><name><surname>Singh</surname><given-names>N.</given-names></name><name><surname>Padayatchi</surname><given-names>N.</given-names></name><name><surname>Master</surname><given-names>I.</given-names></name><name><surname>Naidu</surname><given-names>K.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Cellular therapy in tuberculosis.</article-title>
<source><italic>Int. J. Infect. Dis.</italic></source>
<volume>32</volume>
<fpage>32</fpage>&#x02013;<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2015.01.016</pub-id>
<?supplied-pmid 25809753?><pub-id pub-id-type="pmid">25809753</pub-id></mixed-citation></ref><ref id="B130"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parihar</surname><given-names>S. P.</given-names></name><name><surname>Guler</surname><given-names>R.</given-names></name><name><surname>Khutlang</surname><given-names>R.</given-names></name><name><surname>Lang</surname><given-names>D. M.</given-names></name><name><surname>Hurdayal</surname><given-names>R.</given-names></name><name><surname>Mhlanga</surname><given-names>M. M.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Statin therapy reduces the <italic>Mycobacterium tuberculosis</italic> burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>209</volume>
<fpage>754</fpage>&#x02013;<lpage>763</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit550</pub-id>
<?supplied-pmid 24133190?><pub-id pub-id-type="pmid">24133190</pub-id></mixed-citation></ref><ref id="B131"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pefura-Yone</surname><given-names>E. W.</given-names></name><name><surname>Fodjeu</surname><given-names>G.</given-names></name><name><surname>Kengne</surname><given-names>A. P.</given-names></name><name><surname>Roche</surname><given-names>N.</given-names></name><name><surname>Kuaban</surname><given-names>C.</given-names></name></person-group> (<year>2015</year>). <article-title>Prevalence and determinants of chronic obstructive pulmonary disease in HIV infected patients in an African country with low level of tobacco smoking.</article-title>
<source><italic>Respir. Med.</italic></source>
<volume>109</volume>
<fpage>247</fpage>&#x02013;<lpage>254</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2014.12.003</pub-id>
<?supplied-pmid 25538018?><pub-id pub-id-type="pmid">25538018</pub-id></mixed-citation></ref><ref id="B132"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petty</surname><given-names>T. L.</given-names></name><name><surname>Dalrymple</surname><given-names>G. V.</given-names></name></person-group> (<year>1964</year>). <article-title>Inhibition of pyrazinamide hyperuricemia by small doses of acetylsalicylic acid.</article-title>
<source><italic>Ann. Intern. Med.</italic></source>
<volume>60</volume>
<fpage>898</fpage>&#x02013;<lpage>900</lpage>. <pub-id pub-id-type="doi">10.7326/0003-4819-60-5-898</pub-id>
<?supplied-pmid 14156616?><pub-id pub-id-type="pmid">14156616</pub-id></mixed-citation></ref><ref id="B133"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plit</surname><given-names>M. L.</given-names></name><name><surname>Anderson</surname><given-names>R.</given-names></name><name><surname>Van Rensburg</surname><given-names>C. E.</given-names></name><name><surname>Page-Shipp</surname><given-names>L.</given-names></name><name><surname>Blott</surname><given-names>J. A.</given-names></name><name><surname>Fresen</surname><given-names>J. L.</given-names></name><etal/></person-group> (<year>1998</year>). <article-title>Influence of antimicrobial chemotherapy on spirometric parameters and pro-inflammatory indices in severe pulmonary tuberculosis.</article-title>
<source><italic>Eur. Respir. J.</italic></source>
<volume>12</volume>
<fpage>351</fpage>&#x02013;<lpage>356</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.98.12020351</pub-id>
<?supplied-pmid 9727784?><pub-id pub-id-type="pmid">9727784</pub-id></mixed-citation></ref><ref id="B134"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>N. M.</given-names></name><name><surname>Farrar</surname><given-names>J.</given-names></name><name><surname>Tran</surname><given-names>T. T.</given-names></name><name><surname>Nguyen</surname><given-names>T. H.</given-names></name><name><surname>Tran</surname><given-names>T. H.</given-names></name><name><surname>Friedland</surname><given-names>J. S.</given-names></name></person-group> (<year>2001</year>). <article-title>Identification of a matrix-degrading phenotype in human tuberculosis in vitro and in vivo.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>166</volume>
<fpage>4223</fpage>&#x02013;<lpage>4230</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.166.6.4223</pub-id>
<?supplied-pmid 11238675?><pub-id pub-id-type="pmid">11238675</pub-id></mixed-citation></ref><ref id="B135"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Radovic</surname><given-names>M.</given-names></name><name><surname>Ristic</surname><given-names>L.</given-names></name><name><surname>Ciric</surname><given-names>Z.</given-names></name><name><surname>Dinic-Radovic</surname><given-names>V.</given-names></name><name><surname>Stankovic</surname><given-names>I.</given-names></name><name><surname>Pejcic</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Changes in respiratory function impairment following the treatment of severe pulmonary tuberculosis - limitations for the underlying COPD detection.</article-title>
<source><italic>Int. J. Chron. Obstruct. Pulmon. Dis.</italic></source>
<volume>11</volume>
<fpage>1307</fpage>&#x02013;<lpage>1316</lpage>. <pub-id pub-id-type="doi">10.2147/COPD.S106875</pub-id>
<?supplied-pmid 27366058?><pub-id pub-id-type="pmid">27366058</pub-id></mixed-citation></ref><ref id="B136"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralph</surname><given-names>A. P.</given-names></name><name><surname>Kenangalem</surname><given-names>E.</given-names></name><name><surname>Waramori</surname><given-names>G.</given-names></name><name><surname>Pontororing</surname><given-names>G. J.</given-names></name><name><surname>Sandjaja</surname></name><name><surname>Tjitra</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2013a</year>). <article-title>High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis: under-recognised phenomena.</article-title>
<source><italic>PLoS One</italic></source>
<volume>8</volume>:<issue>e80302</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0080302</pub-id>
<?supplied-pmid 24312209?><pub-id pub-id-type="pmid">24312209</pub-id></mixed-citation></ref><ref id="B137"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ralph</surname><given-names>A. P.</given-names></name><name><surname>Waramori</surname><given-names>G.</given-names></name><name><surname>Pontororing</surname><given-names>G. J.</given-names></name><name><surname>Kenangalem</surname><given-names>E.</given-names></name><name><surname>Wiguna</surname><given-names>A.</given-names></name><name><surname>Tjitra</surname><given-names>E.</given-names></name><etal/></person-group> (<year>2013b</year>). <article-title>L-arginine and vitamin D adjunctive therapies in pulmonary tuberculosis: a randomised, double-blind, placebo-controlled trial.</article-title>
<source><italic>PLoS One</italic></source>
<volume>8</volume>:<issue>e70032</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0070032</pub-id>
<?supplied-pmid 23967066?><pub-id pub-id-type="pmid">23967066</pub-id></mixed-citation></ref><ref id="B138"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rand</surname><given-names>L.</given-names></name><name><surname>Green</surname><given-names>J. A.</given-names></name><name><surname>Saraiva</surname><given-names>L.</given-names></name><name><surname>Friedland</surname><given-names>J. S.</given-names></name><name><surname>Elkington</surname><given-names>P. T.</given-names></name></person-group> (<year>2009</year>). <article-title>Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPK-dependent, p-aminosalicylic acid-sensitive signaling cascade.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>182</volume>
<fpage>5865</fpage>&#x02013;<lpage>5872</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.0801935</pub-id>
<?supplied-pmid 19380835?><pub-id pub-id-type="pmid">19380835</pub-id></mixed-citation></ref><ref id="B139"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rangel Moreno</surname><given-names>J.</given-names></name><name><surname>Estrada Garcia</surname><given-names>I.</given-names></name><name><surname>De La Luz Garcia Hernandez</surname><given-names>M.</given-names></name><name><surname>Aguilar Leon</surname><given-names>D.</given-names></name><name><surname>Marquez</surname><given-names>R.</given-names></name><name><surname>Hernandez Pando</surname><given-names>R.</given-names></name></person-group> (<year>2002</year>). <article-title>The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis.</article-title>
<source><italic>Immunology</italic></source>
<volume>106</volume>
<fpage>257</fpage>&#x02013;<lpage>266</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2567.2002.01403.x</pub-id>
<?supplied-pmid 12047755?><pub-id pub-id-type="pmid">12047755</pub-id></mixed-citation></ref><ref id="B140"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rathinam</surname><given-names>V. A.</given-names></name><name><surname>Vanaja</surname><given-names>S. K.</given-names></name><name><surname>Fitzgerald</surname><given-names>K. A.</given-names></name></person-group> (<year>2012</year>). <article-title>Regulation of inflammasome signaling.</article-title>
<source><italic>Nat. Immunol.</italic></source>
<volume>13</volume>
<fpage>333</fpage>&#x02013;<lpage>342</lpage>. <pub-id pub-id-type="doi">10.1038/ni.2237</pub-id>
<?supplied-pmid 22430786?><pub-id pub-id-type="pmid">22430786</pub-id></mixed-citation></ref><ref id="B141"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravimohan</surname><given-names>S.</given-names></name><name><surname>Tamuhla</surname><given-names>N.</given-names></name><name><surname>Kung</surname><given-names>S. J.</given-names></name><name><surname>Nfanyana</surname><given-names>K.</given-names></name><name><surname>Steenhoff</surname><given-names>A. P.</given-names></name><name><surname>Gross</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Matrix metalloproteinases in tuberculosis-immune reconstitution inflammatory syndrome and impaired lung function among advanced HIV/TB co-infected patients initiating antiretroviral therapy.</article-title>
<source><italic>EBioMedicine</italic></source>
<volume>3</volume>
<fpage>100</fpage>&#x02013;<lpage>107</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2015.11.040</pub-id>
<?supplied-pmid 27014741?><pub-id pub-id-type="pmid">27014741</pub-id></mixed-citation></ref><ref id="B142"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ravimohan</surname><given-names>S.</given-names></name><name><surname>Tamuhla</surname><given-names>N.</given-names></name><name><surname>Steenhoff</surname><given-names>A. P.</given-names></name><name><surname>Letlhogile</surname><given-names>R.</given-names></name><name><surname>Nfanyana</surname><given-names>K.</given-names></name><name><surname>Bellamy</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.</article-title>
<source><italic>Lancet Infect. Dis.</italic></source>
<volume>15</volume>
<fpage>429</fpage>&#x02013;<lpage>438</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(15)70008-3</pub-id>
<?supplied-pmid 25932576?><pub-id pub-id-type="pmid">25672566</pub-id></mixed-citation></ref><ref id="B143"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riou</surname><given-names>C.</given-names></name><name><surname>Perez Peixoto</surname><given-names>B.</given-names></name><name><surname>Roberts</surname><given-names>L.</given-names></name><name><surname>Ronacher</surname><given-names>K.</given-names></name><name><surname>Walzl</surname><given-names>G.</given-names></name><name><surname>Manca</surname><given-names>C.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Effect of standard tuberculosis treatment on plasma cytokine levels in patients with active pulmonary tuberculosis.</article-title>
<source><italic>PLoS One</italic></source>
<volume>7</volume>:<issue>e36886</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0036886</pub-id>
<?supplied-pmid 22606304?><pub-id pub-id-type="pmid">22606304</pub-id></mixed-citation></ref><ref id="B144"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname><given-names>S.</given-names></name><name><surname>Kauffman</surname><given-names>K. D.</given-names></name><name><surname>Sallin</surname><given-names>M. A.</given-names></name><name><surname>Sharpe</surname><given-names>A. H.</given-names></name><name><surname>Young</surname><given-names>H. A.</given-names></name><name><surname>Ganusov</surname><given-names>V. V.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary <italic>Mycobacterium tuberculosis</italic> infection and must be actively repressed by PD-1 to prevent lethal disease.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>12</volume>:<issue>e1005667</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1005667</pub-id>
<?supplied-pmid 27244558?><pub-id pub-id-type="pmid">27244558</pub-id></mixed-citation></ref><ref id="B145"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakamoto</surname><given-names>K.</given-names></name><name><surname>Kim</surname><given-names>M. J.</given-names></name><name><surname>Rhoades</surname><given-names>E. R.</given-names></name><name><surname>Allavena</surname><given-names>R. E.</given-names></name><name><surname>Ehrt</surname><given-names>S.</given-names></name><name><surname>Wainwright</surname><given-names>H. C.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Mycobacterial trehalose dimycolate reprograms macrophage global gene expression and activates matrix metalloproteinases.</article-title>
<source><italic>Infect. Immun.</italic></source>
<volume>81</volume>
<fpage>764</fpage>&#x02013;<lpage>776</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.00906-12</pub-id>
<?supplied-pmid 23264051?><pub-id pub-id-type="pmid">23264051</pub-id></mixed-citation></ref><ref id="B146"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salahuddin</surname><given-names>N.</given-names></name><name><surname>Ali</surname><given-names>F.</given-names></name><name><surname>Hasan</surname><given-names>Z.</given-names></name><name><surname>Rao</surname><given-names>N.</given-names></name><name><surname>Aqeel</surname><given-names>M.</given-names></name><name><surname>Mahmood</surname><given-names>F.</given-names></name></person-group> (<year>2013</year>). <article-title>Vitamin D accelerates clinical recovery from tuberculosis: results of the SUCCINCT Study [Supplementary Cholecalciferol in recovery from tuberculosis]. A randomized, placebo-controlled, clinical trial of vitamin D supplementation in patients with pulmonary tuberculosis&#x02019;.</article-title>
<source><italic>BMC Infect. Dis.</italic></source>
<volume>13</volume>:<issue>22</issue>. <pub-id pub-id-type="doi">10.1186/1471-2334-13-22</pub-id>
<?supplied-pmid 23331510?><pub-id pub-id-type="pmid">23331510</pub-id></mixed-citation></ref><ref id="B147"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Samperiz</surname><given-names>G.</given-names></name><name><surname>Guerrero</surname><given-names>D.</given-names></name><name><surname>Lopez</surname><given-names>M.</given-names></name><name><surname>Valera</surname><given-names>J. L.</given-names></name><name><surname>Iglesias</surname><given-names>A.</given-names></name><name><surname>Rios</surname><given-names>A.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Prevalence of and risk factors for pulmonary abnormalities in HIV-infected patients treated with antiretroviral therapy.</article-title>
<source><italic>HIV Med.</italic></source>
<volume>15</volume>
<fpage>321</fpage>&#x02013;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1111/hiv.12117</pub-id>
<?supplied-pmid 24314004?><pub-id pub-id-type="pmid">24314004</pub-id></mixed-citation></ref><ref id="B148"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sathyamoorthy</surname><given-names>T.</given-names></name><name><surname>Tezera</surname><given-names>L. B.</given-names></name><name><surname>Walker</surname><given-names>N. F.</given-names></name><name><surname>Brilha</surname><given-names>S.</given-names></name><name><surname>Saraiva</surname><given-names>L.</given-names></name><name><surname>Mauri</surname><given-names>F. A.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Membrane type 1 matrix metalloproteinase regulates monocyte migration and collagen destruction in tuberculosis.</article-title>
<source><italic>J. Immunol.</italic></source>
<volume>195</volume>
<fpage>882</fpage>&#x02013;<lpage>891</lpage>. <pub-id pub-id-type="doi">10.4049/jimmunol.1403110</pub-id>
<?supplied-pmid 26091717?><pub-id pub-id-type="pmid">26091717</pub-id></mixed-citation></ref><ref id="B149"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoeman</surname><given-names>J. F.</given-names></name><name><surname>Janse van Rensburg</surname><given-names>A.</given-names></name><name><surname>Laubscher</surname><given-names>J. A.</given-names></name><name><surname>Springer</surname><given-names>P.</given-names></name></person-group> (<year>2011</year>). <article-title>The role of aspirin in childhood tuberculous meningitis.</article-title>
<source><italic>J. Child Neurol.</italic></source>
<volume>26</volume>
<fpage>956</fpage>&#x02013;<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1177/0883073811398132</pub-id>
<?supplied-pmid 21628697?><pub-id pub-id-type="pmid">21628697</pub-id></mixed-citation></ref><ref id="B150"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schutz</surname><given-names>C.</given-names></name><name><surname>Davis</surname><given-names>A. G.</given-names></name><name><surname>Sossen</surname><given-names>B.</given-names></name><name><surname>Lai</surname><given-names>R. P.</given-names></name><name><surname>Ntsekhe</surname><given-names>M.</given-names></name><name><surname>Harley</surname><given-names>Y. X.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Corticosteroids as an adjunct to tuberculosis therapy.</article-title>
<source><italic>Expert. Rev. Respir. Med.</italic></source>
<volume>12</volume>
<fpage>881</fpage>&#x02013;<lpage>891</lpage>. <pub-id pub-id-type="doi">10.1080/17476348.2018.1515628</pub-id>
<?supplied-pmid 30138039?><pub-id pub-id-type="pmid">30138039</pub-id></mixed-citation></ref><ref id="B151"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scriba</surname><given-names>T. J.</given-names></name><name><surname>Penn-Nicholson</surname><given-names>A.</given-names></name><name><surname>Shankar</surname><given-names>S.</given-names></name><name><surname>Hraha</surname><given-names>T.</given-names></name><name><surname>Thompson</surname><given-names>E. G.</given-names></name><name><surname>Sterling</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Sequential inflammatory processes define human progression from <italic>M. tuberculosis</italic> infection to tuberculosis disease.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>13</volume>:<issue>e1006687</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1006687</pub-id>
<?supplied-pmid 29145483?><pub-id pub-id-type="pmid">29145483</pub-id></mixed-citation></ref><ref id="B152"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seddon</surname><given-names>J.</given-names></name><name><surname>Kasprowicz</surname><given-names>V.</given-names></name><name><surname>Walker</surname><given-names>N. F.</given-names></name><name><surname>Yuen</surname><given-names>H. M.</given-names></name><name><surname>Sunpath</surname><given-names>H.</given-names></name><name><surname>Tezera</surname><given-names>L.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Procollagen III N-terminal propeptide and desmosine are released by matrix destruction in pulmonary tuberculosis.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>208</volume>
<fpage>1571</fpage>&#x02013;<lpage>1579</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit343</pub-id>
<?supplied-pmid 23922364?><pub-id pub-id-type="pmid">23922364</pub-id></mixed-citation></ref><ref id="B153"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepper</surname><given-names>R.</given-names></name><name><surname>Konttinen</surname><given-names>Y. T.</given-names></name><name><surname>Ding</surname><given-names>Y.</given-names></name><name><surname>Takagi</surname><given-names>M.</given-names></name><name><surname>Sorsa</surname><given-names>T.</given-names></name></person-group> (<year>1995</year>). <article-title>Human neutrophil collagenase (MMP-8), identified in bronchiectasis BAL fluid, correlates with severity of disease.</article-title>
<source><italic>Chest</italic></source>
<volume>107</volume>
<fpage>1641</fpage>&#x02013;<lpage>1647</lpage>. <pub-id pub-id-type="doi">10.1378/chest.107.6.1641</pub-id>
<?supplied-pmid 7781360?><pub-id pub-id-type="pmid">7781360</pub-id></mixed-citation></ref><ref id="B154"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shu</surname><given-names>C. C.</given-names></name><name><surname>Wu</surname><given-names>M. F.</given-names></name><name><surname>Hsu</surname><given-names>C. L.</given-names></name><name><surname>Huang</surname><given-names>C. T.</given-names></name><name><surname>Wang</surname><given-names>J. Y.</given-names></name><name><surname>Hsieh</surname><given-names>S. L.</given-names></name><etal/></person-group> (<year>2013</year>). <article-title>Apoptosis-associated biomarkers in tuberculosis: promising for diagnosis and prognosis prediction.</article-title>
<source><italic>BMC Infect. Dis.</italic></source>
<volume>13</volume>:<issue>45</issue>. <pub-id pub-id-type="doi">10.1186/1471-2334-13-45</pub-id>
<?supplied-pmid 23356448?><pub-id pub-id-type="pmid">23356448</pub-id></mixed-citation></ref><ref id="B155"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sigal</surname><given-names>G. B.</given-names></name><name><surname>Segal</surname><given-names>M. R.</given-names></name><name><surname>Mathew</surname><given-names>A.</given-names></name><name><surname>Jarlsberg</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name><name><surname>Barbero</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Biomarkers of tuberculosis severity and treatment effect: a directed screen of 70 host markers in a randomized clinical trial.</article-title>
<source><italic>EBioMedicine</italic></source>
<volume>25</volume>
<fpage>112</fpage>&#x02013;<lpage>121</lpage>. <pub-id pub-id-type="doi">10.1016/j.ebiom.2017.10.018</pub-id>
<?supplied-pmid 29100778?><pub-id pub-id-type="pmid">29100778</pub-id></mixed-citation></ref><ref id="B156"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Kubler</surname><given-names>A.</given-names></name><name><surname>Singh</surname><given-names>U. K.</given-names></name><name><surname>Singh</surname><given-names>A.</given-names></name><name><surname>Gardiner</surname><given-names>H.</given-names></name><name><surname>Prasad</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2014a</year>). <article-title>Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>58</volume>
<fpage>4657</fpage>&#x02013;<lpage>4665</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.02141-13</pub-id>
<?supplied-pmid 24890593?><pub-id pub-id-type="pmid">24890593</pub-id></mixed-citation></ref><ref id="B157"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Saraiva</surname><given-names>L.</given-names></name><name><surname>Elkington</surname><given-names>P. T.</given-names></name><name><surname>Friedland</surname><given-names>J. S.</given-names></name></person-group> (<year>2014b</year>). <article-title>Regulation of matrix metalloproteinase-1, -3, and -9 in <italic>Mycobacterium tuberculosis</italic>-dependent respiratory networks by the rapamycin-sensitive PI3K/p70(S6K) cascade.</article-title>
<source><italic>FASEB J.</italic></source>
<volume>28</volume>
<fpage>85</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1096/fj.13-235507</pub-id>
<?supplied-pmid 24076964?><pub-id pub-id-type="pmid">24076964</pub-id></mixed-citation></ref><ref id="B158"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>S.</given-names></name><name><surname>Maniakis-Grivas</surname><given-names>G.</given-names></name><name><surname>Singh</surname><given-names>U. K.</given-names></name><name><surname>Asher</surname><given-names>R. M.</given-names></name><name><surname>Mauri</surname><given-names>F.</given-names></name><name><surname>Elkington</surname><given-names>P. T.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis.</article-title>
<source><italic>J. Pathol.</italic></source>
<volume>244</volume>
<fpage>311</fpage>&#x02013;<lpage>322</lpage>. <pub-id pub-id-type="doi">10.1002/path.5013</pub-id>
<?supplied-pmid 29210073?><pub-id pub-id-type="pmid">29210073</pub-id></mixed-citation></ref><ref id="B159"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>A.</given-names></name><name><surname>Jie</surname><given-names>L.</given-names></name><name><surname>Kumar</surname><given-names>P.</given-names></name><name><surname>Hong</surname><given-names>G. S.</given-names></name><name><surname>Leow</surname><given-names>M. K.</given-names></name><name><surname>Paleja</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Metformin as adjunct antituberculosis therapy.</article-title>
<source><italic>Sci. Transl. Med.</italic></source>
<volume>6</volume>:<issue>263ra159</issue>. <pub-id pub-id-type="doi">10.1126/scitranslmed.3009885</pub-id>
<?supplied-pmid 25411472?><pub-id pub-id-type="pmid">25411472</pub-id></mixed-citation></ref><ref id="B160"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skoura</surname><given-names>E.</given-names></name><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Bomanji</surname><given-names>J.</given-names></name></person-group> (<year>2015</year>). <article-title>Imaging in tuberculosis.</article-title>
<source><italic>Int. J. Infect. Dis.</italic></source>
<volume>32</volume>
<fpage>87</fpage>&#x02013;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijid.2014.12.007</pub-id>
<?supplied-pmid 25809762?><pub-id pub-id-type="pmid">25809762</pub-id></mixed-citation></ref><ref id="B161"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Skrahin</surname><given-names>A.</given-names></name><name><surname>Jenkins</surname><given-names>H. E.</given-names></name><name><surname>Hurevich</surname><given-names>H.</given-names></name><name><surname>Solodovnikova</surname><given-names>V.</given-names></name><name><surname>Isaikina</surname><given-names>Y.</given-names></name><name><surname>Klimuk</surname><given-names>D.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>Effectiveness of a novel cellular therapy to treat multidrug-resistant tuberculosis.</article-title>
<source><italic>J. Clin. Tuberc. Other Mycobact. Dis.</italic></source>
<volume>4</volume>
<fpage>21</fpage>&#x02013;<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1016/j.jctube.2016.05.003</pub-id>
<?supplied-pmid 27284577?><pub-id pub-id-type="pmid">27284577</pub-id></mixed-citation></ref><ref id="B162"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smego</surname><given-names>R. A.</given-names></name><name><surname>Ahmed</surname><given-names>N.</given-names></name></person-group> (<year>2003</year>). <article-title>A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>7</volume>
<fpage>208</fpage>&#x02013;<lpage>213</lpage>. <?supplied-pmid 12661833?><pub-id pub-id-type="pmid">12661833</pub-id></mixed-citation></ref><ref id="B163"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sodhi</surname><given-names>A.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Silva</surname><given-names>C.</given-names></name><name><surname>Qian</surname><given-names>D.</given-names></name><name><surname>Barnes</surname><given-names>P. F.</given-names></name></person-group> (<year>1997</year>). <article-title>Clinical correlates of interferon gamma production in patients with tuberculosis.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>25</volume>
<fpage>617</fpage>&#x02013;<lpage>620</lpage>. <pub-id pub-id-type="doi">10.1086/513769</pub-id><pub-id pub-id-type="pmid">9314449</pub-id></mixed-citation></ref><ref id="B164"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Songane</surname><given-names>M.</given-names></name><name><surname>Kleinnijenhuis</surname><given-names>J.</given-names></name><name><surname>Netea</surname><given-names>M. G.</given-names></name><name><surname>van Crevel</surname><given-names>R.</given-names></name></person-group> (<year>2012</year>). <article-title>The role of autophagy in host defence against <italic>Mycobacterium tuberculosis</italic> infection.</article-title>
<source><italic>Tuberculosis</italic></source>
<volume>92</volume>
<fpage>388</fpage>&#x02013;<lpage>396</lpage>. <pub-id pub-id-type="doi">10.1016/j.tube.2012.05.004</pub-id>
<?supplied-pmid 22683183?><pub-id pub-id-type="pmid">22683183</pub-id></mixed-citation></ref><ref id="B165"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>V. Y.</given-names></name><name><surname>Su</surname><given-names>W. J.</given-names></name><name><surname>Yen</surname><given-names>Y. F.</given-names></name><name><surname>Pan</surname><given-names>S. W.</given-names></name><name><surname>Chuang</surname><given-names>P. H.</given-names></name><name><surname>Feng</surname><given-names>J. Y.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Statin use is associated with a lower risk of TB.</article-title>
<source><italic>Chest</italic></source>
<volume>152</volume>
<fpage>598</fpage>&#x02013;<lpage>606</lpage>. <pub-id pub-id-type="doi">10.1016/j.chest.2017.04.170</pub-id>
<?supplied-pmid 28479115?><pub-id pub-id-type="pmid">28479115</pub-id></mixed-citation></ref><ref id="B166"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>W. L.</given-names></name><name><surname>Perng</surname><given-names>W. C.</given-names></name><name><surname>Huang</surname><given-names>C. H.</given-names></name><name><surname>Yang</surname><given-names>C. Y.</given-names></name><name><surname>Wu</surname><given-names>C. P.</given-names></name><name><surname>Chen</surname><given-names>J. H.</given-names></name></person-group> (<year>2010</year>). <article-title>Association of reduced tumor necrosis factor alpha, gamma interferon, and interleukin-1beta (IL-1beta) but increased IL-10 expression with improved chest radiography in patients with pulmonary tuberculosis.</article-title>
<source><italic>Clin. Vaccine Immunol.</italic></source>
<volume>17</volume>
<fpage>223</fpage>&#x02013;<lpage>231</lpage>. <pub-id pub-id-type="doi">10.1128/CVI.00381-09</pub-id>
<?supplied-pmid 20007364?><pub-id pub-id-type="pmid">20007364</pub-id></mixed-citation></ref><ref id="B167"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subbian</surname><given-names>S.</given-names></name><name><surname>Tsenova</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>M. J.</given-names></name><name><surname>Wainwright</surname><given-names>H. C.</given-names></name><name><surname>Visser</surname><given-names>A.</given-names></name><name><surname>Bandyopadhyay</surname><given-names>N.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Lesion-specific immune response in granulomas of patients with pulmonary tuberculosis: a pilot study.</article-title>
<source><italic>PLoS One</italic></source>
<volume>10</volume>:<issue>e0132249</issue>. <pub-id pub-id-type="doi">10.1371/journal.pone.0132249</pub-id>
<?supplied-pmid 26133981?><pub-id pub-id-type="pmid">26133981</pub-id></mixed-citation></ref><ref id="B168"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subbian</surname><given-names>S.</given-names></name><name><surname>Tsenova</surname><given-names>L.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Koo</surname><given-names>M. S.</given-names></name><name><surname>Peixoto</surname><given-names>B.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Phosphodiesterase-4 inhibition combined with isoniazid treatment of rabbits with pulmonary tuberculosis reduces macrophage activation and lung pathology.</article-title>
<source><italic>Am. J. Pathol.</italic></source>
<volume>179</volume>
<fpage>289</fpage>&#x02013;<lpage>301</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajpath.2011.03.039</pub-id>
<?supplied-pmid 21703411?><pub-id pub-id-type="pmid">21703411</pub-id></mixed-citation></ref><ref id="B169"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadokera</surname><given-names>R.</given-names></name><name><surname>Meintjes</surname><given-names>G.</given-names></name><name><surname>Skolimowska</surname><given-names>K. H.</given-names></name><name><surname>Wilkinson</surname><given-names>K. A.</given-names></name><name><surname>Matthews</surname><given-names>K.</given-names></name><name><surname>Seldon</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome.</article-title>
<source><italic>Eur. Respir. J.</italic></source>
<volume>37</volume>
<fpage>1248</fpage>&#x02013;<lpage>1259</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.00091010</pub-id>
<?supplied-pmid 20817712?><pub-id pub-id-type="pmid">20817712</pub-id></mixed-citation></ref><ref id="B170"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tadokera</surname><given-names>R.</given-names></name><name><surname>Meintjes</surname><given-names>G. A.</given-names></name><name><surname>Wilkinson</surname><given-names>K. A.</given-names></name><name><surname>Skolimowska</surname><given-names>K. H.</given-names></name><name><surname>Walker</surname><given-names>N.</given-names></name><name><surname>Friedland</surname><given-names>J. S.</given-names></name><etal/></person-group> (<year>2014</year>). <article-title>Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome.</article-title>
<source><italic>Eur. J. Immunol.</italic></source>
<volume>44</volume>
<fpage>127</fpage>&#x02013;<lpage>136</lpage>. <pub-id pub-id-type="doi">10.1002/eji.201343593</pub-id>
<?supplied-pmid 24136296?><pub-id pub-id-type="pmid">24136296</pub-id></mixed-citation></ref><ref id="B171"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>J. L.</given-names></name><name><surname>Hattle</surname><given-names>J. M.</given-names></name><name><surname>Dreitz</surname><given-names>S. A.</given-names></name><name><surname>Troudt</surname><given-names>J. M.</given-names></name><name><surname>Izzo</surname><given-names>L. S.</given-names></name><name><surname>Basaraba</surname><given-names>R. J.</given-names></name><etal/></person-group> (<year>2006</year>). <article-title>Role for matrix metalloproteinase 9 in granuloma formation during pulmonary <italic>Mycobacterium tuberculosis</italic> infection.</article-title>
<source><italic>Infect. Immun.</italic></source>
<volume>74</volume>
<fpage>6135</fpage>&#x02013;<lpage>6144</lpage>. <pub-id pub-id-type="doi">10.1128/IAI.02048-05</pub-id>
<?supplied-pmid 16982845?><pub-id pub-id-type="pmid">16982845</pub-id></mixed-citation></ref><ref id="B172"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Theegarten</surname><given-names>D.</given-names></name><name><surname>Kahl</surname><given-names>B.</given-names></name><name><surname>Ebsen</surname><given-names>M.</given-names></name></person-group> (<year>2006</year>). <article-title>[Frequency and morphology of tuberculosis in autopsies: increase of active forms].</article-title>
<source><italic>Dtsch. Med. Wochenschr.</italic></source>
<volume>131</volume>
<fpage>1371</fpage>&#x02013;<lpage>1376</lpage>. <pub-id pub-id-type="doi">10.1055/s-2006-946581</pub-id>
<?supplied-pmid 16783670?><pub-id pub-id-type="pmid">16783670</pub-id></mixed-citation></ref><ref id="B173"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tobin</surname><given-names>D. M.</given-names></name><name><surname>Roca</surname><given-names>F. J.</given-names></name><name><surname>Oh</surname><given-names>S. F.</given-names></name><name><surname>McFarland</surname><given-names>R.</given-names></name><name><surname>Vickery</surname><given-names>T. W.</given-names></name><name><surname>Ray</surname><given-names>J. P.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections.</article-title>
<source><italic>Cell</italic></source>
<volume>148</volume>
<fpage>434</fpage>&#x02013;<lpage>446</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2011.12.023</pub-id>
<?supplied-pmid 22304914?><pub-id pub-id-type="pmid">22304914</pub-id></mixed-citation></ref><ref id="B174"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>T. C.</given-names></name><name><surname>Hong</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Liao</surname><given-names>S. K.</given-names></name><name><surname>Chang</surname><given-names>K. S.</given-names></name></person-group> (<year>1999</year>). <article-title>Increased TNF-alpha, IL-1 beta and IL-6 levels in the bronchoalveolar lavage fluid with the upregulation of their mRNA in macrophages lavaged from patients with active pulmonary tuberculosis.</article-title>
<source><italic>Tuber. Lung Dis.</italic></source>
<volume>79</volume>
<fpage>279</fpage>&#x02013;<lpage>285</lpage>. <pub-id pub-id-type="doi">10.1054/tuld.1999.0215</pub-id>
<?supplied-pmid 10707256?><pub-id pub-id-type="pmid">10707256</pub-id></mixed-citation></ref><ref id="B175"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>T. C.</given-names></name><name><surname>Hong</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>L. F.</given-names></name><name><surname>Hsieh</surname><given-names>M. J.</given-names></name><name><surname>Liao</surname><given-names>S. K.</given-names></name><name><surname>Chang</surname><given-names>K. S.</given-names></name></person-group> (<year>2000</year>). <article-title>Imbalances between tumor necrosis factor-alpha and its soluble receptor forms, and interleukin-1beta and interleukin-1 receptor antagonist in BAL fluid of cavitary pulmonary tuberculosis.</article-title>
<source><italic>Chest</italic></source>
<volume>117</volume>
<fpage>103</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1378/chest.117.1.103</pub-id>
<?supplied-pmid 10631206?><pub-id pub-id-type="pmid">10631206</pub-id></mixed-citation></ref><ref id="B176"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>T. C.</given-names></name><name><surname>Huang</surname><given-names>C. C.</given-names></name><name><surname>Chiou</surname><given-names>W. K.</given-names></name><name><surname>Yang</surname><given-names>P. Y.</given-names></name><name><surname>Hsieh</surname><given-names>M. J.</given-names></name><name><surname>Tsao</surname><given-names>K. C.</given-names></name></person-group> (<year>2002</year>). <article-title>Levels of interferon-gamma and interleukin-2 receptor-alpha for bronchoalveolar lavage fluid and serum were correlated with clinical grade and treatment of pulmonary tuberculosis.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>6</volume>
<fpage>720</fpage>&#x02013;<lpage>727</lpage>. <?supplied-pmid 12150485?><pub-id pub-id-type="pmid">12150485</pub-id></mixed-citation></ref><ref id="B177"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ulrichs</surname><given-names>T.</given-names></name><name><surname>Kosmiadi</surname><given-names>G. A.</given-names></name><name><surname>Jorg</surname><given-names>S.</given-names></name><name><surname>Pradl</surname><given-names>L.</given-names></name><name><surname>Titukhina</surname><given-names>M.</given-names></name><name><surname>Mishenko</surname><given-names>V.</given-names></name><etal/></person-group> (<year>2005</year>). <article-title>Differential organization of the local immune response in patients with active cavitary tuberculosis or with nonprogressive tuberculoma.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>192</volume>
<fpage>89</fpage>&#x02013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1086/430621</pub-id>
<?supplied-pmid 15942898?><pub-id pub-id-type="pmid">15942898</pub-id></mixed-citation></ref><ref id="B178"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Crevel</surname><given-names>R.</given-names></name><name><surname>Karyadi</surname><given-names>E.</given-names></name><name><surname>Preyers</surname><given-names>F.</given-names></name><name><surname>Leenders</surname><given-names>M.</given-names></name><name><surname>Kullberg</surname><given-names>B. J.</given-names></name><name><surname>Nelwan</surname><given-names>R. H.</given-names></name><etal/></person-group> (<year>2000</year>). <article-title>Increased production of interleukin 4 by CD4<sup>+</sup> and CD8<sup>+</sup> T cells from patients with tuberculosis is related to the presence of pulmonary cavities.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>181</volume>
<fpage>1194</fpage>&#x02013;<lpage>1197</lpage>. <pub-id pub-id-type="doi">10.1086/315325</pub-id>
<?supplied-pmid 10720554?><pub-id pub-id-type="pmid">10720554</pub-id></mixed-citation></ref><ref id="B179"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vecino</surname><given-names>M.</given-names></name><name><surname>Pasipanodya</surname><given-names>J. G.</given-names></name><name><surname>Slocum</surname><given-names>P.</given-names></name><name><surname>Bae</surname><given-names>S.</given-names></name><name><surname>Munguia</surname><given-names>G.</given-names></name><name><surname>Miller</surname><given-names>T.</given-names></name><etal/></person-group> (<year>2011</year>). <article-title>Evidence for chronic lung impairment in patients treated for pulmonary tuberculosis.</article-title>
<source><italic>J. Infect. Public Health</italic></source>
<volume>4</volume>
<fpage>244</fpage>&#x02013;<lpage>252</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2011.08.005</pub-id>
<?supplied-pmid 22118719?><pub-id pub-id-type="pmid">22118719</pub-id></mixed-citation></ref><ref id="B180"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidyarani</surname><given-names>M.</given-names></name><name><surname>Selvaraj</surname><given-names>P.</given-names></name><name><surname>Jawahar</surname><given-names>M. S.</given-names></name><name><surname>Narayanan</surname><given-names>P. R.</given-names></name></person-group> (<year>2007</year>). <article-title>1, 25 Dihydroxyvitamin D3 modulated cytokine response in pulmonary tuberculosis.</article-title>
<source><italic>Cytokine</italic></source>
<volume>40</volume>
<fpage>128</fpage>&#x02013;<lpage>134</lpage>. <pub-id pub-id-type="doi">10.1016/j.cyto.2007.08.005</pub-id>
<?supplied-pmid 17911026?><pub-id pub-id-type="pmid">17911026</pub-id></mixed-citation></ref><ref id="B181"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vilaplana</surname><given-names>C.</given-names></name><name><surname>Marzo</surname><given-names>E.</given-names></name><name><surname>Tapia</surname><given-names>G.</given-names></name><name><surname>Diaz</surname><given-names>J.</given-names></name><name><surname>Garcia</surname><given-names>V.</given-names></name><name><surname>Cardona</surname><given-names>P. J.</given-names></name></person-group> (<year>2013</year>). <article-title>Ibuprofen therapy resulted in significantly decreased tissue bacillary loads and increased survival in a new murine experimental model of active tuberculosis.</article-title>
<source><italic>J. Infect. Dis.</italic></source>
<volume>208</volume>
<fpage>199</fpage>&#x02013;<lpage>202</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jit152</pub-id>
<?supplied-pmid 23564636?><pub-id pub-id-type="pmid">23564636</pub-id></mixed-citation></ref><ref id="B182"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Volkman</surname><given-names>H. E.</given-names></name><name><surname>Pozos</surname><given-names>T. C.</given-names></name><name><surname>Zheng</surname><given-names>J.</given-names></name><name><surname>Davis</surname><given-names>J. M.</given-names></name><name><surname>Rawls</surname><given-names>J. F.</given-names></name><name><surname>Ramakrishnan</surname><given-names>L.</given-names></name></person-group> (<year>2010</year>). <article-title>Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium.</article-title>
<source><italic>Science</italic></source>
<volume>327</volume>
<fpage>466</fpage>&#x02013;<lpage>469</lpage>. <pub-id pub-id-type="doi">10.1126/science.1179663</pub-id>
<?supplied-pmid 20007864?><pub-id pub-id-type="pmid">20007864</pub-id></mixed-citation></ref><ref id="B183"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>N. F.</given-names></name><name><surname>Clark</surname><given-names>S. O.</given-names></name><name><surname>Oni</surname><given-names>T.</given-names></name><name><surname>Andreu</surname><given-names>N.</given-names></name><name><surname>Tezera</surname><given-names>L.</given-names></name><name><surname>Singh</surname><given-names>S.</given-names></name><etal/></person-group> (<year>2012</year>). <article-title>Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.</article-title>
<source><italic>Am. J. Respir. Crit. Care Med.</italic></source>
<volume>185</volume>
<fpage>989</fpage>&#x02013;<lpage>997</lpage>. <pub-id pub-id-type="doi">10.1164/rccm.201110-1769OC</pub-id>
<?supplied-pmid 22345579?><pub-id pub-id-type="pmid">22345579</pub-id></mixed-citation></ref><ref id="B184"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walker</surname><given-names>N. F.</given-names></name><name><surname>Wilkinson</surname><given-names>K. A.</given-names></name><name><surname>Meintjes</surname><given-names>G.</given-names></name><name><surname>Tezera</surname><given-names>L. B.</given-names></name><name><surname>Goliath</surname><given-names>R.</given-names></name><name><surname>Peyper</surname><given-names>J. M.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Matrix degradation in human immunodeficiency virus type 1-associated tuberculosis and tuberculosis immune reconstitution inflammatory syndrome: a prospective observational study.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>65</volume>
<fpage>121</fpage>&#x02013;<lpage>132</lpage>. <pub-id pub-id-type="doi">10.1093/cid/cix231</pub-id>
<?supplied-pmid 28475709?><pub-id pub-id-type="pmid">28475709</pub-id></mixed-citation></ref><ref id="B185"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>R. S.</given-names></name></person-group> (<year>2014</year>). <article-title>Corticosteroid effects on sputum culture in pulmonary tuberculosis: a meta-regression analysis.</article-title>
<source><italic>Open Forum Infect. Dis.</italic></source>
<volume>1</volume>:<issue>ofu020</issue>. <pub-id pub-id-type="doi">10.1093/ofid/ofu020</pub-id>
<?supplied-pmid 25734093?><pub-id pub-id-type="pmid">25734093</pub-id></mixed-citation></ref><ref id="B186"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>R. S.</given-names></name><name><surname>Hafner</surname><given-names>R.</given-names></name></person-group> (<year>2015</year>). <article-title>Advancing host-directed therapy for tuberculosis.</article-title>
<source><italic>Nat. Rev. Immunol.</italic></source>
<volume>15</volume>
<fpage>255</fpage>&#x02013;<lpage>263</lpage>. <pub-id pub-id-type="doi">10.1038/nri3813</pub-id>
<?supplied-pmid 25765201?><pub-id pub-id-type="pmid">25765201</pub-id></mixed-citation></ref><ref id="B187"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>R. S.</given-names></name><name><surname>Kyambadde</surname><given-names>P.</given-names></name><name><surname>Johnson</surname><given-names>J. L.</given-names></name><name><surname>Horter</surname><given-names>L.</given-names></name><name><surname>Kittle</surname><given-names>R.</given-names></name><name><surname>Pohle</surname><given-names>M.</given-names></name><etal/></person-group> (<year>2004</year>). <article-title>A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis.</article-title>
<source><italic>AIDS</italic></source>
<volume>18</volume>
<fpage>257</fpage>&#x02013;<lpage>264</lpage>. <pub-id pub-id-type="doi">10.1097/00002030-200401230-00015</pub-id>
<?supplied-pmid 15075543?><pub-id pub-id-type="pmid">15075543</pub-id></mixed-citation></ref><ref id="B188"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallis</surname><given-names>R. S.</given-names></name><name><surname>van Vuuren</surname><given-names>C.</given-names></name><name><surname>Potgieter</surname><given-names>S.</given-names></name></person-group> (<year>2009</year>). <article-title>Adalimumab treatment of life-threatening tuberculosis.</article-title>
<source><italic>Clin. Infect. Dis.</italic></source>
<volume>48</volume>
<fpage>1429</fpage>&#x02013;<lpage>1432</lpage>. <pub-id pub-id-type="doi">10.1086/598504</pub-id>
<?supplied-pmid 19364287?><pub-id pub-id-type="pmid">19364287</pub-id></mixed-citation></ref><ref id="B189"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C. H.</given-names></name><name><surname>Lin</surname><given-names>H. C.</given-names></name><name><surname>Lin</surname><given-names>S. M.</given-names></name><name><surname>Huang</surname><given-names>C. D.</given-names></name><name><surname>Liu</surname><given-names>C. Y.</given-names></name><name><surname>Huang</surname><given-names>K. H.</given-names></name><etal/></person-group> (<year>2010</year>). <article-title>MMP-1(-1607G) polymorphism as a risk factor for fibrosis after pulmonary tuberculosis in Taiwan.</article-title>
<source><italic>Int. J. Tuberc. Lung Dis.</italic></source>
<volume>14</volume>
<fpage>627</fpage>&#x02013;<lpage>634</lpage>. <?supplied-pmid 20392358?><pub-id pub-id-type="pmid">20392358</pub-id></mixed-citation></ref><ref id="B190"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willcox</surname><given-names>P. A.</given-names></name><name><surname>Ferguson</surname><given-names>A. D.</given-names></name></person-group> (<year>1989</year>). <article-title>Chronic obstructive airways disease following treated pulmonary tuberculosis.</article-title>
<source><italic>Respir. Med.</italic></source>
<volume>83</volume>
<fpage>195</fpage>&#x02013;<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1016/S0954-6111(89)80031-9</pub-id><pub-id pub-id-type="pmid">2595036</pub-id></mixed-citation></ref><ref id="B191"><mixed-citation publication-type="book"><collab>World Health Organization</collab> (<year>2017</year>). <source><italic>Global Tuberculosis Report 2017.</italic></source>
<publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>.</mixed-citation></ref><ref id="B192"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>C. W.</given-names></name><name><surname>Wu</surname><given-names>J. Y.</given-names></name><name><surname>Lee</surname><given-names>M. G.</given-names></name><name><surname>Lai</surname><given-names>C. C.</given-names></name><name><surname>Wu</surname><given-names>I. L.</given-names></name><name><surname>Tsai</surname><given-names>Y. W.</given-names></name><etal/></person-group> (<year>2017</year>). <article-title>Risk of incident active tuberculosis disease in patients treated with non-steroidal anti-inflammatory drugs: a population-based study.</article-title>
<source><italic>BMC Pulm. Med.</italic></source>
<volume>17</volume>:<issue>82</issue>. <pub-id pub-id-type="doi">10.1186/s12890-017-0425-3</pub-id>
<?supplied-pmid 28472944?><pub-id pub-id-type="pmid">28472944</pub-id></mixed-citation></ref><ref id="B193"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H. P.</given-names></name><name><surname>Hua</surname><given-names>C. C.</given-names></name><name><surname>Chuang</surname><given-names>D. Y.</given-names></name></person-group> (<year>2007</year>). <article-title>Decreased in vitro interferon-gamma production in patients with cavitary tuberculosis on chest radiography.</article-title>
<source><italic>Respir. Med.</italic></source>
<volume>101</volume>
<fpage>48</fpage>&#x02013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.rmed.2006.04.016</pub-id>
<?supplied-pmid 16753289?><pub-id pub-id-type="pmid">16753289</pub-id></mixed-citation></ref><ref id="B194"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wynn</surname><given-names>T. A.</given-names></name><name><surname>Ramalingam</surname><given-names>T. R.</given-names></name></person-group> (<year>2012</year>). <article-title>Mechanisms of fibrosis: therapeutic translation for fibrotic disease.</article-title>
<source><italic>Nat. Med.</italic></source>
<volume>18</volume>
<fpage>1028</fpage>&#x02013;<lpage>1040</lpage>. <pub-id pub-id-type="doi">10.1038/nm.2807</pub-id>
<?supplied-pmid 22772564?><pub-id pub-id-type="pmid">22772564</pub-id></mixed-citation></ref><ref id="B195"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zimmerman</surname><given-names>M. D.</given-names></name><name><surname>Chen</surname><given-names>K. Y.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Fu</surname><given-names>D. J.</given-names></name><etal/></person-group> (<year>2018</year>). <article-title>Matrix metalloproteinase inhibitors enhance the efficacy of frontline drugs against <italic>Mycobacterium tuberculosis</italic>.</article-title>
<source><italic>PLoS Pathog.</italic></source>
<volume>14</volume>:<issue>e1006974</issue>. <pub-id pub-id-type="doi">10.1371/journal.ppat.1006974</pub-id>
<?supplied-pmid 29698476?><pub-id pub-id-type="pmid">29698476</pub-id></mixed-citation></ref><ref id="B196"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamura</surname><given-names>Y.</given-names></name><name><surname>Ogawa</surname><given-names>Y.</given-names></name><name><surname>Maeda</surname><given-names>H.</given-names></name><name><surname>Yamamura</surname><given-names>Y.</given-names></name></person-group> (<year>1974</year>). <article-title>Prevention of tuberculous cavity formation by desensitization with tuberculin-active peptide.</article-title>
<source><italic>Am. Rev. Respir. Dis.</italic></source>
<volume>109</volume>
<fpage>594</fpage>&#x02013;<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1164/arrd.1974.109.6.594</pub-id>
<?supplied-pmid 4209492?><pub-id pub-id-type="pmid">4209492</pub-id></mixed-citation></ref><ref id="B197"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamura</surname><given-names>Y.</given-names></name><name><surname>Ogawa</surname><given-names>Y.</given-names></name><name><surname>Yamagata</surname><given-names>H.</given-names></name><name><surname>Yamamura</surname><given-names>Y.</given-names></name></person-group> (<year>1968</year>). <article-title>Prevention of tuberculous cavity formation by immunosuppressive drugs.</article-title>
<source><italic>Am. Rev. Respir. Dis.</italic></source>
<volume>98</volume>
<fpage>720</fpage>&#x02013;<lpage>723</lpage>. <pub-id pub-id-type="doi">10.1164/arrd.1968.98.4.720</pub-id>
<?supplied-pmid 4175665?><pub-id pub-id-type="pmid">4175665</pub-id></mixed-citation></ref><ref id="B198"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuhas</surname><given-names>Y.</given-names></name><name><surname>Azoulay-Alfaguter</surname><given-names>I.</given-names></name><name><surname>Berent</surname><given-names>E.</given-names></name><name><surname>Ashkenazi</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>). <article-title>Rifampin inhibits prostaglandin E2 production and arachidonic acid release in human alveolar epithelial cells.</article-title>
<source><italic>Antimicrob. Agents Chemother.</italic></source>
<volume>51</volume>
<fpage>4225</fpage>&#x02013;<lpage>4230</lpage>. <pub-id pub-id-type="doi">10.1128/AAC.00985-07</pub-id>
<?supplied-pmid 17908941?><pub-id pub-id-type="pmid">17908941</pub-id></mixed-citation></ref><ref id="B199"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zak</surname><given-names>D. E.</given-names></name><name><surname>Penn-Nicholson</surname><given-names>A.</given-names></name><name><surname>Scriba</surname><given-names>T. J.</given-names></name><name><surname>Thompson</surname><given-names>E.</given-names></name><name><surname>Suliman</surname><given-names>S.</given-names></name><name><surname>Amon</surname><given-names>L. M.</given-names></name><etal/></person-group> (<year>2016</year>). <article-title>A blood RNA signature for tuberculosis disease risk: a prospective cohort study.</article-title>
<source><italic>Lancet</italic></source>
<volume>387</volume>
<fpage>2312</fpage>&#x02013;<lpage>2322</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(15)01316-1</pub-id><pub-id pub-id-type="pmid">27017310</pub-id></mixed-citation></ref><ref id="B200"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>M.</given-names></name><name><surname>Gong</surname><given-names>J.</given-names></name><name><surname>Iyer</surname><given-names>D. V.</given-names></name><name><surname>Jones</surname><given-names>B. E.</given-names></name><name><surname>Modlin</surname><given-names>R. L.</given-names></name><name><surname>Barnes</surname><given-names>P. F.</given-names></name></person-group> (<year>1994</year>). <article-title>T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection.</article-title>
<source><italic>J. Clin. Invest.</italic></source>
<volume>94</volume>
<fpage>2435</fpage>&#x02013;<lpage>2442</lpage>. <pub-id pub-id-type="doi">10.1172/JCI117611</pub-id>
<?supplied-pmid 7989601?><pub-id pub-id-type="pmid">7989601</pub-id></mixed-citation></ref><ref id="B201"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Lam</surname><given-names>W. K.</given-names></name><name><surname>Tipoe</surname><given-names>G. L.</given-names></name><name><surname>Shum</surname><given-names>I. H.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Leung</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2002</year>). <article-title>Overexpression of matrix metalloproteinase-8 and -9 in bronchiectasis airways in vivo.</article-title>
<source><italic>Eur. Respir. J.</italic></source>
<volume>20</volume>
<fpage>170</fpage>&#x02013;<lpage>176</lpage>. <pub-id pub-id-type="doi">10.1183/09031936.02.00282402</pub-id>
<?supplied-pmid 12166566?><pub-id pub-id-type="pmid">12166566</pub-id></mixed-citation></ref><ref id="B202"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A.</given-names></name><name><surname>Rao</surname><given-names>M.</given-names></name><name><surname>Parida</surname><given-names>S. K.</given-names></name><name><surname>Keshavjee</surname><given-names>S.</given-names></name><name><surname>Cassell</surname><given-names>G.</given-names></name><name><surname>Wallis</surname><given-names>R.</given-names></name><etal/></person-group> (<year>2015</year>). <article-title>Inflammation and tuberculosis: host-directed therapies.</article-title>
<source><italic>J. Intern. Med.</italic></source>
<volume>277</volume>
<fpage>373</fpage>&#x02013;<lpage>387</lpage>. <pub-id pub-id-type="doi">10.1111/joim.12256</pub-id>
<?supplied-pmid 24717092?><pub-id pub-id-type="pmid">24717092</pub-id></mixed-citation></ref></ref-list></back></article>